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Abstract 
Hematopoietic stem cell transplantation (HSCT) is currently used as a 
potential curative therapy for several malignant and non-malignant disorders. 
In recent years our understanding of complexity of immunogenetics of HSCT 
has led to new indications for the procedure.  Therefore the demand for 
unrelated hematopoietic stem cell (HSC) donors keeps rising. HLA matching 
remains the main determining factor when searching for an HSC donor. An 
HLA-identical sibling still remains the most suitable donor, but only around 
30% of patients (requiring HSCT) have this option. Others require a search 
for an alternative donor. Because the HLA system is highly polymorphic, the 
chance of finding a suitable matched unrelated donor is limited. When bone 
marrow or peripheral blood are used as source of HSC, stringent HLA-
matching is required to lower the risk of transplant-related complications. The 
donor pool is especially limited for patients with diverse racial and ethnic 
backgrounds because such ethnicities are underrepresented on current 
worldwide donor registries (Barker, Byam, et al., 2010). To overcome this 
problem, unrelated umbilical cord blood units (UCB) can be selected as readily 
available alternatives for patients who lack both HLA-matched siblings and 
suitable unrelated donors.  
 
This thesis provides an insight into the contemporary factors influencing 
selection of unrelated umbilical cord blood (UCB) for transplantation.  
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Studies in this thesis provide a detailed analysis of current UCB selection 
practice and explore new factors that can help to develop a patient tailored 
approach to the UCB selection process. Work is based on the understanding 
of a tri-dimensional donor-recipient interaction process in the context of UCBT, 
which involves not only direct donor-recipient interaction, but also involves 
foeto-maternal exchange of information.  
 
My key finding was that maternal characteristics (i.e. previous pregnancy and 
exposure to infections) influence quality characteristics of UCB and potentially 
have an impact on transplant outcomes.  
 
Based on my study findings, a new project has been initiated. It will study a 
larger cohort of patients and investigate the impact of birth order and previous 
child’s sex on UCBT outcome.  
  
Table of Contents 
 5 
Table of Contents  
ABSTRACT ................................................................................................................................................................. 3 
TABLE OF CONTENTS ............................................................................................................................................ 5 
ACKNOWLEDGEMENTS ........................................................................................................................................ 9 
MANUSCRIPTS IN PREPARATION .................................................................................................................. 12 
PEER-REVIEWED PRESENTATIONS .............................................................................................................. 13 
LIST OF FIGURES .................................................................................................................................................. 14 
TABLE OF TABLES ............................................................................................................................................... 16 
GLOSSARY ............................................................................................................................................................... 18 
THESIS OVERVIEW .............................................................................................................................................. 25 
CHAPTER 1. INTRODUCTION AND LITERATURE REVIEW ................................................................... 28  HISTORY AND CONTEXT ........................................................................................................................................ 28  Umbilical cord blood (UCB) as a source of stem cell procurement .......................................... 28  UCB BANKING ........................................................................................................................................................ 35  FACTORS KNOWN TO INFLUENCE UMBILICAL CORD BLOOD TRANSPLANT OUTCOMES ............................ 37  Introduction ................................................................................................................................................... 37  TNC and UCB Selection .............................................................................................................................. 38  UCB selection and CD34+ cell count ..................................................................................................... 45  UCB graft selection and non-inherited maternal antigens (NIMA) and inherited 
paternal antigens (IPA) .............................................................................................................................................. 47  UCB selection and Killer-immunoglobulin-like receptor (KIR) ligands ................................. 50  OTHER FACTORS ..................................................................................................................................................... 51  Functional assays of UCB quality .......................................................................................................... 51  Cytomegalovirus .......................................................................................................................................... 52  UCB selection, donor-specific HLA allo-antibodies and ABO mismatch ................................. 55 
Table of Contents 
 6 
 UCB unit cryopreservation time and transplant outcomes ........................................................ 56  THE ROLE OF HLA IN UCBT ............................................................................................................................... 58  Introduction................................................................................................................................................... 58  UCB-patient HLA-matching and the impact on transplant outcome. .................................... 58  IMMUNE RECONSTITUTION POST UCBT ............................................................................................................ 61  CONCLUSION ........................................................................................................................................................... 65 
CHAPTER 2. DELIVERY MODE INFLUENCE ON THE VOLUME AND TOTAL NUCLEATED CELL 
COUNT OF THE UCB ............................................................................................................................................ 67  INTRODUCTION ...................................................................................................................................................... 67  MATERIALS AND METHODS .................................................................................................................................. 69  RESULTS .................................................................................................................................................................. 71  Collection mode ............................................................................................................................................ 71  UCB volume .................................................................................................................................................... 71  UCB TNC .......................................................................................................................................................... 71  Mode of the delivery and UCBs stored for clinical use .................................................................. 72  DISCUSSION ............................................................................................................................................................. 74 
CHAPTER 3. DONOR-RECIPIENT ALLELE-LEVEL HLA MATCHING OF UNRELATED CORD 
BLOOD UNITS. ....................................................................................................................................................... 78  INTRODUCTION ...................................................................................................................................................... 78  MATERIALS AND METHODS .................................................................................................................................. 81  RESULTS .................................................................................................................................................................. 81  Characteristics of recipients .................................................................................................................... 81  Extent of UCB-recipient pair HLA mismatch at low/intermediate resolution .................... 83  Extent of UCB-recipient HLA mismatch at high resolution......................................................... 84  UCB-recipient HLA allelic match and TNC dose .............................................................................. 86  DISCUSSION ............................................................................................................................................................. 86 
CHAPTER 4. RELATIONSHIP BETWEEN DONOR MOTHERS PREVIOUS EXPOSURE TO THE 
VIRAL INFECTIONS AND UCBS CELL COUNT. ............................................................................................. 89 
Table of Contents 
 7 
 INTRODUCTION ....................................................................................................................................................... 89  MATERIALS AND METHODS. ................................................................................................................................ 94  Statistical analysis ...................................................................................................................................... 96  RESULTS .................................................................................................................................................................. 97  Frequency of positive IgG class antibodies for the CMV, EBV and Toxoplasma gondii .... 97  Cell count in the UCBs from both CBB ................................................................................................. 99  Relationship between TNC, CD34+ cells, mononuclear cells and lymphocytes count and 
maternal CMV serological status. ........................................................................................................................... 99 4.3.3.1. Anthony Nolan Cell Therapy Centre ........................................................................................................ 100 4.3.3.2. Barcelona’s CBB ................................................................................................................................................. 100  Relationship between TNC, CD34+ cells, mononuclear cell and lymphocytes count and 
maternal EBV serological status. ......................................................................................................................... 101 4.3.4.1. Anthony Nolan Cell Therapy centre ......................................................................................................... 101 4.3.4.2. Barcelona’s CBB. ................................................................................................................................................ 102  Relationship between TNC, CD34+ cells, mononuclear cell and lymphocytes count and 
maternal Toxoplasma gondii serological status. ........................................................................................... 103 4.3.5.1. Anthony Nolan Cell Therapy centre ......................................................................................................... 103 4.3.5.2. Barcelona’s CBB. ................................................................................................................................................ 104  DISCUSSION .......................................................................................................................................................... 105 
CHAPTER 5. MATERIALS AND METHODS ................................................................................................ 109  INTRODUCTION .................................................................................................................................................... 109  STUDY POPULATION ........................................................................................................................................... 109  DATA COLLECTION .............................................................................................................................................. 110  STUDY END-POINTS AND STATISTICAL ANALYSIS .......................................................................................... 110 
CHAPTER 6. IMPACT OF MATERNAL CMV SEROLOGICAL STATUS ON UCBT OUTCOME IN 
RECIPIENTS WITH ACUTE LEUKAEMIA ..................................................................................................... 115  INTRODUCTION .................................................................................................................................................... 115  STUDY POPULATION ........................................................................................................................................... 118  MATERIALS AND METHODS ............................................................................................................................... 118 
Table of Contents 
 8 
 RESULTS ............................................................................................................................................................... 119  Patients, disease and graft characteristics ..................................................................................... 119  Neutrophil engraftment.......................................................................................................................... 121  Acute and chronic Graft-versus-Host Disease (GvHD) ................................................................ 125  Relapse ........................................................................................................................................................... 127  Non-relapse mortality ............................................................................................................................. 130  Overall survival and disease-free free survival. ............................................................................. 135  DISCUSSION .......................................................................................................................................................... 145 
CHAPTER 7. CONCLUSIONS ........................................................................................................................... 159  SUMMARY ............................................................................................................................................................. 159  CHALLENGES ........................................................................................................................................................ 162  FUTURE PROJECTS .............................................................................................................................................. 163  Immunophenotyping of cord blood units collected from CMV seropositive mothers ..... 163  A study of the influence of previous donor pregnancies on the outcome of unrelated 
cord blood transplants for malignant disorders. ............................................................................................ 164  CONCLUSION ........................................................................................................................................................ 165 
REFERENCES ........................................................................................................................................................ 167 
APPENDIX – SUPPLEMENTAL TABLES AND FIGURES ........................................................................... 181 
  
Acknowledgements 
 9 
Acknowledgements 
I would like to thank the following for their assistance with writing this thesis: 
 
Professor Alejandro Madrigal, who has been an inspiring supervisor and a 
patient, warm and generous mentor during my stay at Anthony Nolan.  
 
Professor Paul Veys, under whose tutelage at BMT department in GOSH, I 
had fantastic time learning and practicing my trade. 
 
Professor Elaine Gluckman, expiring and amazing EUROCORD director, who 
gave me an opportunity to work with the EUROCORD staff on the project that 
is reflected in my thesis. 
 
Prof Vanderson Rocha, who supported my analysis work and helped me 
complete it. 
 
Dr Sergio Querol, for reviewing the data that I collected for my research and 
the invaluable advice that he provided. 
 
Dr Richard Szydlo, who has helped me on multiple occasions with statistical 
input and valuable advice. 
 
Dr Robert Danby, who has helped me on multiple occasions with statistical 
input. 
Acknowledgements 
 10 
 
Dr Chloe Anthias, who has supported and provided invaluable feedback on 
this work throughout the last two years, and who has generously supported 
my attendance at numerous conferences and meetings. 
 
Professor Steven GE Marsh and Kathy Latham, who kindly gave critical 
feedback on the chapter relating to HLA. 
 
Dr Irina Evseeva, who provided me with her enormous knowledge on HLA 
during my whole stay at Anthony Nolan. 
 
Dr Susana Gomez, former director of the CTC, who has been inspiring, 
enthusiastic and utterly supporting leader for me. 
 
Mar Sanchez Martinez, for her efficient and professional rendering of data for 
my research. 
 
Henny Braund Chief Executive of Anthony Nolan, for employing me. 
 
Daniel Gibson and other members of the Cell Therapy Centre. 
 
Helen Ogilvie, for reviewing my thesis and offering her advice. 
 
Others at Anthony Nolan including Katherine Aitchinson and Laila Ramzi. 
 
Acknowledgements 
 11 
Staff at UCL and Eurocord who have helped in various ways and made the 
completion of this work possible.  
  
Manuscripts in Preparation 
 12 
Manuscripts in Preparation 
 
 
 
Nikolajeva O. et al.  Delivery mode influence on the volume and total 
nucleated cell count of the collected umbilical cord blood unit.  
 
Nikolajeva O. et al.  Maternal CMV status does not have an impact on UCBT 
outcomes for patients with acute leukaemia.   
  
Peer-Reviewed Presentations 
 13 
Peer-Reviewed Presentations 
 
 
Poster sessions 
 
 
September 2015,  British Society of Histocompatibility Annual Meeting 
Nikolajeva O. et al. Level of patient -umbilical cord blood unit HLA matching 
in cord blood haematopoietic stem cell transplantation.  
 
 April 2016, European Bone Marrow Transplantation (EBMT) Annual Meeting 
Nikolajeva O. et al. Patient-umbilical cord blood four loci high resolution 
matching may significantly change cord blood unit selection.  
 
 
  
List of Figures 
 14 
List of Figures 
Figure 1-1: The number of banked Cord Blood Units Worldwide (“WMDA-
Home”) ..................................................................................................... 36 
Figure 1-2: Number of UCBT in adults per year reported to Eurocord (Annalisa 
Ruggeri, 2016) .......................................................................................... 40 
Figure 1-3: IPA and NIMA in UCB (Milano, Lee Nelson, & Delaney, 2013) ...... 48 
Figure 1-4 : Diagram of the study on the incidence of CMV infection post UCBT
 ................................................................................................................. 54 
Figure 2-1 : Clinical conversion rates with breakdown of collection type .......... 73 
Figure 3-1: Distribution of low/intermediate level umbilical cord blood unit-
recipient HLA match ................................................................................. 83 
Figure 3-2: Comparison of patient/UCB 4-loci allelic level matching and “classic” 
level of matching ....................................................................................... 86 
Figure 4-1: CMV-specific CD8+ T-cells phenotypes. La Rosa, C., & Diamond, 
D. J. (2012) ............................................................................................... 91 
Figure 4-2 : Study groups: schematic representation ....................................... 95 
Figure 4-3 : Frequency of maternal positive serologic status for CMV, EBV and 
Toxoplasma gondii in both CBBs.............................................................. 98 
Figure 4-4: Association between maternal anti-CMV IgG positivity and UCBs 
TNC and lymphocyte count .................................................................... 100 
Figure 4-5 : Association between maternal anti-CMV IgG positivity and UCBs 
TNC and lymphocyte count .................................................................... 101 
Figure 4-6: Association between maternal anti-EBV IgG positivity and 
lymphocyte and mononuclear cell count ................................................. 103 
List of Figures 
 15 
Figure 6-1: Probability of neutrophil engraftment at Day 60. (A): all patients. (B): 
effect of collected TNC dose. (C): effect of collected CD34+ cell dose. .. 125 
Figure 6-2: Cumulative incidence of 5-y relapse after unrelated UCBT for acute 
leukaemia. (A): for all patients. (B): effect of disease stage before UCBT. 
(C): effect of conditioning regimen. (D): effect of serotherapy (ATG). ..... 129 
Figure 6-3: Cumulative incidence of 5-y NRM after unrelated UCBT for acute 
leukaemia. (A): for all patients. (B):  effect of maternal previous 
pregnancies. (C):: effect of number of maternal prior pregnancies. ........ 134 
Figure 6-4. Influence of maternal numbers of previous pregnancies to 5-year 
OS. ......................................................................................................... 137 
Figure 6-5: Influence of maternal CMV status on 5-year OS. ......................... 138 
Figure 6-6: The probability of 5-year DFS according to disease stage ........... 139 
Figure 6-7. Influence of maternal previous pregnancies to 5-year DFS. ......... 141 
Figure 6-8: Influence of maternal number of previous pregnancies to 5-year 
DFS. ....................................................................................................... 142 
 
Figure S- 1: Study Proposal of Examining the Association between Maternal 
CMV Serostatus and UCB Cell Count ….……………………………..181 
 
Figure S- 2:  Study Proposal for the Project on Donor Recipient Allele-level 
HLA Matching of Unrelated UCB …….….……………………………..184 
 
Figure S- 3: Study Proposal for the Eurocord Study …..…………………...186 
 
Figure S- 4: Letter sent to CBB giving synopsis of the study and requesting 
approval …..………………….............................................................191 
   
  
Table of Tables 
 16 
Table of Tables  
Table 1-1: Results of comparative studies on BMT, PBSCT and UCBT in adults 
and children .............................................................................................. 30 
Table 1-2 : Advantages and limitations of umbilical cord blood unit in comparison 
with bone marrow or peripheral blood stem cells...................................... 33 
Table 1-3 : Overview of the studies that evaluated influence of TNC dose on 
UCBT outcomes after single UCB infusion ............................................... 40 
Table 1-4 : Overview of the studies exploring UCB expansion ......................... 43 
Table 2-1: Maternal and obstetric factors influence on the quality of UCB. ...... 68 
Table 2-2 : Collected UCBs parameters (volume and TNC) ............................. 72 
Table 3-1 : Patients Characteristics .................................................................. 82 
Table 4-1 : Summary of UCBs cell count .......................................................... 99 
Table 4-2 : Association between maternal anti-EBV IgG positive AB and UCBs 
cell content ............................................................................................. 102 
Table 4-3: Association between maternal anti-EBV IgG positive AB and UCBs 
cell content ............................................................................................. 103 
Table 4-4: Association between maternal anti-Toxoplasma gondii IgG positive 
AB and UCBs cell content ...................................................................... 104 
Table 5-1: Definitions of Outcomes ................................................................. 111 
Table 6-1: Characteristics of 1177 study patients and UCB grafts .................. 120 
Table 6-2: Univariate analysis of neutrophil engraftment for 1177 patients with 
Acute Leukaemia. ................................................................................... 122 
Table 6-3: Factors associated with Grade II-IV acute GvHD in univariate and 
multivariate analysis. .............................................................................. 126 
Table of Tables 
 17 
Table 6-4: Univariate analysis of main factors associated with 5-year NRM ... 130 
Table 6-5: Univariate analysis of factors associated with 5-year OS after UCBT 
for 1177 patients with Acute Leukaemia. ................................................ 135 
Table 6-6: Univariate analyses of 5-year DFS after UCBT for 1177 patients with 
Acute Leukaemia .................................................................................... 140 
Table 6-7: Multivariate analysis of risk factors for each main outcome after UCBT 
for 1177 children and adults with AL. ...................................................... 143 
  
Table S-1: Example of a Spreadsheet used for the Study Examining the 
Association between Maternal CMV Serostatus and UCB Cell Count ...183 
 
Table S-2: Example of a Spreadsheet used for the Study on Donor Recipient 
Allele-level HLA Matching of Unrelated UCB ……………..……………...185 
 
Table S-3: Example of a Spreadsheet used for the Collection of Information on 
UCBs from CBBs participating in the Eurocord study …..……………...193 
 
Table S-4: Example of a Spreadsheet on Patients, Graft and Transplant 
Characteristics and UCBT Outcome Received from the Eurocord 
Electronic Database – Part 1…………………………..…..……………...194 
 
Table S-5: Example of a Spreadsheet on Patients, Graft and Transplant 
Characteristics and UCBT Outcome Received from the Eurocord 
Electronic Database – Part 2…………………………..…..……………...195 
 
Table S-6: Example of a Spreadsheet on Patients, Graft and Transplant 
Characteristics and UCBT Outcome Received from the Eurocord 
Electronic Database – Part 3…………………………..…..……………...196 
 
 
 
  
Glossary 
 18 
Glossary 
Term Definition 
 
 
Allele 
 
One of a number of different forms of a particular 
genetic locus. The HLA genes together have 
several thousand different alleles. 
Allo-HSCT See 'Allogeneic hematopoietic stem cell 
transplant (allo-HSCT). 
Allogeneic 
hematopoietic stem 
cell transplant (allo-
HSCT) 
In humans, allo-HSCT refers to the use of 
donated HSC from another individual for 
transplantation. Examples of HSC sources for 
allo-HSCT include: syngeneic (twin) donor, HLA-
identical sibling donor, haplo-identical related 
donor, unrelated adult donor, and cord blood unit.  
Antigen A substance that is bound by a particular 
antibody. In terms of HLA, and antigen is the 
protein product of a particular HLA gene to which 
a specific antibody binds. 
BMDW Bone Marrow Donors Worldwide. A global 
collaborative collation system designed to provide 
a searchable interface for unrelated donors listed 
by participating registries.  
BSBMT The British Society of Blood and Marrow 
Transplantation 
CBU See 'Cord Blood Unit' 
CBWG 
 
 
Cord Blood Working Group was established in 
2008 to provide UK transplant centers with recent 
recommendations on selection of cord blood units 
for the HSCT. 
Glossary 
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CFU 
 
Colony-forming unit.  
Chimerism In allo-HSCT, chimerism refers to the relative 
proportion of donor and recipient cells (of 
hematopoietic origin) found in the recipient blood 
or bone marrow following transplant. Chimerism 
studies are particularly necessary following 
reduced-intensity conditioned allo-HSCT. 
CMV See 'Cytomegalovirus' 
Collection center A medical center equipped to carry out collection 
of hematopoietic stem cells, either by peripheral 
blood stem cell apheresis or bone marrow 
harvest. Many will also undertake medical 
assessment of donors to establish fitness to 
donate.  
Conditioning A chemotherapy regimen with or without 
radiotherapy or immunotherapy designed to 
prepare the recipient bone marrow and immune 
system for receipt of donor HSC. Regimens may 
be myeloablative (full-intensity) or non-
myeloablative (reduced-intensity). 
Cord blood unit A donation of blood, rich in HSC, derived from the 
umbilical cord and placenta of a newborn infant. 
Cord blood units are generally cryopreserved and 
may be used for allo-HSCT if found to be 
appropriately matched to a patient. 
Cytomegalovirus 
(CMV) 
A herpes virus prevalent in most populations, 
which generally causes a self-limiting illness in 
affected immunocompetent individuals. The virus 
persists asymptomatically for life. However, in 
those with a compromised immune system, 
particularly following allo-HSCT, the virus may 
Glossary 
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reactivate and cause severe morbidity and 
mortality. 
Donor Any individual, living or dead, providing solid 
organs, tissues or cells for the purposes of 
transplantation or transfusion. For the purposes of 
this thesis, a donor is an individual providing 
hematopoietic stem cells (either their own or cord 
blood HSC from a newborn infant) or lymphocytes 
for the allogeneic transplantation. 
DFS Disease free survival is defined as time from 
transplant to relapse, death or last follow-up 
EBMT 
 
The European Group for Blood and Marrow 
Transplantation 
Ebstein-Barr Virus  
(EBV)  
 
A herpes virus and one of the most common 
viruses in humans. The virus causes infectious 
mononucleosis. In most cases persists 
asymptomatic for life. In immunocompromised 
people is associated with post-transplant 
lymphoprolipherative disease.  
 
Engraftment 
 
Evidence of hematopoiesis erasing form the 
donors HSC. Usually considered when absolute 
neutrophil count reaches >0.5x10^9/L for 2 
consecutive days and platelets count >20x10^9/L 
without platelets transfusion.   
Graft-versus-
leukemia effect 
 
A desired effect of allo-HSCT, describing “the 
immunological activity of the engrafted donor 
immune system against malignant recipient 
cells”.  
G-CSF Granulocyte colony-stimulating factor 
Glossary 
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Hematopoietic 
Stem cell (HSC) 
A multipotent cell capable of self-replication and 
differentiation into cells of myeloid, erythroid or 
lymphoid lineage. 
Haploidentical A related donor who, whilst not being fully HLA-
matched, is found to share one HLA haplotype in 
common with the potential recipient (and 
therefore is at least 5/10 matched). 
Haplotype In the context of HLA, the haplotype refers to a 
particular combination of HLA alleles encoded by 
one copy of chromosome 6. Thus any normal 
individual carrying two copies of chromosome 6 
will have two HLA haplotypes. Haplotypes are 
usually inherited intact, so individuals will inherit 
one haplotype from each parent.  
Histocompatible The property of having a sufficiently similar set of 
HLA alleles to enable allogeneic transplantation. 
HLA Initially 'Human Locus-A, now usually an 
abbreviation of 'Human Leukocyte Antigen', HLA 
refers to the antigen system encoded by the Major 
Histocompatibility Complex that forms the 
cornerstone of the ability of the immune system to 
differentiate between 'self' and 'non-self'.  
HSCT Haematopoietic stem cell transplantation, which 
may be autologous (self-transplant), or allogeneic 
(donor, allo-HSCT). 
HTA See 'Human Tissue Authority' 
Human Tissue 
Authority (HTA) 
The UK legislative authority responsible for 
regulation pertaining to the handling of human 
cells, tissues and organs.  
 
NIMA 
 
Non-inherited maternal antigens 
 
 
IPA  
 
Inherited paternal antigens  
Glossary 
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NRM Non-relapse mortality is defined as death without 
prior relapse  
 
JACIE 
 
 
 
 
 
Joint Accreditation Committee ISCT-EBMT. A 
collaborative global organization providing 
standards, inspection and accreditation for 
organizations involved in the collection, 
processing and transplantation of hematopoietic 
stem cells and related products.  
 
KIR  
 
Killer-immunoglobulin receptor  
 
Major 
histocompatibility 
complex (MHC) 
 
That region of chromosome 6 that encodes the 
chief determinants of histocompatibility and in 
particular the HLA molecules. 
 
 
MiHA 
 
Minor histocompatibility complex 
MHC See ‘Major histocompatibility complex’ 
NK Natural killer cells. Critical cells in innate immunity 
with cytotoxic potency to cancer and viral cells.  
OS Overall survival  
Phenotype In the context of HLA, the phenotype refers to a 
particular combination of HLA alleles in an 
individual. When matching at a 10/10 level, the 
phenotype describes the alleles present for each 
of two copies of HLA-A, -B, -C, -DRB1 and -
DQB1.  
Serology In histocompatibility, the diagnostic investigation 
of antigens encoded by the MHC using antibody-
based assays. However, serology also 
encompasses many other tests, such as 
Glossary 
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identification of antibodies indicating exposure to 
infectious diseases.  
SaBTO Advisory committee on the safety of blood, tissue 
and organs  
TC See 'Transplant center' 
TGS 
 
 
Third-generation sequencing is a Pacific 
Biosciences SMRT (single-molecule real-time) 
DNA sequencing method. 
TNC Total nucleated cell count. It’s a measure of the 
cell count reported after cord blood processing. 
TNC count is automated and measured by flow 
cytometer.  
Transplant centre 
 
 
 
A unit (usually within a hospital) capable of 
carrying out hematopoietic stem cell 
transplantation. For the purposes of this thesis, 
these centers carry out allogeneic HSCT.  
 
 
Toxoplasma gondii  
It’s a parasite, which cause disease called 
Toxoplasmosis. It usually causes no symptoms in 
adults. In immunocompromised people disease 
might cause life threatening and debilitating 
organs damage.  
Typing 
 
 
In transplantation, typing is the process of 
establishing the HLA phenotype, and may include 
other non-HLA transplant determinants, such as 
KIR, NOD2, and CCR5.  
 
UCBT 
 
Unrelated cord blood transplant  
WMDA The World Marrow Donor Association. The 
WMDA was founded in order to provide a global 
forum for all matters relating to donors of 
hematopoietic stem cells.  
Glossary 
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Work-up The process of preparing an unrelated adult 
donor for donation, generally involving logistic 
arrangements such as travel and 
accommodation, as well as a thorough medical 
examination, hematological and biochemical 
tests and infectious disease marker testing, in 
order to confirm the donor's fitness to donate.  
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Thesis overview 
The primary aim of my thesis was to provide contemporary data on new factors 
that can influence the choice of unrelated umbilical cord blood units for 
transplantation. The results will help towards providing more targeted strategies 
for umbilical cord blood unit collection and selection, and I believe such 
strategies will improve overall transplant outcomes.  
 
I started my research with a review of the literature, which is outlined in Chapter 
1. This chapter explores the historical context of unrelated umbilical cord blood 
donation and gives an insight into factors that can influence umbilical cord blood 
units transplant outcomes.  
 
The first study of this thesis, a prospective analysis of 2,411 UCBs stored at 
Anthony Nolan Cell Therapy Centre (AN CTC) between August 2012 and 
November 2013, explores the influence of delivery mode on UCB total 
nucleated cell dose (TNC) and volume.  
 
In the second study of my thesis I focused on an evaluation of the extent of HLA 
mismatch at high resolution (for HLA-A, -B, -C and -DRB1 genes) between 208 
UCB-recipient pairs for whom work-up for UCBT was requested via Anthony 
Nolan between 1st January 2013 and 31st December 2015 from 12 UK 
Transplant Centres. My study revealed that, some units showed substantial 
HLA disparity with the recipient when typed to high resolution for HLA-A, -B, -C 
Thesis overview 
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and –DRB1 genes, with units as low as 3/8 HLA match being used for 
transplant. The transplant centres should be aware of the possibility of choosing 
“sub-optimal “cord blood units for transplantation when applying HLA matching 
at the “classical level” (i.e. low/intermediate level for HLA Class I genes (-A and-
B) and high resolution for HLA Class II genes (mainly-DRB1)). This is 
particularly important when selecting the cord blood unit for a single unit UCBT.  
 
In the third study of my thesis, I designed a retrospective study which 
explored a possible correlation between the cell counts of 14,408 UCBs 
(4,654 UCBs from AN CTC and 9,754 UCBs from Barcelona’s Cord Blood 
Bank (CBB)) and their donors history of exposure or non-exposure to 
infections (in particular CMV, Epstein-Barr Virus (EBV) and Toxoplasma 
gondii). The study included cord blood units stored by both banks between 
1st October 2008 and 30th September 2014.  
 
I subsequently designed the prospective study in collaboration with Eurocord, 
as described in Chapters 5 and 6. As part of the preparation for my prospective 
study and to ensure the adequate capture of my outcome data, I spent one 
week in Eurocord’s main office in Paris, working closely with staff members.  
 
This study is the core of my thesis and assesses the influence of maternal CMV 
serological status and previous pregnancies on unrelated cord blood units 
transplant (UCBT) outcomes for recipients with acute leukaemia between 1st 
January 2000 and 31st December 2012.  Chapter 5 explains the methodology 
behind the study described in Chapters 6. Chapter 6 provides an analysis of the 
Thesis overview 
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impact of maternal CMV serological status and provides an analysis of the 
influence of maternal previous pregnancy on single-unit UCBT on the single-
unit UCBT outcomes for 1177 paediatric and adult patients with acute 
leukaemia.  
 
Chapter 7 summarises the findings of this thesis and describes some of the 
challenges encountered, and future plans to expand on this work.  
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Chapter 1. Introduction and 
literature review 
 History and Context 
 Umbilical cord blood (UCB) as a source of stem cell 
procurement 
Barnes and Loutit proposed the idea of the potential curative effect of bone 
marrow transplantation for malignant diseases back in the late 1950’s. They had 
observed an “anti-leukaemic effect of transplanted spleen cells in experimental 
murine models” (On & Block, 1956). In 1959, the first human bone marrow 
transplant proved the possibility of haematological reconstitution in lethally 
irradiated patients with acute leukaemia. Early on, results were not promising, 
mainly due to the high death rate of graft-versus-host disease (GvHD), graft 
failure or disease relapse (Mathe, Amiel, Schwarzenberg, Cattan, & Schneider, 
1963), (Mathé, Amiel, Schwarzenberg, Catran, & Schneider, 1965). The major 
breakthrough in the success of human bone marrow transplantation came as a 
result of the pioneering work of both Dausset and Van Rood, who discovered 
the HLA system. This opened up a new era in the understanding of 
haematopoietic stem cell (HSC) immunogenicity.  
 
For a long time, only two major HSC sources were used for transplantation – 
bone marrow (BM) and granulocyte colony stimulating factor (G-CSF) mobilised 
peripheral blood stem cells (PBSC). In 1982, Hal Broxmeyer suggested using 
umbilical cord blood as a source of allo-HSC graft. E. Gluckman’s group brought 
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it to clinical practise in 1988 by successfully infusing a sibling’s UCB into a child 
with Fanconi anaemia (Ballen, Gluckman, & Broxmeyer, 2013). This event 
marked the beginning of a new field in allo-HSCT. Since then, there has been 
a significant increase in understanding of UCB immunology, collection, 
processing and cryopreservation, thawing and shipping around the world 
(Bradley & Cairo, 2005).  
 
Large numbers of transplant centres (TCs) have reported successful related 
and unrelated umbilical cord blood unit transplants (UCBTs) with transplant 
outcomes comparable to those using other HSC sources. Grewal at al., 
performed a matched–pair analysis comparing the outcomes of (predominantly 
paediatric) recipients having both malignant and non-malignant disorders and 
0 to 3 HLA-mismatched UCB with HLA-A, -B and –DRB1 matched BM) (Grewal 
et al., 2003). The study showed comparable results in acute and chronic GvHD 
rates and overall survival OS.  A similar study was performed in Europe on 541 
children with acute leukaemia. Patients received either unrelated donor BM or 
T-cell depleted UCBT. The study showed comparable results for 2-year OS rate 
(49% and 41% respectively) and event-free survival rate (43% and 37%) in the 
unrelated donor BM and UCB recipients (Rocha et al., 2001). Results of other 
studies comparing umbilical cord blood to other graft sources in adults and 
children are summarised in Table 1-1. 
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Table 1-1: Results of comparative studies on BMT, PBSCT and UCBT in adults and children 
Study 
Population 
(N) 
Graft 
Sourc
e (N) 
Condit- 
ioning 
Results Referenc
e 
Adults with 
haematolo
gical 
malignanci
es (113) 
UD 
(45) 
UCB 
(68) 
MAC -Delayed 
neutrophil and 
platelets 
engraftment 
-Decreased TRM 
and DFS 
 
(Takahas
hi et al., 
2004) 
Adult with 
haematolo
gical 
malignanci
es (1280) 
UD 
(1132) 
UCB 
(9148) 
MAC -Delayed 
neutrophil 
engraftment 
(versus BM) 
-Increased NRM 
-Comparable OS 
and DFS (vs BM) 
(M. Eapen 
et al., 
2010) 
Children 
with HS 
(258) 
MSD 
(37) 
UD 
(105) 
UCB 
(116) 
MAC -Higher enzyme 
levels and full 
donor chimerism 
(versus MSD) 
-Comparable OS 
(with MSD) n 
 
(Boelens 
et al., 
2010) 
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Children 
with 
malignant 
and non-
malignant 
conditions 
(1180) 
MSD 
(469) 
UCB 
(711) 
 
MAC 
(55%) 
RIC 
 (45%) 
Decreased cGvHD (Brunstein 
et al., 
2010) 
Adults with 
haematolo
gical 
malignanci
es (285) 
dUCB 
(64) 
UD 
(221) 
RIC -Decreased 
cGvHD 
-Higher NRM 
-Comparable OS 
and DFS 
(Chen et 
al., 2012) 
Adults with 
haematolo
gical 
malignanci
es (556) 
UCB 
(112) 
UD 
(334) 
MAC -Pre-transplant 
MRD does not 
have influence on 
RR after UCBT 
-Lower RR 
Milano et 
al, ASH 
2014 
Infants with 
SCID (240) 
UCB 
(43) 
UD 
(197) 
RIC(35) 
MAC(46) 
None 
(120) 
IS (39) 
Decreased OS (Pai et al., 
2014) 
 
 
Adults with 
haematolo
gical 
dUCB 
(128) 
MAC Lower RR (Lazaryan 
et al., 
2015) 
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malignanci
es (536)  
MSD 
(204) 
UD 
(204) 
BMT: bone marrow transplantation; PBSCT: peripheral blood stem cell transplantation; 
UCBT; umbilical cord blood transplantation; MAC: 32yeloablative conditioning regimen; 
RIC: reduced intensity conditioning regimen; MSD: matched sibling donor; UCB: umbilical 
cord blood; dUCB: double umbilical cord blood; aGvHD: acute graft-versus-host disease; 
cGvHD: chronic graft-versus-host disease; UD: unrelated donor; NRM: non-relapse 
mortality; OS: overall survival; DFS: disease- free survival; SCID: severe combined 
immunodeficiency; IS: immunosuppression; HS: Hurler syndrome; RR: relapse rate 
 
Compared to BM and PBSC, UCB offers several advantages over adult HSC 
sources. These include: no risk to the donor, no donor attrition, immediate 
availability of fully tested and HLA-typed UCB in a frozen state when HSCT is 
required, lower risk of transmitting infections and the possibility of 
cryopreserved storage for more than 20 years with efficient recovery of HSC 
(Gluckman & Rocha, 2006 and ),(Stanevsky, Goldstein, & Nagler, 2009) .  
 
Also, UCB banks have a greater proportion of rare HLA phenotypes, which is 
extremely relevant for ethnic minority patients in need of HSCT (Boo, Ballen, & 
Maiers, 2011). Last but not the least; high quality UCB decreases the probability 
of chronic GvHD in comparison with other graft sources (Boelens et al., 2010), 
(Y. Cohen & Nagler, 2004). 
 
“Development of moderate to severe acute or chronic GvHD is associated with 
diminished quality of life, as well as decreased overall survival” (Nash et al., 
1992). “Grades II to IV acute GvHD is reported in 43% to 70% of matched adult 
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unrelated donor (MUD) BM transplants, and in 63% to 95% of single HLA-
antigen mismatched adult unrelated donor transplants. Chronic GvHD affects 
more than 55% of MUD transplant recipients and as many as 80% of those 
receiving single HLA antigen mismatched unrelated donor grafts” (Martin et al., 
2006). UCBT studies have reported incidences of 33% to 44% grades II to IV 
and 11% to 22% grades III to IV acute GvHD respectively, and a 0% to 25% 
incidence of chronic GvHD (Rubinstein et al., 1998), (Wagner et al., 2002). 
Table 1-2 lists main advantages and limitations of umbilical cord blood unit in 
comparison with other stem cell sources.  
 
Table 1-2 : Advantages and limitations of umbilical cord blood unit in comparison with bone 
marrow or peripheral blood stem cells 
Advantages Limitations 
Prompt availability Limited cell dose per recipient’s 
weight 
No risk to the donor Delay in neutrophil and platelets 
engraftment 
No donor attrition No chance for the second 
donation/donor lymphocyte 
infusion 
No risk of donor attrition Lack of transfer of T and B memory 
cells 
Reduced risk of chronic graft-
versus-host disease 
Theoretically increased risk of 
transferring hereditary disorders 
More HLA-mismatch tolerance is 
observed  
Slower immune reconstitution if 
serotherapy given 
Low risk of viral contamination   
Better representation of ethnic 
minorities  
 
Long-term cryopreservation   
Introduction and literature review 
 34 
Easy to schedule or re-schedule 
transplantation  
 
 
 
Due to the development of safer protocols for T-cell replete haploidentical 
transplantation, the use of family mismatched donors has increased over the 
recent years. This approach seems to be very attractive to the clinicians, 
because it is relatively easy and quick to schedule, almost every patient has a 
suitable donor and the financial burden to the transplant centre is moderate. 
Recently, the EBMT and Eurocord group compared outcomes of single or 
double UCBT with T-cell replete haploidentical transplantation in patients 
receiving either 34yeloablative (MAC) or reduced intensity (RIC) regimen for 
patients with haematological malignancies (A. Ruggeri et al., 2015). No 
statistically significant difference was found between the two graft sources for 
leukaemia-free survival, overall survival, relapse incidence or transplant related 
mortality. However, UCBT was associated with delayed engraftment but a lower 
incidence of chronic GvHD in the multivariate analysis.  
 
One of the major limitations of UCBT which is mentioned above is “delayed 
engraftment and slower immune reconstitution owing to the qualitative and 
quantitative characteristics of UCB, such as naȉvity of cord blood T- cells and a 
fixed cell count” (L. Tucunduva et al., 2014), (Danby & Rocha, 2014). The 
influence of UCB quality parameters on UCBT outcome will be outlined in the 
following sections of this chapter.  
  
Introduction and literature review 
 35 
 UCB Banking  
When bone marrow transplantation became an effective and feasible curative 
approach for many patients, the need for unrelated bone marrow donor 
registries was identified too, because not everyone could find a HLA-matched 
sibling or other family donor. The first unrelated bone marrow donor registry 
was established in London in 1974, by Shirley Nolan, whose son Anthony 
unfortunately passed away, without the chance of being cured, from 
immunodeficiency. Since that time, the number of registries has continued to 
grow and currently over 25 million unrelated donors are registered worldwide 
(“WMDA - Home,”).  
 
The first cord blood banks (CBB) for unrelated and related units were 
established in 1993 in New York, Milan and Dusseldorf (Bradley & Cairo, 2005). 
The first CBB in the UK was established in 1996 by National Health Services 
Blood and Transplant (NHSBT). Although the management of available CBB 
varies between countries, certain rules for the quality of the system and product 
apply.  Organisations such as The American Association of Blood Banks, 
European Blood and Marrow Transplantation Society, Eurocord, NETCORD 
and FACT are in place to ensure that the quality and standards for minimal 
volumes collected, sterile processing, red blood cell depletion, volume 
reduction, measurement of CD34+ count and other cell subsets and cell 
recovery after processing are established (EBMT-ESH handbook 6th Edition, 
2012), (Bradley & Cairo, 2005). According to the Bone Marrow Donors 
Worldwide (BMDW) database, 53 cord blood registries from 36 countries with 
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684,896 CBUs are registered (as of March 2016)(“BMDW: Home,”)  (see Figure 
1-1). 
 
 
 
Figure 1-1: The number of banked Cord Blood Units Worldwide (“WMDA-Home”) 
 
 
“Establishment of CBBs has resulted in reduced search times for unrelated cord 
blood donors compared to adult donor HSC sources” (Mayani, 2011). 
In the modern era, cost management plays an increasing role in determining 
UCB selection and use. Therefore, it is of paramount importance to understand 
when and how UCBT can be utilised in the most beneficial way for both the 
recipient and TC. Characteristics of UCB that influence the banking and unit 
selection for HSCT will be outlined in the following sections of this chapter. 
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 Factors known to influence Umbilical Cord Blood 
Transplant Outcomes 
 Introduction 
The current selection strategies for the optimal allo-HSCT graft include 
considerations such as donor age, preferred method of donation, gender, 
infectious markers (in particular CMV) and HLA-type. Recipient considerations 
include: disease type (malignant versus non-malignant), age, concomitant 
morbidities and characteristics and type of the conditioning regimen (reduced 
intensity versus 37 yeloablative) used in preparation for the transplant. Of 
primary importance is sufficient HLA matching between donor and recipient to 
ensure engraftment and acceptable rates of GvHD. Another important factor is 
the donor and recipient CMV status, which plays a crucial role in HSCT outcome 
(Green et al., 2013a), (Schmidt-Hieber, 2013). Other factors that may be 
considered are recipient-graft gender and ABO mismatch. Sometimes, length 
of time to transplant can be crucial for successful transplant outcome. The rapid 
donor identification and imminent availability of UCB grafts gives patients with 
high-risk diseases a better chance of success.   
 
 As mentioned previously, “UCBT can be associated with delayed engraftment, 
poor immune reconstitution and higher rates of acquired infections compared 
to other HSC sources” (Danby & Rocha, 2014), (Gluckman et al., 2004). Three 
major UCB related factors that have been associated with transplant outcome 
are: total nucleated cell count (TNC), CD34+ dose per recipient’s weight and 
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level of HLA-matching. These factors are interconnected and will be described 
below.  
 
 TNC and UCB Selection  
“While UCB contains a higher concentration of HSC than adult peripheral blood, 
each unit contains a one or two log lower TNC dose in relation to recipients size 
compared to BM and PBSC” (Danby & Rocha, 2014). On average, a UCB unit 
contains 0.5-3x10^9 TNC. The time taken to achieve haematopoietic recovery 
post-transplant, identified by recovery of donor-derived neutrophil and platelet 
count, directly depends on TNC infused.  Median time to neutrophil engraftment 
(count >0.5x10^9/L for 2 consecutive days) post single-unit UCBT is as long as 
28 days and 90 days for platelets (count >20x10^9/L without transfusion) 
(Rubinstein et al., 1998). A Eurocord study showed that a TNC dose higher than 
3.7X10^7/kg of recipient’s weight is associated with shorter time to neutrophil 
recovery: 25 versus 35 days (Gluckman et al., 2004). In addition, several 
studies have shown that the number of TNC infused is associated with lower 
transplant related mortality (TRM) and better OS rates (Gluckman et al., 2004) 
(Rocha & Gluckman, 2009). There is an overall consensus that a minimal TNC 
dose of 2.5x10^7/kg of recipient’s body weight is an accepted minimum 
standard in clinical practise for optimal engraftment (V Bachanova et al., 2014).  
 
Therefore the time to haematopoietic recovery might be prolonged (Gluckman 
et al., 2004). This exposes the recipient to an increased risk of acquired 
infections. The optimum timing of measurement and actual number of TNC 
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required still remains under discussion. Most published studies report the 
impact of pre-freeze TNC dose on transplant outcome. However, one should 
be aware that after processing and thawing of UCB, up to 20% of TNC will be 
lost (Hough et al., 2015). Therefore, knowing the actual dose at infusion (post 
–thaw) becomes more important. The fixed cell count in UCB represents the 
major limiting factor, particularly for adult recipients with greater disparity of 
weight/size between UCB and patient. Therefore, for many years the 
advantages of UCBTs were only being appreciated in the paediatric population, 
where outcome was comparable to that of transplantation from adult unrelated 
donors (M E Horwitz, 2014).  
 
Relatively lower cell dose per recipient’s weight was the main obstacle for 
performing UCBT in adults. For most adult recipients, a single-unit UCBT is 
almost always insufficient to provide enough cell dose. However, recent data 
from the Eurocord registry showed that, after 2004, the number of adults 
transplanted using UCB per year has increased (Figure 1-2) to reach a peak in 
2011, with a slight drop in numbers after that time. This increase is might to be 
related to the possibility of use of double-unit cord blood transplantation(Majhail, 
Brunstein, & Wagner, 2006), demonstration that reduced intensity conditioning 
regimens are safe in the context of cord blood transplantation (Barker et al., 
2003), advances in UCBT unit selection, growing experience of transplant 
centres and improvement in supportive care (Annalisa Ruggeri, 2016).  
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Figure 1-2: Number of UCBT in adults per year reported to Eurocord (Annalisa Ruggeri, 2016) 
 
Table 1-3 provides an overview of the studies that have evaluated the impact 
of TNC dose of the single-unit infusion to UCBT outcomes in both adult and 
paediatric recipients.  
 
Table 1-3 : Overview of the studies that evaluated influence of TNC dose on UCBT outcomes 
after single UCB infusion 
Study population 
(N) 
Objectives Outcomes 
Eurocord study on 
both adults and 
paediatric recipients 
with malignant and 
non-malignant 
disorders (925) 
(Gluckman & Rocha, 
2006) 
To evaluate 
influence of cell dose 
and HLA matching 
on UCBT outcomes  
Median infused TNC 
dose of 3.7x10^7/kg 
associated with 
better platelets and 
neutrophil 
engraftment and 
overall survival  
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Paediatric recipients 
with mainly non-
malignant disorders 
(562) 
(Rubinstein et al., 
1998) 
To evaluate 
influence of cell dose 
on UCBT outcomes 
-Speed of neutrophil 
engraftment 
positively correlated 
with the leukocyte 
cell dose in the graft   
-Pre-freeze cell dose 
< 2.4x10^7/kg was 
associated with 
higher mortality rate 
Adult recipients with 
haematological 
malignancies (68)  
(Laughlin et al., 
2001)  
To evaluate the cell 
dose on UCBT 
outcomes  
Median pre-freeze 
TNC dose of 2.4 
x10^7/kg associated 
with better neutrophil 
engraftment  
Adult recipients with 
haematological 
malignancies after 
MAC (171) 
(Arcese et al., 2006) 
 
To evaluate the 
transplant outcomes  
A TNC dose > 
2.7x10^7/kg was 
associated with 
faster neutrophil 
engraftment  
Adult recipients with 
ALL after MAC (27) 
(Ooi et al., 2009) 
To evaluate 
transplant outcomes  
TNC dose was not 
associated with 
faster neutrophil 
engraftment  
Eurocord study on 
adults 925 recipients 
with malignant (925) 
and non-malignant 
(279) haematological 
disorders  
(Danby & Rocha, 
2014) 
To evaluate 
transplant outcomes 
-Pre-freeze TNC 
dose of minimum 
3x10^7/kg 
associated with 
better transplant 
outcomes for 
malignant disorders 
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- Pre-freeze TNC 
dose of minimum 
4.9x10^7/kg 
associated with 
better transplant 
outcomes for non-
malignant disorders. 
ALL: acute myeloid leukaemia; MAC: myeloablative conditioning; RIC: reduced intensity 
conditioning; TNC: total nucleated cell dose 
 
 
In order to overcome cell dose limitations for adult patients, double-unit 
infusions were suggested. Studies on HSCT with double-unit UCB showed a 
cumulative incidence of neutrophil recovery of 91% at a median of 21 days 
(Wagner, 2009). Both units contributed to early engraftment but only one unit 
predominated later (Barker et al., 2005). Data relating to quality characteristics 
of the dominant  unit are sparse, regarding better CD3+ cell dose (Barker et al., 
2005) or higher CD34+ cell dose  (Purtill et al., 2014). In addition to the potential 
for improved engraftment, some studies “demonstrated a decrease in relapse 
rate when two UCB units were used, possibly due to a superior graft-versus-
leukaemia (GvL) effect” (Ballen & Lazarus, 2016), (Verneris et al., 2009).  
However, a recent report has shown similar outcomes in terms of disease-free 
survival, neutrophil engraftment, transplant related mortality and incidence of 
relapse in 224 children and adolescents, recipients of either single- (n=113) or 
double-unit (n=111) UCBT for  haematological malignancies, providing that 
single UCB contains sufficient TNC dose (Wagner et al., 2014).  Similar results 
were observed in another study on 151 paediatric patients with acute 
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leukaemia, who received single – (n=74) or double-unit (n=77) UCBT (Michel 
et al., 2016). 
 
Other approaches to overcome the limitations of cell dose include  “in vivo and 
ex-vivo expansion of UCBs using growth cytokines, improving UCB homing, 
addition of third-party mesenchymal cells, intrabone injection of HSCs and co-
infusion with haploidentical T-cell depleted graft” (Delaney, Ratajczak, & 
Laughlin, 2011) (Mitchell E. Horwitz & Frassoni, 2015). Table 1-4 provides an 
overview of studies that implement ex vivo expansion of the umbilical cord blood 
unit and stem cell manipulation before transplantation. 
 
Table 1-4 : Overview of the studies exploring UCB expansion 
Study Compound Modality Clinical 
trial 
Delaney  
((Delaney et al., 
2011) 
Notch ligand Ex vivo 
expansion 
Yes  
Horwitz  
(Mitchell E. 
Horwitz & 
Frassoni, 2015) 
Nicotinamide  
(NiCord ) 
Ex vivo 
expansion 
Yes  
Peled 
(Peled et al., 
2004) 
Copper 
chelation  
Ex vivo 
expansion  
Yes  
Cutler 
(Cutler et al., 
2013) 
Prostaglandin 
E2 
Enhancing 
homing  
Yes  
Robinson 
(Robinson et al., 
2011) 
Mesenchymal 
cell co-culture 
Ex vivo 
expansion 
Yes  
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Brunstein 
(Brunstein et al., 
2013) 
Complement 
fragment 3a co-
culture  
Enhancing 
homing  
Requires 
more 
data  
Robinson 
(Robinson et al., 
2012) 
Fucosylation  Enhancing 
homing 
Yes  
Wagner  
(Wagner et al., 
2016) 
StemRegenin1 Stem cell 
expansion 
Yes  
Shpall 
(Shpall, 1999) 
Cytokine (SCF, 
TPO, Flt-3L, G-
CSF, MGDF) 
Stem cell 
expansion 
Yes  
Farag 
(Farag et al., 
2013) 
Inhibition of 
CD26/DPP-4 
Enhancing 
homing  
Yes  
 
 
“Clinical data on these techniques are already available and short-term safety 
has also been demonstrated” (Mitchell E. Horwitz & Frassoni, 2015). However, 
long-term follow up is required for confirmation of these results. “No randomised 
studies have been completed to date to demonstrate improved survival rates 
with expanded versus unexpanded cells” (Ballen & Lazarus, 2016). 
Nevertheless, these methods look like an extremely attractive approach for 
clinicians. However, because of the logistical and financial complexity 
associated with production of a patient-specific expanded UCB graft, this 
approach is not widely implemented in routine clinical practice (Mitchell E. 
Horwitz & Frassoni, 2015).  
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As selection of the optimal and appropriate UCB graft is a more complex 
process than selecting the most suitable BM or PBSC donor, the British Society 
of Bone Marrow Transplantation (BSBMT) Cord Blood working Group (CBWG) 
published UK consensus recommendations for selection of individual UCB 
grafts. According to latest guidelines published in 2015, the minimum 
recommended TNC count at freezing should be 3.0x10^7/kg of recipient’s 
weight for malignant disorders and 3.5x10^7/kg for non-malignant disorders in 
the case of single-unit UCBT. When a single unit contains an insufficient cell 
count, double-unit infusion is recommended. The recommended total TNC 
count at freezing should be > 3.5x10^7/kg, with a minimum TNC count of each 
unit being 1.5x10^7/kg (Hough et al., 2015).A combination of cell dose and 
HLA-matching, as well as recipient’s condition (malignant versus non-malignant 
disease) should also be taken into consideration. 
 
 UCB selection and CD34+ cell count 
The CD34+ cell count represents and reflects the actual content of immature 
haematopoietic progenitors in the graft. “The loss of CD34+ cells after thawing 
is less important, therefore, the number of CD34+ cells at freezing might be 
considered when selecting a UCB graft for transplant” (Rocha & Gluckman, 
2009). Some studies have revealed a “less mature phenotype of UCB CD34+ 
cells compared to adult marrow and peripheral blood grafts but with higher 
proliferative potential” (Danby & Rocha, 2014). In a series of 102 adult allo-
UCBT recipients, in 2002, Wagner et al observed a “significantly inferior speed 
and probability of engraftment with a CD34+ cell dose lower than 1.7x10^5/kg. 
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Moreover, the group showed a decreased OS rate in patients who received a 
CD34+ cell dose which was less than 1.7x10^6/kg, compared to patients who 
had received a CD34+ cell dose greater than 1.7x10^6/kg (29% versus 68% 
respectively)” (Wagner et al., 2002). In 2013, the Anthony Nolan (AN) Cell 
Therapy Centre (CTC) performed a retrospective study within WMDA members 
to evaluate the parameters considered to be most important when selecting 
UCB grafts. Both providers (CBBs) and selectors (TCs and registries) were sent 
a survey. Interestingly, out of 50 responders who submitted a completed survey, 
UCB graft selectors did not indicate that the CD34+ pre-freeze or post-thaw cell 
dose was a top requirement (personal communication with Dr S G Gomez, 
former head of AN CTC). Unfortunately, the absence of a standardised counting 
method between centres precludes CD34+ cell count from being used for 
comparative clinical studies. 
 
According to the BSBMT CBWG guidelines, the minimum recommended 
CD34+ cell dose for malignant disorders should be 1.1-1.7 x10^5/ kg of 
recipient’s weight pre-freezing and around 1.0-1.2 x10^5/kg after thawing. In 
the case of non-malignant disorders, the recommended CD34+ cell dose 
should be >1.7x10^5/kg of recipient’s weight at freezing or after thawing. In the 
case of double-unit selection, the recommended total dose at freezing or after 
thawing should be >1.8x10^5/kg (Hough et al., 2015).  
 
 
 
Introduction and literature review 
 47 
 UCB graft selection and non-inherited maternal antigens 
(NIMA) and inherited paternal antigens (IPA)  
Recent studies have indicated that alloreactivity in transplantation involves not 
only direct donor-recipient reactivity but also maternal and paternal reactivity.  
 
During pregnancy, bi-directional transplacental cell trafficking results in UCB 
containing cells derived from both the foetus and the mother. Maternal cells are 
sensitised against HLA antigens that the fetus has inherited from the father 
(IPA) and cord blood cells are sensitised to those not inherited from mother 
(NIMA) (Van Rood et al., 2012). Because of the existence of fetomaternal 
tolerance, non-inherited paternal antigens are more immunogenic then NIMA 
(Hirayama, Azuma, & Komada, 2012). Anti-IPA immunity in the mother can 
persist for many decades after delivery and passes to other siblings during 
subsequent pregnancies (Dierselhuis et al., 2012). Please see Figure 1-3 for 
schematic explanation of the NIMA and IPA immunogenicity. 
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Figure 1-3: IPA and NIMA in UCB (Milano, Lee Nelson, & Delaney, 2013) 
 
 
 
(a) “HLA typing is used as an example to illustrate the IPA in cord blood 
transplantation (CBT). Anti-relapse benefit is predicted in the example illustrated because 
the mother’s T cells would be sensitized to the HLA-B antigen encoded by HLA-B*15 (IPA) 
and the cord blood (CB) recipient has HLA-B*15 (shared IPA target). Patient and donor 
CB unit match for B antigens encoded by HLA-B*08 and HLA-B*15. Based on the HLA 
typing of the CB and its mother, HLA-B*15 is the IPA in the CB. In this case, the patient 
also has HLA-B*15, so IPA-sensitized maternal cells have a target.” 
(b) “Decreased transplant related mortality was reported for patients receiving one or 
two antigen-mismatched CBT when the patient had the same HLA antigen as the CB’s 
NIMA. Patient and donor CB unit are mismatched at the HLA-B locus: patient has HLA-
B*07 while CB has HLA-B*35. However, the patient’s mismatched HLA-B*07 matches the 
CB’s NIMA at the same locus” ( (Milano, Lee Nelson, & Delaney, 2013). 
 
 
  
Several studies have been performed to investigate the influence of NIMA and 
IPA on transplantation and outcome. There is a hypothesis suggesting that 
HLA-mismatches which are matched to the donor’s NIMA might be permissible 
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after UCBT (van Rood et al., 2009). One study showed that single-unit UCBT 
recipients with acute myeloid malignancies, who were NIMA matched to the 
UCB, showed lower relapse rate and better OS (van Rood et al., 2009). To date, 
the effect of NIMA matching in double-unit UCBT has not been investigated. In 
clinical practise, when no fully matched UCB graft is available, an HLA-
mismatched graft, which is NIMA-matched, is preferred over an HLA-
mismatched graft which is NIMA-mismatched. If it is possible to implement 
NIMA matching in UCB graft selection, it might further enlarge the pool of 
suitable unrelated UCB grafts in the future. Currently, not all CBB have maternal 
HLA typing available.  
 
The same mechanism is observed with paternal antigens. Michrochimeric 
maternal cells that are sensitised toward fetal IPA during pregnancy can be co-
infused with UCB. Therefore, maternal immunity towards IPA might influence 
UCBT outcome. “Patients with acute myeloid or lymphoid malignancies who 
share one or more antigens with their UCB graft’s IPAs had a significant 
decrease in leukemic relapse post UCBT (HR=0.38, p<0.001) compared with 
those that did not” (Rood et al., 2012). Like maternal HLA typing, paternal HLA 
typing is most likely not performed at all. Further clinical data is needed in order 
to implement it in routine practice.  
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 UCB selection and Killer-immunoglobulin-like receptor (KIR) 
ligands  
“Natural killer (NK) cells are critical to the innate immune system because they 
mediate cytotoxic lysis to cancer and virally infected cells” (Yoo et al., 2007) . 
 
In the adult donor HSCT setting, NK cells play an important role in mediating 
the GvL effect (L. Ruggeri et al., 2007). Among NK cell receptors, inhibitory 
killer cell immunoglobulin-like receptors (iKIR) are of paramount importance 
because of their ability to recognise ubiquitously expressed host MHC class I 
ligands, and their regulatory role due to NK cell education or licensing (Kim et 
al., 2005). When donor NK cells lack inhibitory KIRs on their cellular surface 
which interact with recipient HLA ligands (in particular HLA-C molecule in the 
C1 group), the donor is considered KIR ligand mismatched (Sekine et al., 2016). 
In a study of 218 patients with acute leukaemia, recipients who had received 
single-unit UCBT, donor KIR ligand incompatibility in the GvHD direction was 
associated with decreased relapse incidence (HR=0.53, p=0.05) and improved 
leukaemia–free survival (HR=2.0, p=0.0016). Effect was more evident for AML 
transplant recipients  (Willemze et al., 2009). However, a recent study of 461 
patients with acute myeloid leukaemia treated with a MAC single-unit UCBT 
showed no difference in relapse incidence, non-relapse mortality and overall 
survival based on KIR ligand match/mismatch status. However in recipients of 
grafts with three or more HLA mismatches, KIR ligand mismatched grafts 
provided  lower non-relapse mortality (HR=2.26, p=0.008) (Rocha et al., 2016). 
Sekine at al., in 2016 showed on a group of 110 recipients of single-unit UCBT 
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for haematological malignancies that optimal CBU-recipient KIR-HLA genotype 
was an independent predictor factor of transplant outcome. Patients 
homozygous for HLA-C2 group had a higher relapse rate and inferior overall 
survival in comparison to patients with HLA-C1/C1 or HLA-C1/C2 groups 
(68.8%, 26% and 15% respectively, p=0.001) (Sekine et al., 2016). The authors 
suggest that effect is explained by NK cells licensing and alloreactivity.  On the 
basis of these data, KIR-ligand matching might become an important factor in 
current UCB graft selection criteria. 
 
 Other factors  
 Functional assays of UCB quality  
Graft potency is the ability of HSC to engraft. It is usually assessed by cell 
viability on flow cytometry in both TNC and CD34+ compartments. Some 
researchers reported an association between good CD34+ and TNC viability, 
and improved transplant outcome (Barker et al., 2009). Unfortunately, as with 
CD34+ cell count assessment, there are no standardised methodologies to 
measure this.  
 
Another surrogate marker of HSC actual clonogenic potential, which can be 
used, is enumeration of granulocyte–macrophage colony-forming units (CFU-
GM) in UCB. Unfortunately, different methods of cell isolation and growth exist 
between laboratories. Currently there are controversial reports on the clinical 
significance of CFU-GM count. A group from the US performed analysis on the 
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predictive value of CFU-GM across four US cord blood banks. They did not find 
any predictive value to the assay which would correlate with neutrophil 
engraftment (van Besien, 2014). Other studies showed an inverse correlation 
between the dose of GM-CFC and time to engraftment (Migliaccio et al., 2000). 
Given the fact that this correlation was not always reproducible, this marker is 
very difficult to apply in routine practise.  
 
Recently, based on the correlation between CFU-GM and CD34+ cells, the 
Barcelona group has proposed the use of the clonogenic efficiency (CLONE, 
i.e. the ratio between post-thaw CFU-GM counts and pre-freezing CD34+ cell 
numbers) as a new measure of HSC potency (Castillo et al., 2015). The group 
has studied the outcomes of 110 adult patients with haematological 
malignancies who were recipients of a single-unit UCBT. CLONE  of ≥20% predicted a faster neutrophil (p=0.005) and platelet (p=0.02) engraftment 
and contribution to a decrease in the non-relapse mortality (p=0.02). In addition, 
they found that the infusion of >2.0x10^7/kg of recipient’s weight post-thaw of 
viable CD45+ cells “was significantly associated with faster neutrophil (p=0.01) 
and platelet (p=0.01) engraftment,  higher disease-free survival (p=0.01) and 
OS (p=0.02)” (Castillo et al., 2015).  
 
 
 Cytomegalovirus  
CMV is the most common blood product –transmitted virus. Prior to arrival 
of effective antiviral therapy in early 1990, cytomegalovirus (CMV) disease 
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was the leading infectious cause of death among CMV-seropositive 
recipients of HSCT (Hannachi et al., 2011). In the context of adult unrelated 
HSCT, the pre-transplantation CMV status of the donor and recipient is an 
important risk factor for post-transplantation outcome (Ljungman, Hakki, & 
Boeckh, 2010). Several cohort studies showed that CMV seropositive 
transplant recipients and seronegative recipients of CMV positive grafts 
appeared to have higher transplant related mortality when compared with 
seronegative recipients with a seronegative donor (Boeckh & Nichols, 
2004). “Umbilical cord blood is presumed to have a low risk of transmitting 
CMV because of the low rate of congenital CMV infection (reported to 0.2% 
to 2.5% depending on socio-economic status and geographical location)” 
(Griffiths, Baraniak, & Reeves, 2015). Options for CMV screening for UCB 
include serologic testing of the donor infant’s mothers or serologic testing of 
the UCB. “Interpretation of data obtained by serologic methods alone is 
complicated in cord blood donors because of active transport of maternal 
IgG antibody across the placenta. Thus, CMV antibody positivity in cord 
bloods generally reflects the mother’s lifetime exposure to CMV” (Albano et 
al., 2006). In 2006, Albano et al had assessed the incidence of post-
transplantation CMV infection in recipients of UCB donated to the New York 
Blood Centre National Cord Blood Program (Albano et al., 2006). Figure 1-4 
displays the diagram of the study.  
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As a result of the study, it was determined that there was no association 
between the UCB donor’s maternal CMV antibody status and incidence of 
post-transplantation CMV infection. In line with previous studies, “the 
incidence of post-transplantation CMV infection was associated with 
recipient’s pre-transplantation CMV serology, age, HLA mismatch and 
ethnicity. This was the first study that evaluated whether there is an 
association between UCB donor serology for CMV antibody and post-
transplantation CMV infection in the recipient. It showed for the first time 
that unlike studies on adult donors’ recipients, post-transplantation CMV 
infection in UCB recipients had no association with donor serology (i.e., 
the donor mother’s CMV antibody status)” (Albano et al., 2006). 
 
Routine post transplant CMV DNA by PCR monitoring 
anti-CMV IgG anti-CMV IgM
anti-CMV IgG anti-CMV IgM
Figure 1-4 : Diagram of the study on the incidence of CMV infection post UCBT 
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An effect of CMV infection on the relapse rate post transplantation for 
malignant disorders was described in adult recipients of unrelated adult 
donors. In adult recipients a lower incidence of relapse of acute myeloid 
leukaemia was associated with CMV reactivation (Elmaagacli et al., 2011) 
(Green et al., 2013b)(Ito et al., 2013). This effect was thought to be 
attributed to the NK cells alloreactivity and potential Graft Versus 
Leukaemia effect. Conversely, a very recent large retrospective study from 
the CIBMTR showed that CMV reactivation had no preventative effect on 
haematologic disease relapse and was associated with a higher non-
relapse mortality (Teira et al., 2016). To date, only one study has been 
published on the incidence of leukaemia relapse with post- transplant CMV 
infection when UCB was graft source in paediatric recipients (Jeljeli, 
Guérin-El Khourouj, Porcher, Fahd, Leveillé, Yakouben, Ouachée-Chardin, 
Legoff, et al., 2014). In contrast to published studies on adult acute 
myeloid leukaemia, CMV reactivation was associated with increased 
relapse rate in this paediatric series. Of note, UCB was the stem cell 
source only in 16% of the patients. Therefore the role of CMV infection 
post UCBT in relapse incidence rate is to be yet explored.  
 UCB selection, donor-specific HLA allo-antibodies and ABO 
mismatch  
Pre-formed donor-specific HLA allo-antibodies play a role in transplant 
outcome, “owing to the higher risk of graft failure and increased GvHD risk” 
(Spellman et al., 2010). Antibodies against the UCB HLA have been reported 
to have a negative impact on neutrophil and platelet engraftment in a single-
Introduction and literature review 
 56 
unit UCBT setting (Takanashi et al., 2010). With regard to double-unit UCBTs, 
study results are inconclusive. “Although not replicated in all centres, many 
institutions performing UCBT will exclude an UCB unit for which the patient has 
pre-formed HLA-specific antibodies” (Ballen & Lazarus, 2016). Patient anti-HLA 
antibody testing to detects antibodies directed against HLA of the available UCB 
unit using standardised methodology might be included in the algorithm of UCB 
selection. In general, the use of UCB units with donor specific antibodies is not 
advisable  due to the increased risk of graft failure and transplant related 
mortality (Cutler et al., 2011),(Mary Eapen et al., 2011),(Annalisa Ruggeri et al., 
2013).  
 
The significance of recipient-UCB ABO group mismatch has not been fully 
explored. However, some groups described decreased OS and disease-free 
survival rates in UCBTs for adults with haematological malignancies in cases 
where an ABO major incompatibility was present (Arcese et al., 2006). Recent 
study on double cord blood unit transplantation for adults with haematological 
malignancies revealed the importance of ABO compatible CBUs on improved 
overall survival post UCBT (Vanderson at al., 2015). 
 UCB unit cryopreservation time and transplant outcomes 
The first CBBs were established in the early 1990s. Umbilical cord blood unit 
can be collected and cryopreserved for years. Storage of UCB units comes at 
a financial cost to cord blood banks, which is ultimately passed on to the 
transplantation cost to the transplant centres. Another important factor is the 
impact of long-term cryopreservation on transplants outcomes. The impact of 
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cryopreservation time on progenitor cell function has been addressed. It was 
demonstrated that UCB units stored for up to 20 years do not lose function when 
used in vitro and in murine assays of progenitor cell function (Broxmeyer et al., 
2003). In 2015, Mitchell at al analysed 288 single UCBs units used for the 
transplantation from 1992 to 2013, with duration of cryopreservation ranging 
from 0.8-11.07 years. The group established that “the number of years the UCB 
unit spent in cryopreservation had no impact on TNC recovery or UCB post-
thaw viability. Duration of cryopreservation also had no impact on neutrophil or 
platelet engraftment in single UCB transplantations” (Mitchell et al., 2015). The 
authors admitted that one of the limitations of the study was presence of only 
few units that had been cryopreserved for > 10 years. In summary, results of 
the study were reassuring and supported the idea that UCB units can be 
clinically used even after long-term cryopreservation.   
 
The Eurocord group study assessed 1351 UCBT recipients given single-unit 
UCBT following a 57yeloablative conditioning regimen and found that storage 
duration was not associated with neutrophil recovery or survival (median 
storage time was 2.3 years, range 0.3-14) (Rocha & Gluckman, 2009).  
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 The role of HLA in UCBT 
 Introduction 
Alloantigens can be divided into major (MHC) and minor (MiHA) 
histocompatibility complex antigens (Hirayama & Azuma, 2011). The MHC is 
referred to as the HLA complex in humans. The genes related to the HLA 
system encode a complex array of histocompatibility molecules which play a 
central role in immune responsiveness and determining the outcome of HSCT 
in humans (Hirayama et al., 2012). “The primary goal of histocompatibility 
testing for patients who are undergoing HSCT is the identification of a suitable 
HLA-matched donor to reduce the risk of post-transplant complications, which 
may result from HLA incompatibility” (Hirayama & Azuma, 2011). In the UK, a 
fully matched unrelated donor can be identified for approximately 70% of 
patients of white Northern European descent but only 20% of non-white 
Northern European descent (S. G. Marsh et al., 2013), (Hough et al., 2016). 
The availability of mismatched unrelated donors, haploidentical and cord blood 
donors has increased access to transplant for people from ethnic minority 
groups.  This is particularly the case with UCBT, where less stringent patient-
UCB HLA matching is permitted (Ballen et al., 2013).  
 
 UCB-patient HLA-matching and the impact on transplant 
outcome. 
The effect of HLA mismatches after bone marrow transplantation from unrelated 
donors has been well studied (Atsuta et al., 2013). “Four loci, HLA-A, -B, -C and 
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HLA-DRB1 allelic level matched (i.e. 8/8) to the patient bone marrow is currently 
the first alternative if a suitable HLA-identical sibling donor is not available” 
(Atsuta et al., 2013). An increase in the number of donor-recipient allelic level 
HLA mismatches at four loci from 8/8 to 7/8 or less is associated with higher 
mortality, with approximately 10% reduction in OS in unrelated bone marrow 
transplantation (Atsuta et al., 2013), (Lee et al., 2007). The first UCBT was 
performed using UCB from an HLA-matched sibling. Subsequent studies have 
shown that UCBT is permissive at one or two HLA mismatches, “since HLA 
mismatches are better tolerated after UCBT with lower incidence of severe 
GvHD” (Mary Eapen et al., 2007),(Wagner et al., 2002)(Barker, Scaradavou, & 
Stevens, 2010).  
 
Traditionally, UCB units had been matched to the patient for HLA-A and –B 
antigens, and HLA-DRB1 alleles (Ballen & Lazarus, 2016). With these criteria, 
HLA matching for UCB transplantation is less stringent compared with 
transplantation with BM or PBSC because these treatment methods require at 
least high resolution HLA-A, -B, -C and –DRB1 matching for optimal transplant 
outcome, as mentioned above. “This less stringent HLA matching of UCB 
transplantation extends the available donor pool and increases the probability 
of finding a suitable donor, especially for patients with rare HLA alleles” (Barker, 
Byam, et al., 2010). Recently, the importance of HLA-C matching on UCBT 
transplant outcome has been established. In the case of adult unrelated HSCT, 
several studies have reported more acute GvHD and higher mortality after 
transplantation mismatched at HLA-C (Lee et al., 2007) (Bray et al., 2008). 
“Matching at HLA-C antigen, at least for  myeloablative conditioning in acute 
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haematological malignancies and single–unit UCBT also has been shown to 
improve survival” (Mary Eapen et al., 2011). Recently, the importance of allelic-
level UCB-recipient matching in single-unit UCB selection has been proposed. 
Patients who were transplanted with units matched HLA-A, -B, -C and –DRB1 
alleles had a lower TRM than patients with one or more allelic level mismatches 
at these loci in a  myeloablative UCBT setting for haematological malignancies 
(Mary Eapen et al., 2014). The impact of patient-UCB allelic level HLA matching 
in the case of double-unit UCBT is still under investigation. The reports on this 
topic are controversial, favouring a greater or lesser degree of mismatching. In 
2015, Oran et al published data on 133 predominantly adult patients with 
haematological malignancies who underwent a double-unit UCBT. They 
showed substantial difference in 2-year TRM in the 7-8/8 matched group in 
comparison to the 5-6/8 and 4/8 or less matched groups (0% versus 39% versus 
60% respectively) (Oran et al., 2015). A recent report by Brunstein et al, showed 
that in a cohort of 342 patients with haematological malignancies 
(predominantly adults), a greater level of allelic level HLA-mismatching between 
recipient and UCB graft did not negatively impact on the incidence of 
engraftment, rate of acute and chronic GvHD or non-relapse mortality. 
Furthermore, greater HLA-mismatching protected against leukemic relapse in 
a subset of 174 patients (Brunstein et al., 2015).  
 
There is a strong relationship between HLA-mismatch and cell dose in UCBT. 
In 2009, a Eurocord study published data suggesting that HLA disparity might 
be abrogate by increasing the number of TNCs in the UCB graft. They 
recommended a higher dose of TNC if the single-unit UCB graft is only 4/6 HLA 
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matched (“TNC> 3.5x10^7/kg upon freezing and >2.5x10^7/kg on thawing for 
malignant disorders; TNC > 4.0x10^7/kg upon freezing and >3.5x10^7/kg on 
thawing for non-malignant disorders”) (Rocha & Gluckman, 2009). In line with 
the above study, Baker et al in 2010, showed that in 1061 UCB recipients with 
haematological malignancies, “a better HLA-match compensated for lower TNC 
dose” (Barker, Scaradavou, et al., 2010a).  
 
In the case of single-unit UCBT, BSBMT CBWG guidelines take into 
consideration both HLA matching (recommended at allelic level for all four loci) 
and cell dose of the UCB. In the case of a single locus mismatched UCB, 
avoidance of –DRB1 mismatch is recommended. In the case of 4-7/8 matched 
units, TNC dose should be as high as > 5.0x10^7/kg of recipient’s weight. CBUs 
which are matched at 3/8 are not recommended for transplant. In the case of 
double-unit UCBT, there are still insufficient data and “the role of high resolution 
typing is not yet defined” (Hough et al., 2016). HLA matching between the two 
units in a double CBU transplant is not required (Hough et al., 2015).  
 
 Immune reconstitution post UCBT  
“Despite considerable progress in the management of HSCT complications, 
infections remain an important cause of post-transplant morbidity and mortality. 
The major advance in the management of infectious complications has come 
from a better understanding of the mechanisms of the complex depression of 
immunity observed during the first months after HSCT.” (Sauter,Barker, et al., 
2011). “Reconstitution of T-cells post HSCT occurs in 2 phases” (Grewal et al., 
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2003) . In the first months post HSCT, the recipient’s defence mainly consists 
of peripheral proliferation of memory (previously antigen-exposed) T-cells, 
either infused with the graft or residual host T-cells which escaped pre-
transplant conditioning. This response is restricted to the T-cell population with 
limited T-cell receptors (TCR) and also occurs faster in CD8+ compared to 
CD4+ T-cells (Grewal et al., 2003),(Seggewiss & Einsele, 2010). “Later, 
thymus-dependent proliferation of T-cells derived from the graft occurs” (Grewal 
et al., 2003), (EBMT-ESH handbook 6th Edition, 2012). This pathway is a much 
more prolonged process and may be completed as late as 8-12 months after 
HSCT (Danby & Rocha, 2014). This pathway may be impaired by the age-
dependent involution of the thymus, GvHD and the conditioning regimen itself 
(Danby & Rocha, 2014), (Barrett, 2008).  
 
Immune reconstitution after UCBT has always been considered slower, 
compared to BM or PBSC grafts, owing to the naïve nature (antigen – 
inexperienced) of infused T-cells, lower cell dose, low T-cell levels of activation 
markers and reduced levels of cytokines produced in response to antigens 
(Szabolcs & Niedzwiecki, 2007), (Remberger, Persson, Mattsson, Gustafsson, 
& Uhlin, 2012). The majority of the studies have reported delayed immune 
reconstitution after UCBT when serotherapy (in particular ATG) was used in 
order to prevent graft rejection.  This resulted in a higher risk of opportunistic 
infections. Early comparative studies on graft sources showed that “the risk of 
bacterial and viral infections was higher after UCBT than after a full matched or 
mismatched unrelated donor transplant” (Ballen et al., 2014). For these 
reasons, many centres have abandoned the use of ATG resulting in better 
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immune reconstitution without increasing the rates of rejection or acute GvHD 
(Boiron et al., 1998) (Mohty & Gaugler, 2010). Sauter at al., in 2011 published 
data on rapid (within 4 month) immune reconstitution after double-unit UCBT 
with no serotherapy in older patients (Sauter, 2011). However, recently 
published laboratory data reports refuted this. There is a suggestion that fetal 
and adult T-cells are different. The majority of UCB T-cells have a naïve 
(CD4+CD45RA+) antigen phenotype. Despite this, it was demonstrated that 
under stimulation, these naïve T-cells can transform more quickly than adult T-
cells into functionally active central memory (CD4+CD45RO+) T-cells in vitro 
(Early & Reen, 1999). Interestingly, Zhang et al in 2014, demonstrated a 
presence in UCB cell populations of fetally developed CD4+ T-cells with an 
effector memory phenotype (CD4+RO+) that displayed a large variety of 
inflammatory effector functions (Zhang et al., 2014). Later, these data were 
complimented by clinical observations. Talvensaari et al., in 2002, compared 
data from paediatric patients (with malignant disorders) who received either a 
UCBT or matched sibling donor transplant and demonstrated that UCB 
recipients had higher naïve CD4+ T-cells and T- cell receptor  (TCR) diversity 
(Talvensaari et al., 2002). In 2012, Chiesa at al showed “ early (within 2 months) 
thymic-independent peripheral CD4+T-cell expansion, with a rapid shift from 
naïve to central memory phenotype and early regulatory T-cell recovery”, in a 
group of 30 paediatric recipients of T-cell replete UCBT for malignant and non-
malignant disorders. Both viral infections and acute GvHD were frequent, but 
well controlled (Chiesa et al., 2012). Furthermore, the ability to generate virus-
specific T-cells that target multiple viruses such as CMV, adenovirus and EBV 
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from naïve T-cell populations in UCB, confirms the ability of these cells to 
function (Hanley, Bollard, & Brunstein, 2015).   
 
No major differences have been shown with regards to numbers and distribution 
of NK cells in CBU and adult peripheral blood. Moreover, even more NK cell 
precursors were described in UCB (Gaddy & Broxmeyer, 1997)  with  more 
rapid and sustained expansion (Charrier et al., 2013).  
 
“The immune response of the graft can also result in a GvL effect, potentially 
decreasing the risk of relapse in certain haematological malignancies” (Bleakley 
& Riddell, 2004) (Barrett, 2008). The functional naȉvity of neonatal lymphocytes 
raised concern for a reduced GvL effect, but clinical experience with UCBT 
showed that disease status (i.e. remission versus advanced disease) at HSCT 
still remains the most important factor in predicting outcome (Wagner et al., 
2002) (F Locatelli et al., 1999). Moreover, a report by Hiwarkar et al in 2015, 
demonstrated that UCB T-cells provided a more potent anti-tumour effect than 
adult T-cells in a B-cell lymphoma mouse model, through enhanced recruitment 
of naïve UCB T-cells, prompt induction of memory effector differentiation and 
gaining of cytotoxic effector functions in the tumour microenvironment (Hiwarkar 
et al., 2015).  
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 Conclusion 
In the last few decades of UCBT history, scientists and clinicians have 
accumulated an enormous amount of knowledge and understanding of the 
kinetics of hematopoietic recovery post UCBT. This includes: “a minimum 
safe transplantable dose, quality and characterisation of the UCB inventory; 
use of double-unit CBU for infusion and methods for ex vivo expansion of 
UCB” (M E Horwitz, 2014). UCB graft selection is currently based on HLA 
matching and cell dose. “There is a recognised complex interaction between 
cell dose and HLA type” (Ballen & Lazarus, 2016). Although previously it 
was considered that less stringent HLA matching was acceptable in the 
UCBT setting; however, new data have emerged suggesting that a more 
precise HLA-matching approach might improve transplant outcome. Both 
NIMA and IPA matching also appear to play a role in UCBT outcome. If such 
matching can be implemented in the routine UCB selection algorithm, it will 
give a chance for more patients in need of a transplant to find a suitable 
donor.  
Limitation of cell dose can be overcome by, either performing double-unit 
UCBT or expanding single UCB grafts. As mentioned above, double-unit 
UCBT for paediatric patients with haematological malignancies does not 
provide an additional beneficial effect in terms of relapse incidence and 
transplant-related mortality. However, double cord allows safe 
transplantation in larger adolescence and adults for whom an adequate 
single unit could not be found. Cord blood unit expansion showed promising 
short-term outcomes, but longer follow-up is needed. In addition, the 
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expansion techniques require specialised laboratories and are expensive. A 
more cost-effective option to solve the problem of low cell dose in UCB 
would be to optimise UCB collection techniques based on the knowledge of 
which maternal and delivery factors may have an impact on cell count. In 
the next chapters of my thesis, I will be looking at the impact of delivery 
mode, previous history of maternal infections, CMV status and numbers of 
previous pregnancies on the collected UCB cell count and UBCT outcomes. 
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Chapter 2. Delivery mode influence 
on the volume and total nucleated 
cell count of the UCB 
 Introduction 
From the time the first cord blood transplant was carried out in 1988, Cord Blood 
Banks (CBB) have been established across the globe to collect and 
cryopreserve the cord blood for allo-HSCT. The ever increasing number of 
banked UCBs has underlined the need for cost-efficient management of the 
CBBs (Page et al., 2014). According to the WMDA CBB activity report from 
2012, UCBs with TNC of 200x10^7 have a 5.63% yearly likelihood of being 
used. By contrast, units with TNC below 90x10^7 have a probability of use of 
0.08% per year ( www.wmda.info).  
 
In the introduction to the thesis, I described the numerous UCB qualitative and 
quantitative factors that are believed to influence UCBT outcomes. For this 
reason, CBBs strive to increase the quality of inventories typically through 
stringent selection from collected UCBs. Different CBB employ different 
techniques for UCB collection.  
 
Typically, UCB may be obtained from vaginal deliveries and/or after Caesarean 
section, before or after the placental detachment (i.e. in utero or ex utero). 
Several obstetric, maternal and fetal factors (i.e. mode of delivery, maternal 
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age, maternal ethnicity, birth weight) will make an impact on the quality of 
collected CBU (Shlebak et al., 1998), (Lim et al., 2000), (Jones et al., 2003). 
Maternal and obstetric factors, influencing qualitative and quantitative 
parameters of collected UCB are outlined in Table 2-1.  
 
Table 2-1: Maternal and obstetric factors influence on the quality of UCB. 
Maternal and obstetric factors Fetal factors Reference 
-Better CFU in  NVD > CFU in 
IVD and el/em CS  
-Term pregnancies → higher 
TNC count and larger V 
Larger V collected from 
infants with BW ≥ 2.5 kg 
(Shlebak et al., 
1998) 
Prolonged first stage of labour 
→ higher TNC and CD34+ 
count 
Low umbilical venous 
blood Ph → higher NC 
and CD34+ count 
(Lim et al., 
2000) 
Prolonged labour and em/el 
CS → larger  V 
 (Jones et al., 
2003) 
-Placenta’s weight > 695g→ 
larger V and higher TNC 
count 
-Term pregnancies → higher 
TNC count 
-Prolonged labour → higher 
TNC count 
Infants with BW≥ 3.150 
kg→  larger V collected 
(Solves et al., 
2005) 
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-Placenta’s weight  > 600 g→  
larger V and TNC count 
-Gestational age > 39 weeks 
→  higher CD34+ count 
- em/el CS →  larger V but 
lower TNC count 
Bigger infants (no weight 
specified) → larger V 
and higher TNC and  
CD34+ count and CFU 
(Mancinelli et 
al., 2006) 
-em/el CS→  larger V and 
higher CD34+ count 
- IVD/NVD→ higher MNC 
 (Omori et al., 
2010) 
 High umbilical arterial 
pCO2 and low pH → 
higher MNC 
(Ebina et al., 
2012) 
Abbreviations: BW- body weight; UCB- umbilical cord blood; CFU- colony forming unit;  
emCS- emergency Caesarean section; elCS- elective Caesarean section; IVD- instrumental 
vaginal delivery; NVD- normal vaginal delivery; MNC- mononuclear cell count (x10^8); TNC- 
total nucleated cell count (x10^7); V- volume (ml) 
 
To address the question of practice in UCB collection at Anthony Nolan Cell 
Therapy Center (CTC) a retrospective study on impact of the mode of the 
delivery on the quality indicators of UCB (i.e. volume and TNC) was conducted. 
 
 Materials and methods 
Between August 2012 and November 2013, 8,346 UCB were collected at four 
designated UCB collection centers (Royal Free London NHS Foundation trust, 
University Hospitals of Leicester NHS Trust, University Hospital Birmingham 
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NHS Foundation Trust, and Kings College Hospital NHS Foundation Trust).  Of 
these, 2,411 UCBs met clinical criteria to be included in the clinical inventory of 
the Anthony Nolan CTC (i.e. time from collection to reception<32 hours, volume 
>85ml, TNC >14 x 10^8, CD34 >3.2 x 10^6).   
 
Collections were performed after normal vaginal delivery (NVD), instrumental 
(forceps or ventouse) vaginal delivery and Caesarean (elective and emergency) 
deliveries, by a skilled technician using an ex utero method of collection in line 
with the Royal College of Obstetricians and Gynecologists (RCOG) and Royal 
College of Midwives (RCM) recommendations, which support the practice of 
deferred cord clumping (RCOG, 2009). UCBs were transported from the 
collection centers to the CTC and processed within 24.6 hours on average. 
Results are expressed as mean ± standard deviation (SD). Comparisons 
between groups were performed using the two-way t- test and p- values of less 
than 0.05 were considered to be significant. Graph represents the percentage 
number of units considered as clinical, per group, according to the thresholds 
detailed in the results section.  
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 Results 
 Collection mode  
In the cohort of 3,789 collected UCBs which met the volume threshold and so 
were subsequently analysed for cell content, most of the units were collected 
after CS (46%), of which 32% were elective CS. Normal vaginal deliveries 
(37%) were the second more frequently used collection type.  
 UCB volume 
The volume of UCBs collected from CS was greater than in vaginal deliveries 
(119.55 (±26.52), 110.46 (±23.04) respectively, (p=0.04).  There were no 
differences in the volume of UCB, when CS group was subdivided into elCS 
and emCS, (p>0.05).  
 UCB TNC  
In the CS group, the number of TNC was higher in the UCBs collected from the 
emCS (168.4 ± 80.5x10^7) when compared to the group of elCS (131.72 ± 
63.4x10^7),(p=0.03). However, UCBs collected from the CS showed the lowest 
TNC number (142.9 ± 71.1x10^7) in contrast to IVD (184.5± 79.0 
x10^7),(p=0.03). 
Therefore, highest TNC was observed from the UCBs collected from the IVD 
(184.5 ± 79.0x10^7), (p=0.02).  .A comparison of collected UCB parameters 
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(volume and TNC) obtained from different modes of deliveries is displayed in 
Table 2-2.  
 
Table 2-2 : Collected UCBs parameters (volume and TNC)  
Type of 
Collection 
% (N) Average Volume 
(ml) 
Average TNC 
(x107) 
Elective 
Caesarean 
section 
32% 
(1231) 
120.03 ± 26.85 131.72 ± 
63.43 
Emergency 
Caesarean 
section 
14% 
(547) 
118.47 ± 25.76 168.14 ± 
80.56 
Instrumental 
vaginal 
delivery 
16% 
(625) 
112.46 ± 23.59 184.47 ± 
79.02 
Normal 
vaginal 
delivery 
37% 
(1386) 
109.28 ± 22.63 152.27 ± 
66.47 
 
 
The TNC number was higher in UCB collected from instrumental vaginal 
deliveries and emCS whereas volume of the CBU was much less from the same 
mode of the delivery.  
 Mode of the delivery and UCBs stored for clinical use  
 
There were more CBU collected from the IVD (68.9%) and emCS (53.7%), 
which were suitable for clinical use. Please see Figure 2. 1 
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Figure 2-1 : Clinical conversion rates with breakdown of collection type 
  
CBU collected from the instrumental vaginal delivery in 68% met the criteria for 
the clinical use. In contrast, only 35% CBU collected from emCS group made it 
for the clinical use.  
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 Discussion  
During fetal development, the concentration of hematopoietic stem cells in 
circulation usually remains stable. However, an increase in concentration can 
be observed shortly before delivery. This increase in concentration declines 
rapidly after birth (Ary L Aughlin et al., 2001).  The normal birth process is a 
stress itself and if prolonged, is associated with even increased delivery stress. 
Usually, in response to any stress, levels of cytokines and hormones increase. 
In relation to the birth process, the strongest positive correlations were found 
between UCB progenitor cells number and maternal serum IL-4, IL-10 and GM-
CSF levels (Juutistenaho, Eskola, Sainio, Aranko, & Kekomäki, 2010). UCB 
cortisol level as a marker of fetal stress, was demonstrated to be higher in 
infants born by forceps vaginal deliveries than those born by ventouse vaginal 
deliveries  (Gitau et al., 2001). In addition, under stress, numbers of nucleated 
cells in the cord bloods increase as a result of demargination of cells from the 
vascular endothelium mediated by catecholamines (Solves et al., 2005), (Lim 
et al., 2000).  Gestational age is an important factor too. The number of 
circulating CD34+ cells is significantly higher in pre-term infants when 
compared with full-term newborns (Gonzalez et al., 2009). In addition, cord 
clumping itself, following by oxygen deprivation  may play an additional 
stimulating role in stem cell mobilisation (Gonzalez et al., 2009).  
 
Different delivery modes are associated with different levels and types of stress 
factors on the mother and infant.  Therefore this might potentially influence the 
quality parameters of the obtained UCB.  
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In this study, more TNC were obtained after the IVD (184.47 ± 79.02 x107) 
(p=0.02) and emCS (168.14 ± 80.56 x107),(p=0.03). Both modes of the delivery 
are certainly an additional stress factors for both mother and baby. Within the 
CS group, higher TNC number was observed in the group of the emCS, rather 
than in elCS (168.14 ± 80.56 x107, 131.72 ± 63.43 x107 respectively), (p=0.03) 
Within the VD group, more TNC were obtained from IVD (184.47 ± 79.02 x107) 
rather than in NVD (152.27 ± 66.47 x107), (p=0.04). Vaginal deliveries 
(instrumental or spontaneous) are more likely to be happening from term 
pregnancies when baby’s weight is usually higher than in babies born pre-term. 
Higher neonatal weight was reported to correlate with higher TNC (Mancinelli 
et al., 2006). In addition, neonates with higher weight are more likely to require 
assistance during the obstetric process (cephalo-pelvic disproportion, i.e. 
discordance between size of the babies’ head and the birth canal) that might 
cause increase in the release of stress cytokines. Those two factors- stress and 
infant weight, might explain the higher TNC in UCB obtained from IVD.   
 
Consistent with the previous studies, the volume of UCB collected from the both 
elCS (120.03 ± 26.85 ml) and emCS (118.47 ± 25.76 ml) were higher than the 
volume of the units obtained from both NVD (109.28 ± 22.63 ml) and IVD 
(112.46 ± 23.59 ml) deliveries (Jones et al., 2003),(Omori et al., 2010). “Placing 
the neonate on the maternal abdomen (above the level of the placenta) after 
the delivery prior to clamping the cord increased the volume of the CBU” 
(Grisaru et al., 1999). “The flow of the blood into the placental cord is assisted 
through this method. As per another hypothesis the possibility of blood clot 
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formation is minimised after a C-Section, where manual removal of placenta 
happens quicker as compared to vaginal delivery” (Mancinelli et al., 2006). 
 
This study included significant amount of the UCB collected via el/emCS (46%).  
It showed that bigger volume of the collected UCB did not necessarily result in 
a higher TNC. In our collected UCBs, the TNC number was higher in UCBs 
collected from instrumental vaginal deliveries and emCS whereas volume of the 
UCBs was much less from the same mode of the delivery.  
In daily practice, it is relatively easy to collect UCB in elCS (i.e. easy to consent, 
planned procedure). However, this study has shown that only 36% UCBs 
collected from elCS group were clinical grade (due to the low TNC number). In 
contrast, 68% of the UCBs collected from the instrumental vaginal delivery met 
the criteria for the clinical use.  
 
For decades, timing of cord clumping (immediate versus delayed) has been 
under the continuous discussions. Historically, there was a concern, that 
immediate cord clumping (within the first 15 seconds) increases an infant’s risk 
for jaundice or polycythemia (YAO, 1969). However, in recent years, several 
randomized studies provided a very strong evidence that delayed cord clumping 
(at 2-3 minutes after the delivery) has no harmful effect on the infant (Kluckow 
& Hooper, 2015), (Stuart Hooper et al., 2016). On the other hand, in context of 
CBU collection, the immediate cord clumping results in more blood being 
transferred to the placenta with potentially more numbers of hematopoietic stem 
cells available for the collection (Tolosa et al., 2010).   Nevertheless, the current 
guidelines on of the Royal College of Obstetricians and Gynecologists 
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recommend to avoid delayed cord blood clumping  and therefore an immediate 
clumping is the standard practice in the UK CBUs collection centres (Rcog, 
2009).  
 
Cord blood banking is becoming increasingly expensive mainly due to the strict 
regulations required to guarantee the quality of the product. Therefore, cord 
blood collection procedures might contribute to reduce the cost of maintenance 
by means of storing only the high quality units that would have more chances 
to be utilized clinically.  This study indicates that UCBs harvested after 
instrumental vaginal deliveries and emergency Caesarean section may provide 
optimal units for further stem cell transplantation.  
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Chapter 3. Donor-recipient allele-
level HLA matching of unrelated 
cord blood units. 
 Introduction  
 
Donor-recipient HLA matching remains the most significant factor in donor 
selection for HSCT. As mentioned previously, the selection of UCB was 
traditionally based on low/intermediate resolution typing for HLA Class I genes   
(-A and –B), and high resolution typing for HLA Class II genes (mainly –DRB1).  
 
As a consequence, UCB units that are selected for transplantation frequently 
contain more mismatches when high resolution typed for all 4 loci (HLA-A, -B,-
C, -DRB1). For example, in 2005 in a study of 122 UCB-recipient pairs, Kogler 
et al showed that “after high resolution typing for HLA-A , -B and –DRB1 loci 
and inclusion of HLA-C and HLA-DQB1, 14% of recipients were matched for 9-
10/10 alleles, 63% were matched for 6-8/10 and 23% showed more 
mismatches” (Kögler, Enczmann, Rocha, Gluckman, & Wernet, 2005). The 
group did not evaluate transplant outcomes of the selected units because the 
sample size was too small. In 2008, Cord Blood Transplantation Study (COBLT) 
published results on 179 UCB-recipient pairs. “When typed for all 3 loci at high 
resolution (HLA-A, -B and –DRB1), about one third of the pairs were found to 
be more mismatched than what the initial low resolution typing had indicated” 
(Martin et al., 2006).  
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The impact of UCB-recipient high resolution matching on single and double unit 
UCBT outcome has been discussed in my literature review section. To 
summarise, increased UCB-recipient HLA disparity was associated with inferior 
neutrophil and platelet engraftment along with an enhanced risk of acute GvHD 
and transplant related mortality. “Increasing the TNC dose may ameliorate but 
not completely compensate the negative impact of HLA mismatch” (Barker, 
Scaradavou, & Stevens, 2010). UCB-recipient high resolution matching in the 
case of single unit UCBT is recommended due to the reported higher rates of 
overall survival in UCB-recipient pairs matched at high resolution. In the context 
of adult unrelated donor HSCT, the influence of single allelic level mismatches 
on transplant outcome is well described.  Mismatches at HLA-A and –C are 
reported to be better tolerated than mismatches at HLA-B or –DRB1 (Lee et al., 
2007). Data on ‘’preferable’’ mismatches in the context of UCBT are different 
and still unclear. In  2011, in a study involving 803 recipients of single unit 
UCBT, Eapen et al showed for the first time that specific allelic mismatches, 
such as at HLA-C, should be avoided either as a single mismatch or in 
combination with other allelic mismatches (Mary Eapen et al., 2011). Later, in 
2014, a joint CIBMTR and Eurocord study on the outcome of 1658 recipients of 
single unit UCBT was performed. It showed that a “single allelic mismatch at 
HLA-A, -C or –DRB1 was associated with increased non-relapse mortality” 
(Mary Eapen et al., 2014). However, in 2015, a Japanese group performed an 
analysis of single unit UCBT outcome on 107 adult recipients with malignant 
disorders with UCB-recipient matching at low/intermediate level. In multivariate 
analysis they demonstrated a reduced risk of relapse; and as a consequence, 
improved OS in recipients of mismatched grafts. However, the cumulative 
Donor-recipient allele-level HLA matching of unrelated cord blood units. 
 80 
incidence of grades II-IV acute GvHD was significantly associated with a 
mismatch at HLA-DRB1 (p=0.03). It may be deduced that the presence of acute 
GvHD is a beneficial factor of lower relapse rate due to the possible GvL effect 
(Konuma et al., 2015). The difference between the 2 studies (Eurocord versus 
Japan) is not clear. It might be explained by a difference in age group of 
selected recipients (i.e. predominantly children in the Eurocord study) or even 
different geographic location. Current UK consensus guidelines on UCB 
selection recommend avoiding HLA-DRB1 mismatch (Hough et al., 2015).  For 
non-malignant conditions the data on HLA matching and interaction between 
the cell dose and HLA is not very apparent. However, it is generally 
recommended that better HLA matching and higher TNC dose should be 
considered (Rocha & Gluckman, 2009).  
 
Given the current consensus on selecting cord blood units for transplantation 
based on allelic level HLA matching (at least in the case of single unit cases), I 
retrospectively evaluated the current practice of UCB selection by UK transplant 
centres. The analysis was focused on evaluation of the extent of HLA mismatch 
at high resolution (for HLA –A, –B, –C and –DRB1) between UCB-recipient 
pairs for the available cases (Figure S- 1, Appendix). 
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 Materials and methods  
Cord blood unit work-up requests for 208 recipients from 12 UK transplant 
centres were received by Anthony Nolan between 1st January 2013 and 31st 
December 2015. Selected UCB and recipient HLA-phenotypes were obtained 
from the Anthony Nolan database. UCB-recipient matching was determined at 
antigenic level (for HLA-A, -B antigens) and at allelic level (for HLA-DRB1 allele) 
and at allelic level (for HLA-A, -B, -C and –DRB1) (Table S- 2Table S- 2 
Appendix). In cases where high resolution typing of cord blood unit and/or 
recipient was not performed, HLA matching was predicted based on published 
HLA haplotype frequencies (S. G. E. Marsh, Parham, & Barber, 2000) .  
 
 Results 
 Characteristics of recipients  
Recipient characteristics are described in Table 3-1. In total, 208 
recipients (66% adults and 44% children) from 12 UK transplant centres 
were considered for single or double unit UCBT. Median age of recipients 
was 33 years (range, 5 months to 68 years). In total, 95 recipients (46%) 
were considered for single unit UCBT and 113 recipients (54%) were 
considered for double unit UCBT. Most recipients were undergoing UCBT 
for treatment of acute myeloid (47%) or lymphoblastic (11%) leukaemia. 
Other common indications for UCBT were: inborn errors of metabolism 
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(10%), myelodysplastic and myeloprolipherative syndrome (9%) and 
lymphoma (8%).  
 
Table 3-1 : Patients Characteristics 
Characteristics N (%) 
Age 
≤ 18 y 
≥ 18 y 
 
92 (44%) 
116 (66%) 
Diagnosis 
AML 
ALL 
IEM 
MDS/MPS 
Lymphoma 
ID 
CML/CLL 
BMF 
Other 
Multiple myeloma 
Immune entheropathy 
Not known 
 
 
97 (47%) 
24 (11%) 
20 (10%) 
18 (9%) 
16 (8%) 
14 (7%) 
9 (4%) 
5 (2%) 
5 (2%) 
3 
1 
1 
ALL indicates acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; IEM, 
inborn errors of metabolism; MDS, myelodysplastic syndrome; MPS, 
myeloprolipherative syndrome; ID, immunodeficiency; CML, chronic myeloid leukaemia; 
CLL, chronic lymphocytic leukaemia; BMF, bone marrow failure syndrome; MM, multiple 
myeloma. 
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 Extent of UCB-recipient pair HLA mismatch at 
low/intermediate resolution  
In total, 321 cord blood units were evaluated: 95 units were used as single 
unit grafts and 226 units were used as double unit grafts. Median 
cryopreserved TNC dose was 2.9 x10^7/kg recipient’s body weight (range: 
1.26 to 41.8 x10^7/kg). 
 
At ‘classic level’ of matching (at antigen level for HLA-A and –B and at 
allelic level for HLA-DRB1), most of the cord blood units were 4/6 (n=152, 
47%) or 5/6 (n=130, 40%) HLA matched to the recipient. Only 13 % (n=38) 
of the selected units were 6/6 HLA matched to the recipient. One unit was 
3/6 HLA matched to the recipient and was considered for double unit 
UCBT. The distribution of low/intermediate level UCB-recipient HLA match 
is shown in Figure 3-1: Distribution of low/intermediate level umbilical cord 
blood unit-recipient HLA match (Figure 3-1) 
 
 
Figure 3-1: Distribution of low/intermediate level umbilical cord blood unit-recipient HLA match 
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In the 6/6 UCB-recipient HLA matching group, most units (i.e. 31/38, 82%) 
were considered for single unit UCBT. In contrast, most of the units in the 
4/6 UCB-recipient HLA matching group were considered for double unit 
UCBT (140/152, 92%).  
 Extent of UCB-recipient HLA mismatch at high resolution. 
For all cases patient/UCB allelic level match was evaluated.  
Almost all cord blood units within the 6/6 UCB-recipient HLA matched 
group were found to be matched at 7-8/8 with the recipient at high 
resolution (34/38, 89%). However, 2/38 units from that group were found 
to be ≤ 4/8 HLA matched with the recipient. These 2 units were considered 
for double unit UCBT since cord blood unit allelic matching with the 
recipient on HLA Class I is not recommended at present for the double-unit 
UCBT (Hough et al., 2015). The remaining 2 units were 5-6/8 matched 
with the recipient.  
 
Cord blood units from the 5/6 UCB-recipient HLA matched group in most 
cases appeared to be 5-6/8 HLA matched with the recipient when typed to 
high resolution (73/130, 56%). In 11% (15/130) of cases, the units were 
found to be ≤ 4/8 HLA matched with the recipient when typed to high 
resolution.  In 2 cases from that group, the units were considered for 
single unit UCBT, where ≤ 4/8 UCB- recipient HLA match is not 
recommended (Hough et al., 2015). The remaining units from 5/6 UCB- 
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recipient HLA matched group were 7-8/8 HLA matched with the recipient 
42/130, 33%).  
In the 4/6 UCB- recipient HLA matched group, none of the units were 
found to be 7-8/8 HLA matched to the recipient when typed to high 
resolution. Most of the units were 5-6/8 matched with the recipient 
(106/152, 70%). The remaining cases were ≤ 4/8 HLA matched with the 
recipient (43/152, 30%). In most of these cases (44/46, 96%) the units 
were considered for double unit UCBT. However, in 2 cases, the units 
were used for single unit UCBT, where ≤ 4/8 CBU-recipient HLA match is 
not recommended (Hough et al., 2015). Comparison of patient/UCB 4-loci 
allelic level matching and “classic” level of matching is shown in Figure 3-2 
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Figure 3-2: Comparison of patient/UCB 4-loci allelic level matching and “classic” level of 
matching 
 UCB-recipient HLA allelic match and TNC dose  
I evaluated both UCB-recipient HLA allelic match and TNC dose of the 
selected unit. The indication for UCBT (malignant versus non-malignant 
disorder) in each case was taken into account.  
 
In all but one of the cases, TNC dose per recipient’s weight was in 
accordance with the current UK guidelines (Hough et al., 2015). In one 
case, TNC dose was less than currently recommended for <8/8 HLA 
matched units (i.e. <5x10^7/kg recipient’s weight for a non-malignant 
disorder).  
 
 Discussion 
 
Selection of umbilical cord blood units for transplantation based on HLA allelic 
matching is not well established. In the present study I demonstrated that UCB 
units routinely chosen for transplantation by UK transplant centres are selected 
based mainly on UCB-recipient HLA-A and –B antigenic and –DRB1 allelic level 
in determining the degree of matching.  Some units showed substantial HLA 
disparity with the recipient when typed to high resolution for HLA-A, -B, -C and 
–DRB1, with units as low as 3/8 HLA allelic match being used for transplant.  
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Adoption of higher HLA matching criteria revealed that as many as 30% 
(46/152) of the cord blood units which were double HLA mismatched (i.e. 4/6) 
with the recipient at low/intermediate level, appeared to be ≤ 4/8 HLA match at 
allelic level, which in general is not recommended, especially in the case of 
single unit UCBT. In 5% (5/95) of single unit UCBT cases, selection of the cord 
blood unit could have been changed. Four of these units showed ≤ 4/8 UCB-
recipient HLA matching at allelic level, which in general should be avoided. 
However, in all of these units, TNC dose was acceptable and in accordance 
with the current UK recommendations for that degree of mismatch (i.e. 
>5x10^7/kg) (Hough et al., 2015). But in 1/5 cases, the cord blood unit used 
was 5/8 HLA matched with the recipient at allelic level and TNC dose was below 
the recommended standard (i.e. < 5x10^7/kg of recipient’s weight for non-
malignant condition).  
 
In addition, 10% (4/38) of units which were considered to be a “perfect” HLA 
match with the recipient at low/intermediate level (i.e. 6/6), appeared to be ≤ 6/8 
HLA matched at allelic level. However, 89% (34/38) of these units were 7-8/8 
HLA matched with the recipient at allelic level. 
 
My findings have practical implications for the selection of cord blood unit, 
especially in a single unit UCBT setting. The transplant centres should be aware 
of the possibility of choosing sub-optimal cord blood units for transplantation 
when applying HLA matching at low/intermediate resolution. This is particularly 
important when selecting the cord blood unit for a single unit UCBT and from 
the 4/6 HLA matched group. Adoption of higher HLA matching criteria is 
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possible and may impact the selection of the “optimal’’ graft. Moreover, in my 
study I found that this could be achieved without compromising TNC dose. The 
lower limit of acceptable HLA allele mismatch also requires further investigation. 
The effect of allelic level HLA mismatch at different loci is also not completely 
understood and results reported by different groups are sometimes 
controversial. Unit selection becomes even more complex when TNC and 
CD34+ dose are taken into account. The introduction of high resolution UCB-
recipient HLA matching in the double unit UCBT setting is still under discussion. 
Due to the small sample size I did not evaluate transplant outcome of the 
selected units in this series. 
 
To summarise, as a result of improvements in HLA methodologies, some cord 
blood banks are now typing UCBs to high resolution for HLA-A, -B, -C and –
DRB1. Third Generation Sequencing will deliver allelic level typing on all future 
UCBs stored by Anthony Nolan. Future UCB selection will be greatly supported 
by this information.  
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Chapter 4. Relationship between 
donor mothers previous exposure 
to the viral infections and UCBs 
cell count. 
 Introduction 
In order to improve the chances of survival of the allogeneic foetus the mother’s 
immune system undergoes changes. This also enhances her ability to respond 
to alloantigen’s, especially with respect to infections. One of the most common 
of these infections is the Human Cytomegalovirus infection (CMV), which 
infects many people without producing overt symptoms. The frequency of CMV 
infection depends on age, geographical and socio-economic status (La Rosa & 
Diamond, 2012),(Griffiths et al., 2015). Typically, people born into poor socio-
economic environments acquire CMV earlier than others. Antibody of IgG class, 
is a result of past infection and is present in approximately 60% of adults in 
developed countries; whereas in  developing countries 100% adults have these 
antibodies present (Griffiths et al., 2015).  Seropositivity was reported in over 
90% amongst women of reproductive age in developing countries as opposed 
to western countries where it is  less than 50% (Lissauer et al., 2011). “One of 
the unique features of CMV is the ability of persistence as a lifelong latent 
infection state in the host, particularly in the myeloid lineage cells, which can 
reactivate at any time” (La Rosa & Diamond, 2012).  
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Active infection can be documented by the presence of IgM class antibodies 
and presence of the viraemia detected by the positive qualitative polymerase-
chain reaction (PCR) for the CMV antigen. Several lines of studies have 
presented evidence that “innate immune responses are the first line of defence 
against the CMV in healthy individuals. In particular, NK cells are important in 
virus clearance and protection” (La Rosa & Diamond, 2012). It becomes 
extremely important in case of the viral infection in the perinatal period, when 
adaptive immune responses are not fully developed yet. At a later stage, the 
adoptive immune system takes over. CD8+ cytotoxic T-lymphocytes and CMV-
specific helper CD4+ T-cells are considered the most important cells in 
controlling the virus.  
 
In a study on a healthy adult individuals, primary CMV infection leads to a 
presence of a high percentage of virus-specific T-cells with recently activated 
naïve T-cells co-expressing CD45RA and CD45RO surface cell markers (La 
Rosa & Diamond, 2012). The first CD8+ T-cells detected express CD45RA-
CD28-CD27+ phenotype following by resting CD8+ T-cells with memory 
phenotype (CD45RA-CD45RO+). “In the months following the primary infection, 
CMV-specific CD8+ T-cells gradually re-acquire CD45RA expression” (La Rosa 
& Diamond, 2012). Please see Figure 4-1.  
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Figure 4-1: CMV-specific CD8+ T-cells phenotypes. La Rosa, C., & Diamond, D. J. (2012) 
 
“The CMV genome contains approximately 200 open reading frames” (Lacey, 
Diamond, & Zaia, 2004). One of these is pp65 protein, which “has been most 
studied CMV protein and has been considered the predominant target of 
immune response against the virus” (“The Stealth Virus": Prof Paul D Griffiths), 
(Solache et al. ,1999). After primary CMV infection, virus units are processed 
by  antigen-presenting cells (APC), which stimulate the antigen-specific immune 
response (La Rosa & Diamond, 2012), (van de Berg et al., 2010). Establishment 
of the adaptive immune responses are crucial to prevent overwhelming CMV 
infection. CMV specific T-cells predominantly of a memory phenotype (both 
CD4+ and CD8+) are participating in this process (La Rosa & Diamond, 2012), 
(Sylwester et al., 2005).  
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Congenital CMV infection causes major morbidity in newborn babies and 
affects up to 0.2-1% live births (“The Stealth Virus: Prof Paul D Griffiths: 
9781477566794: Amazon.com: Books,” n.d.). The foetus can be infected when 
mother either contracts new infection or reactivates latent virus or gets 
reinfection with a new strain of the CMV (Griffiths et al., 2015). Among the 
women with primary CMV infection during pregnancy, 32% transmit virus 
across the placenta to produce intrauterine infection (Griffiths et al., 2015).  
 
It is now recognised, that there is a “complex immunological interaction and 
information exchange between mother and foetus, resulting in maternal 
immunological awareness of the foetus” (Dierselhuis et al., 2012) (Szekeres-
Bartho, 2002). The presence of bidirectional transplacental cells and antigens 
trafficking has been confirmed by the detection of male microchimersim in 
maternal UCB samples, pregnant with male foetus (Dierselhuis et al., 2012) and 
specific tolerance toward noninherited maternal alloantigens (van Rood et al., 
2009). In 2003, Marchant et al  reported the presence of mature cytolitic CD8+ 
T-lymphocytes in newborns with congenital CMV infection, suggesting that 
intrauterine antigenic stimulation has the potential to produce protective 
immunity in the foetus, which persists into newborn period (Marchant et al., 
2003). 
 
Serological evidence of EBV infection can be found  in approximately 97% of 
pregnant women, however acute EBV infection during pregnancy is very 
uncommon and can be identified in only approximately 3% of women during 
pregnancy (Haeri, Baker, & Boggess, 2010), (Haut et al., 2001).  Following 
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primary infection EBV can persist in latent state in infected B lymphocytes for 
the whole life (Naher, Gissmann, Freese, Petzoldt, & Helfrich, 1992).  
 
Not much is known about the possibility of congenital transmission of 
Toxoplasma gondii in chronically infected immunocompetent women.  
However, severely immunocompromised chronically infected women could 
pass the infection to the foetus, due to the reactivation of latent Toxoplasma 
gondii infection(Kaye, 2011).  
 
 
I hypothesised, that UCBs collected from the mothers with evidence of previous 
exposure to the infection (in particular to the CMV and EBV determined by the 
presence of anti-CMV/EBV IgG class antibodies in peripheral blood) would 
have had higher total nucleated cell count (particularly in the  lymphocyte 
fraction ) reflecting response to the infectious antigen. To prove this theory, I 
conducted a retrospective study examining the correlation between the cell 
count of UCBs from donors mothers with/without a history of previous exposure 
to infections (particularly CMV, Ebstein-Barr Virus (EBV) and Toxoplasma 
gondii) (Figure S- 1, Appendix).  
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 Materials and Methods. 
In this study I included UCBs and their maternal blood samples that were 
processed in two CBBs- Barcelona’s and AN CTC, between October 2008 and 
September 2014. Out of 17,565 UCBs collected during that period, only 4,654 
UCBs from AN CTC and 9,754 UCBs from Barcelona’s CBB had TNC, CD34+ 
cell count, lymphocyte and mononuclear cells count documented and 
therefore were included in the analysis. UCBs laboratory data included for the 
analysis were: TNC count (x10^7), CD34+ cells count (x10^5), lymphocytes 
(%) and mononuclear cells (%) count. UCBs donors maternal blood samples 
were tested for the CMV (IgG and –IgM class antibodies (AB) and NAT testing 
in case of positive IgM AB), EBV (IgG and –IgM class AB and EBNA or other 
confirmatory test in case of positive anti-IgM), Toxoplasma gondii (IgG and –
IgM AB and NAT testing in case of positive anti-IgM) (Table S- 1, Appendix). 
Based on maternal serological findings, UCBs were placed into two groups 
(with positive or negative serological status separately for CMV, EBV and 
Toxoplasma gondii) and UCB laboratory characteristics were analysed based 
on this group placement. Maternal positive serological status was defined 
when IgG class AB was positive with negative or positive IgM class AB (based 
on manufacturer instructions). Where positive IgM class AB were identified, 
the blood sample was tested for NAT by polymerase chain reaction (PCR). In 
the case of a positive PCR result, UCBs were excluded from the analysis. For 
schematic representation of the study please see   
Figure 4-2.  
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*NAT positive cases were excluded from the analysis.  
Figure 4-2 : Study groups: schematic representation 
 
The two CBBs were analysed separately due to the difference in the methods 
CBU collection/processing (such as timing of cord blood clumping, threshold 
of TNC and CD34+ cells in CBUs, enabling them for the storage) in order to 
maintain homogeneity of the group. Barcelonas’s CBB practices in uthero 
CBU collection and delayed cord blood clumping (which results in ‘higher’ 
TNC, as described in previous chapter of my thesis) as opposed to the AN 
CBB, which do not practice delayed cord blood clumping and in uthero CBU 
collection in line with the Royal College of Obstetricians and Gynaecologists 
guidelines (RCOG, 2009). Also, Barcelona’s CBB has a higher threshold for 
the CBUs TNC (150X107 ) and CD34+ (4x106 ) cells enabling them for the 
storage. AN has a threshold for the TNC of  140x107 and CD34+ of 3.2x106 
cells, which makes AN and Barcelona’s CBBs groups different (personal 
IgM, IgG class AB +confirmatory testing in case of IgM positivity 
Donors mothers serologic screening for CMV, EBV, 
Toxoplasma gondii 
Negative (IgG neg) Positive (IgG pos+IgM+/-and NAT negative. *
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communication with Susana G. Gomez, former director of AN CBB and current 
Head of Barcelona Transfusion Services).  
 
 Statistical analysis 
Statistical analysis was performed using SPSS software. Descriptive 
statistics are shown as arithmetic median and range.  To determine 
differences between two groups, a non-parametric Mann-Witney U-test 
was performed. A value of p<0.05 was considered significant.    
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67.0%
33.0% IgG pos
IgG neg
48.7%
51.3%
IgG pos
IgG neg
 Results 
 Frequency of positive IgG class antibodies for the CMV, EBV 
and Toxoplasma gondii  
Frequency of positive serological status in maternal blood samples from 
both CBB is shown in Figure VI. Anti-CMV IgG class AB were positive in 
48.7% in AN and in 67% in Barcelona’s maternal samples. The overall 
prevalence of positive serologic testing for anti-EBV IgG class AB was 
more than 95% in maternal samples from both CBBs. Previous exposure 
to Toxoplasma gondii infection as detected by the presence of IgG class 
AB in maternal samples from Barcelona was 25% in comparison to AN -
10%.  
 
AN CTC Barcelona CBB 
CMV 
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EBV 
 
 
 
Toxoplasma gondii 
 
 
 
Figure 4-3 : Frequency of maternal positive serologic status for CMV, EBV and Toxoplasma 
gondii in both CBBs 
 
UCBs from donor mothers who tested positive for acute viraemia (by PCR for 
the CMV and Toxoplasma gondii and EBNA negativity in case of the EBV) 
were not analysed due to the small sample size. Only 30/1,408 (0.2%) of 
tested maternal samples were positive for the CMV PCR. EBNA negativity 
was documented in 3 cases and no samples were PCR positive for the 
Toxoplasma gondii.  
  
95.9%
4.1%
IgG pos
IgG neg 97.4%
2.6%
IgG pos
IgG neg
10.0%
90.0%
IgG pos
IgG neg
25.0%
75.0%
IgG pos
IgG neg
Relationship between donor mothers previous exposure to the viral infections 
and UCBs cell count. 
 99 
 Cell count in the UCBs from both CBB  
The characteristics of the cord blood units (TNC (x10^7), CD34+ cells (x10^5), 
lymphocytes (%) and mononuclear cells (%) count) are summarised in Table 
4-1. The cells count numbers parameter expressed in median value. Values 
shown in parenthesis indicate the range of each value.  
Table 4-1 : Summary of UCBs cell count 
 
Result Type AN CTC Barcelona 
Total N of UCBs 4,654 9,754 
TNC (x10^7) 128.4 
(2.2-777.7) 
153.3 (± 51.7) 
CD34+ (x10^5) 2.93 
(0.1-42.2) 
6.08 (± 3.9) 
Lymphocytes (%) 34.7 
(1.2-83.2) 
36.5 (± 10) 
Mononuclear cells 
(%) 
49 
(4.4-99.1) 
40 (± 7.3) 
 
 
Median numbers of TNC in UCBs from Barcelona’s CBB were 153.3x10^7 
and in AN collected UCBs were 128.4x10^7. Numbers of mononuclear cells 
in AN UCBs were 49% and in Barcelona’s units were 40%. 
 Relationship between TNC, CD34+ cells, mononuclear cells 
and lymphocytes count and maternal CMV serological status.  
Each UCB was placed into one of two groups, positive or negative for CMV, 
as described above.  
 
 
Relationship between donor mothers previous exposure to the viral infections 
and UCBs cell count. 
 100 
4.3.3.1. Anthony Nolan Cell Therapy Centre  
A univariate analysis was performed to determine the association between 
maternal CMV status and the TNC, CD34+ cell, lymphocytes and mononuclear 
cells count. As a result, there is a statistically significant difference in TNC count 
(p=0.007) between UCBs collected from CMV positive mothers (median 
130x10^7) when compared to UCBs from CMV negative mothers (median 
127x10^7). In addition, a statistically significant difference was found in 
lymphocyte count (p=0.003) between UCBs collected from CMV positive 
mothers (median 36%) as compared to UCBs from CMV negative mothers 
(median 35.2%)(Figure 4-4). No difference in the CD34+ cell or mononuclear 
cell count was found between UCBs collected from CMV positive or CMV 
negative mothers in AN CTC.  
  
Figure 4-4: Association between maternal anti-CMV IgG positivity and UCBs TNC and 
lymphocyte count 
 
 
4.3.3.2. Barcelona’s CBB   
A univariate analysis was performed to determine the association between 
maternal CMV status and the total TNC, CD34+ cell, lymphocytes and 
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mononuclear cells count. As a result, there is a statistically significant difference 
in TNC count (p=0.005) between UCBs collected from CMV positive (median 
155x10^7) and CMV negative mothers (median 152.2x10^7). In addition, there 
is a statistically significant difference in lymphocyte count (p=0.04) between 
UCBs collected from CMV positive (median 37%) and CMV negative mothers 
(median 36.4%) (Figure 4-5). However, no difference in CD34+ cell and 
mononuclear cell count was found in UCBs collected from CMV positive or 
negative mothers in Barcelona’s CBB.  
 
Figure 4-5 : Association between maternal anti-CMV IgG positivity and UCBs TNC and 
lymphocyte count 
 
 
 Relationship between TNC, CD34+ cells, mononuclear cell 
and lymphocytes count and maternal EBV serological status.  
4.3.4.1. Anthony Nolan Cell Therapy centre  
A univariate analysis was performed to determine the association between 
maternal EBV status and the total TNC, CD34+ cell, lymphocytes and 
mononuclear cells count. I found no difference in TNC, CD34+ cell, 
mononuclear cell or lymphocyte count between UCBs collected from EBV 
positive or negative mothers in AN CTC. Please see Table 4-2. 
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Table 4-2 : Association between maternal anti-EBV IgG positive AB and UCBs cell content 
 TNC CD34 MNC Lym  
Mann-Whitney U 83775.000 32315.500 73129.500 89108.500 
p-value .331 .591 .688 .991 
 
 
 
 
4.3.4.2. Barcelona’s CBB.   
A univariate analysis was performed to determine the association between 
maternal EBV status and the total TNC, CD34+ cell, lymphocytes and 
mononuclear cells count. A statistically significant difference in lymphocyte 
count (p<0.001) was found between UCBs collected from EBV positive (median 
23%) and EBV negative (median 34%) mothers. In addition, there was a 
statistically significant difference in mononuclear cell count (p<0.001) between 
UCBs collected from EBV positive (median 40%) and EBV negative (median 
45%) mothers. There was no difference in TNC and CD34+ cell count. Please 
see Figure 4-6.  
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Figure 4-6: Association between maternal anti-EBV IgG positivity and lymphocyte and 
mononuclear cell count 
 
 Relationship between TNC, CD34+ cells, mononuclear cell 
and lymphocytes count and maternal Toxoplasma gondii 
serological status.  
4.3.5.1. Anthony Nolan Cell Therapy centre  
A univariate analysis was performed to determine the association between 
maternal EBV status and the total TNC, CD34+ cell, lymphocytes and 
mononuclear cells count. The result was no difference in TNC, CD34+ cell, 
mononuclear cell or lymphocyte count between UCBs collected from EBV 
positive or negative mothers in AN CTC. Please see Table 4-3.  
Table 4-3: Association between maternal anti-EBV IgG positive AB and UCBs cell content 
 TNC CD34 MNC Lym  
Mann-Whitney U 83775.000 32315.500 73129.500 89108.500 
p-value .331 .591 .688 .991 
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4.3.5.2. Barcelona’s CBB.  
A univariate analysis was performed to determine the association between 
maternal CMV status and the total TNC, CD34+ cell, lymphocytes and 
mononuclear cells count. No correlation was found between maternal positive 
Toxoplasma gondii serology and cell count in Barcelona’s CBB stored UCBs. 
Please see Table 4-4. 
 
Table 4-4: Association between maternal anti-Toxoplasma gondii IgG positive AB and UCBs 
cell content 
 TNC CD34 MNC Lym  
Mann-Whitney U 308443.000 309707.500 289216.000 280282.500 
p-value .795 .897 .580 .055 
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 Discussion 
The specific interest of this study was the relationship between maternal 
previous exposure to the CMV (as the most common and immunogenic virus) 
and the donated UCBs cell count. Of the 4,654 mothers evaluated at AN CTC, 
anti-CMV IgG class AB were present positive in 48.7% cases. Of the 9,754 
mothers tested at Barcelona’s CBB, 67% showed presence of anti-CMV IgG 
AB. These results were consistent with previously published data on the 
prevalence of anti-CMV IgG antibodies. In 19,757 maternal samples available 
for the evaluation in New York CBB between August 1993 and December 
2004, 11,649 (59%) tested positive for the anti-CMV IgG  AB (Albano et al., 
2006). According to the SaBTO report from March 2012, 50-60% of UK healthy 
adults showed the presence of anti-CMV IgG antibodies (SaBTO, 2012). In 
Spain, the prevalence of anti-CMV IgG positivity was reported as 62.8% in 
between 2013 tested healthy adults (both men and women) in 1993-1994 
(Ludwig & Hengel, 2009). The higher frequency of anti-CMV positivity in 
Barcelona’s maternal samples might be explained by older maternal age and 
difference in socio-economic status between two countries (personal 
communication with Susana G. Gomez).  
 
In healthy adult individuals, T-cells with predominantly memory compartment 
play a crucial role maintaining homeostatic balance between the CMV virus 
and the host (La Rosa & Diamond, 2012). Fetal T-lymphocytes are also 
capable of responding to CMV antigen as shown in a study on newborn babies 
with congenital CMV infection maternal CMV infection in pregnancy was 
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associated with fetal development of mature T-cell responses, including IFN-
γ- producing T-cells. This process involved both CD4+ and CD8+ T-cells 
(Fornara et al., 2011). The same mechanisms might be present in cases, 
where mother did not have an acute infection during the pregnancy, but had 
evidence of previous exposure to the virus, as defined by the presence of anti-
CMV IgG class AB.   
 
In this study, I found that UCBs, collected from the mothers with evidence of 
previous exposure to the CMV virus, as detected by presence of the anti-CMV 
IgG class AB in the blood, had slightly but significantly higher numbers of TNC 
and lymphocytes.  This was observed in UCBs collected and stored in both 
CBBs. However, this finding should be interpreted with the caution, higher cell 
count not necessarily only reflects possible exposure to the maternal viral 
antigens. Many other important factors should be taken into account, such as 
delivery mode, maternal age, timing of cord blood clamping, gestational age 
and others, which was scrutinised in my previous chapters. However, it would 
be of a paramount importance to identify if there is a difference of 
immunophenotype of the lymphocytes present in UCBs from CMV 
seronegative or seropositive mothers and performing a tetramer challenge of 
CBU lymphocytes from CMV seropositive mothers. Due to logistical 
difficulties, I was not able to perform immunophenotyping, chimerism analysis 
or functional assays of the cells present in the UCBs from CMV seropositive 
mothers. However, from the work that has been done on frozen and fresh 
UCBs at the AN Research institute, it was found that low frequency (<4%) of 
memory phenotype CD4+ T-cells (CD4+CD45RA-CDRO+) could be identified 
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in cord blood samples (personal communication, Richard Duggleby, 
unpublished). In concordance with that finding, in 2014, Zhang et al showed 
the presence of CD4+ T-cells with effector memory phenotype in healthy 
neonatal blood. “The frequency of those cells was as high as 6% of total 
neonatal CD4+ T-cells” (Zhang et al., 2014). Moreover, based on X and Y 
fluorescence in situ hybridisation (FISH) staining, all those cells confirmed to 
be non-maternal but baby origin. This would suggest that the increase in 
lymphocytes in UCBs from CMV positive mothers may be due to stimulation 
of fetal memory T cells from transplacental passage of latent CMV antigens 
present in the mother.  
 
The presence of such cells in a transplanted UCB unit might result in better 
clearance of CMV viraemia post transplantation, enhanced alloreactivity, 
potential GvL effects but possible higher rates of acute GvHD.  
 
As far as EBV is concerned, no correlation between the maternal previous 
exposure to the EBV and cell count of donated UCBs was found in AN units. 
However, a positive correlation between anti-EBV IgG class AB presence in 
maternal blood and mononuclear cells and lymphocyte count was found in 
Barcelona’s units. This difference can be explained by a bigger sample size 
of EBV seropositive UCBs collected at Barcelona’s CBB. An increase in the 
lymphocyte count is a well known effect in response to EBV in healthy adult 
individuals (Hislop, Taylor, Sauce, & Rickinson, 2007). This study further 
reaffirms that the fetal immune system is capable of responding to the 
transplacental passage of foreign antigens in a latent state.  
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I encountered several difficulties in this study; for instance, huge sample sizes 
and unwieldy spread sheets etc. But the degree of difficulty was alleviated by 
the highly efficient way AN CTC stores UCB information. Similarly, 
Barcelona’s CBB was extremely helpful and efficient in the way they provided 
the data. One of the limitations of the study was non-availability of information 
on immunophenotype of the UCB cells. It is deemed essential that this 
information is collected and stored.  
 
In conclusion, the findings of the present study show that the number of TNC 
and lymphocytes is correlated with prior maternal exposure to the CMV, but 
many other fetal and maternal factors should be considered in multivariate 
analysis, which was not the part of this current study. With the limitation of 
current data available it is not possible to determine the phenotype of these 
cells. Therefore, further studies are needed to address this question of 
measuring the frequency and specificity of cells in UCBs from CMV 
seropositive mothers. If we were able to show a clinical significance for the 
UCBT outcome (in particular enhanced anti-tumour (GvL) effect) when the 
UCBs are collected from the CMV seropositive mothers, it could change the 
practice of selecting UCBs for the transplant for patients with haematological 
malignancies. 
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Chapter 5. Materials and Methods  
 Introduction  
This chapter describes the methodology used in the two studies detailed later 
in this thesis, namely a retrospective study exploring the impact of maternal 
CMV serological status on UCBT outcome in recipients with acute leukaemia 
and a retrospective study exploring the impact of maternal previous 
pregnancies on UCBT outcome in recipients with acute leukaemia.  
 Study population 
The following eligibility criteria were used to select patients from the Eurocord 
electronic database: adults and children with primary acute lymphoid leukaemia 
(ALL), acute myeloid leukaemia (AML) or biphenotypic acute leukaemia, who 
received an allo UCBT after a 109yeloablative or reduced intensity conditioning 
regimen in European Group for Blood and Marrow Transplantation (EBMT) 
centres between 1st January 2000 and 31st December 2012. Recipients who 
had undergone previous allo HSCT or double-unit UCBT were excluded for the 
purpose of homogeneity. Patients who received a UCB unit provided from non-
European Cord Blood Banks were excluded. A total of 1177 patients were 
considered for this study (Figure S- 3, Appendix).  
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 Data collection 
Data on patients, transplant procedures and outcome were collected from 
the electronic Eurocord database (Table S- 4Table S- 5Table S- 6, 
Appendix). Clinical and outcome data were validated and checked for errors 
and discrepancies. Data managers and physicians in each EBMT transplant 
centre were requested to check and complete missing data. 
 
Data on selected unrelated umbilical cord blood units and their maternal 
characteristics were obtained from European Cord Blood Banks (CBB). All 
participating CBB received the synopsis of the study and gave their written 
approval (Figure S- 4, Appendix). Subsequently they were asked to complete 
the spreadsheet with the required information (Table S- 3, Appendix).  Data 
were checked and validated both by managers at Eurocord and myself. Data 
managers or clinical staff in each CBB was requested to check and complete 
missing data. The Institutional Review Board of Eurocord approved the study.  
 Study end-points and statistical analysis  
The primary end-points were 2-year non-relapse mortality (NRM) and 5-year 
relapse incidence (RI).  
The secondary end-points were 5-year overall survival (OS), 5-year disease-
free survival (DFS), neutrophil engraftment at 60 days and incidence of Grade 
II-IV acute GvHD.  
 
Definitions of outcomes are outlined in Table 5-1. 
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Table 5-1: Definitions of Outcomes 
Outcome Definition 
Neutrophil 
engraftment 
Event time from the date of transplant to first date at 
which a neutrophil count of ≥0.5x109/l for 3 
consecutive days is achieved, without evidence of 
autologous reconstitution or graft rejection in the first 
100 days, with death prior to engraftment considered 
as competing risk.  
Acute GvHD The time from transplantation to onset of aGvHD or 
last follow up. Acute GvHD was defined according to 
the Consensus Conference Classification 
(Przepiorka et al., 1995) 
 
Chronic GvHD The time from transplantation to onset of cGvHD or 
last follow up. 
Evaluable if surviving without relapse for more than 
100 days with sustained donor engraftment. Chronic 
GvHD was defined according to the Shulman 
Classification (Vigorito et al., 2009). 
Relapse Defined on the basis of morphological evidence of 
acute leukaemia in bone marrow, blood or 
extramedullary organs.   
DFS (disease-
free survival) 
Time from transplant to relapse, death or last follow-
up. 
NRM (non-
relapse 
mortality) 
Non-relapse mortality was defined as death without 
prior relapse. 
OS (overall 
survival) 
Overall survival was calculated from the date of 
transplant until death or last observation alive. 
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Median values and ranges were used for continuous variables. 
Percentages were used for categorical variables.  
 
Probabilities of neutrophil engraftment, NRM and chronic GvHD were analysed 
as the cumulative incidence rates and their 95% confidence intervals (Cis), 
estimating death or relapse as a competing event. Due to the significant amount 
of missing data, univariate analysis for factors associated with Grade II-IV acute 
GvHD was conducted using proportions, whilst logistic regression analysis was 
used for multivariate analysis.  
 
Probabilities of OS and DFS were calculated using the Kaplan-Maier method. 
The log-rank test was used for univariate comparisons. Multivariate analyses 
were performed using Cox’s proportional hazard regression model for DFS and 
OS, and Fine and Gray’s proportional hazard regression model for other 
outcomes. Variables that reached a p-value of 0.15 in the univariate analysis 
were included in the initial models. Variables were eliminated one by one in a 
stepwise fashion in order to ensure only those which reached a p-value of 0.05 
in the final model were included.  
 
The following factors were considered potential predictors of outcome: 
recipient’s age, recipient’s CMV status, gender, stage of disease, donor-
recipient ABO match, donor-recipient HLA match, graft collected cell dose (TNC 
and CD34+), year of UCBT (before or after 2008), conditioning regimen (MAC 
versus RIC), ATG use, maternal CMV status, maternal previous pregnancies, 
maternal gestational stage and maternal age.  
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Missing values were found for the important variable of previous maternal 
pregnancies (N=538, 45.7%). This led me to perform a subsequent subgroup 
analysis on patients, for whom this variable was available (N=639).  
 
Statistical analyses were performed using IBM SPSS Statistics 20(Copyright 
IBM Corporation 1989, 2011) and R 2.14.0 (Copyright R Foundation for 
Statistical Computing, Vienna, Austria, 2011) software packages. For all tests, 
p-values <0.05 were considered significant.  
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Chapter 6. Impact of maternal CMV 
serological status on UCBT 
outcome in recipients with acute 
leukaemia  
  Introduction 
Cytomegalovirus (CMV) status of the graft in the context of allogeneic HSCT 
has an impact on transplant outcome. Both CMV seropositivity of the recipient 
and transplantation of seropositive recipient with a seronegative stem cell donor 
are known risk factors for increased transplant related mortality (TRM) with 
respect to allogeneic bone marrow or peripheral blood HSCT(Lanino et al., 
2008), (Matsumura et al., 2007), (Ljungman et al., 2010).  
 
Delayed T-cell recovery post UCBT has, in particular, been associated with a 
high rate of viral reactivation (Sauter et al., 2011), (Brown et al., 2010). In UCBT 
recipients, the data on CMV infection remains controversial. The source of CMV 
after UCBT is almost exclusively host, because the incidence of a congenital 
CMV infection is low. Depending on socioeconomic and geographic factors, 
approximately 0.5-2.0% of neonates are born with congenital CMV infection 
(Griffiths et al., 2015). Although a UCB may be considered CMV negative at the 
time of transplant, many UCBs will test positive for CMV IgG due to the 
transmission of maternal antibodies across the placental barrier (Reynolds, 
Stagno, Hosty, Tiller, & Alford, 1973). The incidence and risk factors for CMV 
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reactivation post UCBT have been explored by several studies. In 2006 Maria 
S. Albano et al, assessed the incidence of CMV infection after transplantation 
of UCB. Post-transplantation CMV infection, was reported in 23% of 1,221 UCB 
recipients and was associated with recipient’s pre-transplantation CMV 
serological status but not with the CMV serological status of donor- mother’s 
UCB. The group did not analyse the impact of the CBU’s serological status on 
transplant outcome (Albano et al., 2006).  
  
The correlation between CMV infection and disease recurrence in recipients 
with haematologic malignancies after allogeneic HSCT has been an area of on-
going scientific interest for several years. Green M et al, demonstrated a 
“modest reduction in early relapse risk after adult related and unrelated donor 
HSCT associated with CMV reactivation in a large cohort of children and adults 
with haematological diseases” (2,354 study subjects) (Green et al., 2013a). The 
authors could not identify the exact biological mechanism(s) between CMV 
reactivation and decreased early relapse observed in allogeneic HSCT 
recipients. Cichocki et al., had analysed the 1-year relapse rate of 674 
paediatric and adult recipients with haematological malignancies after either 
RIC or MAC conditioning regimen allogeneic related/unrelated HSCT (with CBU 
as a graft source in 470 cases). In multivariate analyses adjusted for recipient’s 
CMV status, conditioning regimen, donor type (MSD vs. UCB), diagnosis, 
recipient’s gender, disease risk (standard versus high) and prior autologous 
transplant, CMV reactivation was independently associated with lower relapse 
risk and increased disease-free survival  following RIC, but not following MAC 
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HSCT. They hypothesised that ‘the lower relapse risk was due to in vivo 
expansion and survival of adaptive NK cells” (Cichocki et al., 2014). 
 
In contrast to the above studies, M Jeljeli et al, showed that CMV reactivation 
post allogeneic HSCT was associated with increased relapse rate in 108 
paediatric recipients who received a MAC unrelated/related adult donor or 
cord blood HSCT for acute leukaemia. Of note is that UCB was the graft 
source in 17 cases (M Jeljeli et al., 2014). 
 
There is some evidence that the foetus may be exposed to the CMV virus during 
pregnancy even if the mother shows only IgG antibody positivity and has no 
symptoms of CMV infection (Paul Griffiths, personal communication). It is 
hypothesised that this small viral load may lead to an early activation of the fetal 
immune system and generation of a T- cell immune response but not infection. 
This immunoreactivity might play a potential role in mediating the graft-versus-
leukaemia effect post UCBT. As I found in the study described in Chapter 4, 
there is a difference in TNC and lymphocyte count between UCBs collected 
from CMV seronegative and CMV seropositive mothers, with higher number of 
TNC and lymphocytes in the latter. As discussed in chapter 4, it is possible that 
these cells represent fetal memory T-cells that developed in response to the 
CMV antigen present in latent stage in CMV seropositive mothers and that 
these cells might represent a pool of cells that could mediate GvL effect.  
 
Therefore, the hypothesis of the current study is that maternal previous 
exposure to viruses (CMV in particular) might enhance antiviral and antitumour 
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properties of the UCB unit with an impact on transplant outcome, such as 
decreased relapse rate. Therefore a retrospective study which included 
mother’s characteristics of cord blood units delivered by European Cord Blood 
banks was conducted, the aim being to confirm this theoretical hypothesis.  
 Study population 
The study population is outlined in section 5.2. 
  Materials and methods 
The materials and methods of this study are outlined in sections 5.3 and 5.4 
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 Results  
 Patients, disease and graft characteristics  
 
Patients and transplantation characteristics are summarised in Table 6-1. 
Median age at UCBT was 13.6 years (range, 0.3-70.7). From a total of 1177 
patients, 56.8% (n= 669) were children (i.e. ≤ 18 years). The vast majority 
of patients (81.5%, n=959) were in clinical remission (CR) and 15.1% 
(n=178) had advanced disease. At UCBT, 55.6% of patients (n=654) were 
reported to be CMV seropositive. The median age of UCB was 4.22 years 
(range, 0.2- 16.75). The median total nucleated cell dose at freezing was 
4.74 x10^7/kg (range, 0.4 -44.4). The median CD34+ cell dose at freezing 
was 1.83 x10^5/kg (range, 0.6 – 32). Maternal CMV status was reported as 
positive in 52.1% of cases (n=613) and negative in 43.7% of cases (n=514). 
In most cases, patients received UCBT with either single (41.1%, n=453) or 
double (44.9%, n=495) HLA mismatches out of six. Only 117 patients 
(10.7%) received 6/6 matched UCBs and 37 patients (3.3%) received units 
with three or more mismatches. A myeloablative conditioning regimen 
(MAC) was given to 80.5% (n=947) of the patients. The remaining patients 
(16.7%, n=196) received reduced a RIC. ATG was used in 72.1% (n=849) 
patients.  
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Table 6-1: Characteristics of 1177 study patients and UCB grafts 
Characteristics All patients  
Recipients (n)  1177 
Recipient’s age, median (range), 
years  
13.6 (0.3- 70.7) 
Recipient’s gender 
Male, n (%) 
Female, n (%) 
Missing, n (%) 
 
628 (53.4) 
541 (46.0) 
8(0.6) 
 
Diagnosis 
ALL, n (%) 
AML, n (%) 
 
 
612(52) 
565(48) 
 
Disease stage at UCBT 
CR, n (%) 
Other, n (%) 
Missing, n (%) 
 
959 (81.5) 
178 (15.1) 
40 (3.4) 
Recipient’s CMV status at UCBT 
Negative, n (%) 
Positive, n (%)  
Missing, n (%) 
 
430 (36.5) 
654 (55.6) 
93 (7.9)  
TNC dose at freezing, median 
(range), x10^7/kg  
 
 
4.74 (0.4-44.4) 
CD34+ dose at freezing, median 
(range) x10^5/kg  
 
1.83 (0.6-32) 
Number of HLA mismatches  
0 -1, n (%) 
≥2, n (%) 
Missing, n (%) 
 
571 (48.5) 
532 (45.2) 
74(6.3)  
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Conditioning regimen  
MAC, n (%) 
RIC, n (%) 
Missing, n (%) 
 
 
974 (80.5) 
196 (16.7) 
34 (2.9)  
Serotherapy 
Yes, n (%) 
No, n (%) 
Missing, n (%) 
 
 
849 (80.1) 
211 (19.9) 
117 (9.9) 
Maternal CMV status  
Negative, n (%) 
Positive, n (%) 
Missing, n (%) 
 
 
514 (43.7) 
613 (52.1) 
50 (4.2) 
Abbreviations: ALL: acute lymphoblastic leukemia; AML: acute myeloid 
leukemia; TNC: total nucleated cell; MAC: 121yeloablative conditioning; RIC: 
reduced intensity conditioning; CMV; cytomegalovirus; UCBT: umbilical cord 
blood transplantation, CR: clinical remission.  
 
 Neutrophil engraftment  
 
A total of 1025 patients achieved neutrophil engraftment after a median 
duration of 23 days (range, 4-92). The cumulative incidence of neutrophil 
engraftment at day 60 was 88.6% (95%CI, 86.8-90.4) (Figure 6-1, A).  
 
In univariate analysis, neutrophil engraftment was strongly associated with 
several factors Table 6-2. 
Impact of maternal CMV serological status on UCBT outcome in recipients 
with acute leukaemia 
 122 
 
Table 6-2: Univariate analysis of neutrophil engraftment for 1177 patients with Acute 
Leukaemia. 
Variable N % (95%CI) p-value 
Recipient’s gender 
Male 
Female 
 
620 
530 
 
 
87.9 (85.4-90.5) 
89.6 (87-92.2) 
 
 
0.05 
Recipient’s age 
≤ 18 y 
≥ 18 y 
 
662 
496 
 
90.6 (88.4-92.9) 
85.9 (82.9-89) 
 
 
0.4 
Diagnosis 
ALL 
AML 
 
604 
554 
 
88.2 (85.7-90.8) 
86.4 (88.4-91.6) 
 
 
0.06 
Disease status at UCBT 
CR 
Other 
 
950 
170 
 
90.6 (88.8-92.5) 
78.8 (78.4-85.3) 
 
 
0.0007 
Maternal CMV status 
Negative 
Positive 
 
244 
220 
 
87.7 (84.8-90.6) 
89.8 (87.4-92.2) 
 
 
0.3 
Conditioning 
MAC 
RIC 
 
378 
86 
 
89.4 (87.5-91.4) 
85.1 (80.1-90.4) 
 
 
0.8 
Median TNC collected 
x10^7/kg 
≤ 4.7 
≥ 4.7 
 
 
224 
240 
 
 
86.1 (83.3-89.1) 
91.8 (89.6-94.2) 
 
 
0.03 
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Year of transplantation 
≤ 2008 
≥ 2008 
 
611 
547 
 
87.2 (84.6-89.9) 
90.1 (87.6-92.7) 
 
 
<0.0001 
Median CD34+ collected 
x10^5/kg 
≤ 1.83 
≥ 1.83 
 
 
236 
228 
 
 
87.1 (84.3-90.1) 
91.7 (89.4-94.2) 
 
 
 
<0.0001 
 
 
Neutrophil engraftment was strongly associated with collected TNC and 
CD34+ doses. Those patients who received UCB with a collected TNC 
below the median for our cohort (i.e. <4.7X10^7/kg), had an  engraftment 
rate of 86.1% (95%CI, 83.3-89.6) compared with an engraftment rate of 
91.8% (95%CI, 89.6-94.2) for those patients who received a TNC dose 
above the median (p<0.0001) (Figure 6-1,B). Patients who received UCBs 
with a collected CD34+ cell dose below the median for our cohort (i.e. ≤ 
1.83x10^5/kg), had a rate of engraftment of 87.1% (95%CI, 84.3-90.1) 
compared with an engraftment rate of 91.7% (95%CI, 89.4-94.2) for those 
patients who received a CD34+dose above the median (p<0.0001) (Figure 
6-1, C). Maternal CMV Serostatus was not associated with neutrophil 
engraftment.  
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Figure 6-1: Probability of neutrophil engraftment at Day 60. (A): all patients. (B): effect of 
collected TNC dose. (C): effect of collected CD34+ cell dose. 
 
In multivariate analysis, disease stage (HR=1.3, 95%CI, 1.2-1.5, p=0.0007), 
year of UCBT (HR=1.2, 95%CI, 1.2-1.3, p<0.0001), collected TNC dose (i.e. 
>or <4.7) (HR=1.1, 95%CI, 1.0-1.2, p=0.03) and collected CD34+ dose (i.e. 
>or < 1.83) (HR=1.4, 95%CI, 1.3-1.5, p<0.00001) were the only factors 
associated with neutrophil engraftment.  
 
 Acute and chronic Graft-versus-Host Disease (GvHD) 
 
Overall 380 (32.3%) patients developed Grade II-IV acute GvHD at a median 
of 24 days (range, 4-100) after UCBT. Factors associated with Grade II-IV 
acute GvHD in univariate and multivariate analysis are listed in Table 6-3 
p<0.0001 
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Table 6-3: Factors associated with Grade II-IV acute GvHD in univariate and multivariate 
analysis.  
 
Variable Univariate analysis Multivariate analysis 
% p-value HR 
(95% CI) 
p-value 
Recipient’s age 
≤ 18 y 
≥ 18 y 
 
38 
26.2 
 
<0.0001 
 
0.6  
(0.4-0.8) 
 
0.0001 
Diagnosis 
AML 
ALL 
 
30 
35.6 
 
0.04 
 
n/a 
 
0.6 
Conditioning regimen 
MAC 
RIC 
 
34.3 
25.9 
 
0.02 
 
0.5  
(0.3-0.8) 
 
 
0.05 
Serotherapy 
No 
Yes 
 
39.8 
30.5 
 
0.01 
 
0.4 
(0.3-0.7) 
 
<0.0001 
Median TNC collected 
X10^7/kg 
≤ 4.7 
≥ 4.7 
 
 
25.6 
32.2 
 
 
0.01 
 
 
n/a 
 
 
0.1 
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Of the 785 patients who had engrafted and were still alive at day 100 post-
transplant, chronic GvHD (cGvHD) was observed in 188 of cases. The 
cGvHD was limited in 99 (53%) and extensive in 89 (47%) recipients. The 
estimated cumulative incidence of cGvHD at one year post –transplant 
was 20.1% (95%CI, 17.5-23.2).  
 
 Relapse 
 
A total of 352 patients relapsed (of whom 312 died), with a median time to 
relapse of 8.2 months (range, 1-183). The cumulative incidence of relapse at 
five years was 33.8% (95% CI, 31 – 36.8) (Figure 6-2, A). 
 
For patients in haematological remission before UCBT, the cumulative 
incidence of relapse was 30.0% (95% CI, 27 – 33.2) compared with 54.5% 
(95% CI, 47.1-63.2) (p<0.0001) for patients, who presented with advanced 
stage disease (Figure 6-2, B). In univariate analysis, patients who received 
MAC, had a cumulative incidence of relapse of 31.9% (95% CI, 28.9-35.3) 
compared with 42.3% (95% CI, 35.5-50.4) for patients who received RIC 
(p=0.02))(Figure 6-2, C). Patients who received ATG in the conditioning 
regimen had a cumulative incidence of relapse of 41.8% (95% CI, 35.4 – 
49.4) compared to 31.1% (95% CI, 28-34.6) for patients who did not receive 
ATG (p=0.009) (Figure 6-2, D). Maternal CMV status was not associated 
with relapse (p=0.79).  
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      D   
 
 
 
Figure 6-2: Cumulative incidence of 5-y relapse after unrelated UCBT for acute leukaemia. 
(A): for all patients. (B): effect of disease stage before UCBT. (C): effect of conditioning 
regimen. (D): effect of serotherapy (ATG). 
  
p=0.009 
p=0.02 
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In multivariate analysis relapse was associated with advanced disease at 
the time of UCBT (HR = 2.4, 95% CI, 2.1-2.8, p<0.0001), RIC conditioning 
regimen (HR = 1.3, 95% CI, 1.1-1.5, p=0.01) and ATG use (HR = 1.4, 95% 
CI, 1.3-1.5, p=0.007), (Table 6-7). 
 
 
 Non-relapse mortality  
 
A total of 312 patients died from non- relapse causes at a median of 105 
days after UCBT (range, 1-3626). The 2- year cumulative incidence of NRM 
after UCBT was 25.4% (95%CI, 22.8-28.4) (Figure 6-3, A). 
 
In univariate analysis, the incidence of NRM was associated with: advanced 
stage disease (p<0.0001), recipient’s age (p<0.0001), recipient’s CMV 
status at time of UCBT (p<0.0001), use of ATG (p<0.0001), HLA 
mismatches (p=0.01) (Table 6-4).  
 
Table 6-4: Univariate analysis of main factors associated with 5-year NRM 
Factor n % (95% CI) p-value 
Disease stage 
Advanced 
CR 
 
169 
739 
 
39.5 (32.6-47.9) 
22.2 (19.3-25.4) 
 
<0.0001 
Recipient’s CMV status 
Positive 
Negative  
 
519 
340 
 
29.7 (25.9-34) 
16.9 (13.3-21.4) 
 
<0.0001 
Maternal previous 
pregnancy 
 
320 
 
27.9 (22.8-33.9) 
 
0.03 
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No 
Yes  
319 20.5 (16.0-26.3) 
Maternal number of prior 
pregnancy 
0 
1 
>1 
 
 
320 
218 
111 
 
 
32.5(27.6-38.2) 
22.4 (17.4-28.8) 
31.3 (23.3-42.1) 
 
 
 
0.02 
Maternal CMV status 
Negative 
Positive  
 
411 
487 
 
31.6 (27.7-35.9) 
30.6 (27.3-34.5) 
 
0.5 
Conditioning regimen 
MAC 
RIC 
 
752 
159 
 
30.7 (27.9-33.8) 
30.2 (24.3-37.5) 
 
0.9 
Serotherapy 
No 
Yes 
 
175 
841 
 
22.2 (19.3-25.4) 
39.5 (32.6-42.2) 
 
<0.0001 
Number of HLA 
mismatches  
0-1 
≥2 
 
 
457 
421 
 
 
22.2 (19.3-25.4) 
30.3 (26.2-35.2) 
 
 
0.01 
Recipient’s age 
≤18y 
≥18y  
 
537 
407 
 
22.2 (19.3-25.4) 
39.5 (32.4.8-
47.9) 
 
<0.0001 
 
 
A history of previous maternal pregnancy was associated with NRM. The 
incidence of 5-y NRM was 27.8% (95%CI,22.8-33.9) for those patients who 
received UCB from prima parva compared with 20.5% (95%CI,16.0-26.3) 
for patients whose UCB was from a second or greater pregnancy (range, 2-
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7),(p=0.003),(Figure 6-2, B).  Notably, those patients, whose UCB was from 
the second pregnancy had a lower NRM at 22.4% (95%CI,17.4-28-8) 
compared with 32% (95%CI,27.6-38.2) for patients, who received UCB from 
the first pregnancy and 31.3% (95%CI, 23.3-42.1)  for patients with UCB 
from the third or greater pregnancy (range, 3-7), (p=0.02) ,(Figure 6-2, C).    
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Figure 6-3: Cumulative incidence of 5-y NRM after unrelated UCBT for acute leukaemia. (A): 
for all patients. (B):  effect of maternal previous pregnancies. (C):: effect of number of 
maternal prior pregnancies.  
 
. 
NRM was not associated with recipient’s gender, ABO mismatch, diagnosis 
(ALL versus AML), year of UCBT (< and > 2008), conditioning (MAC versus 
RIC) and maternal CMV status (p=0.42).  
In multivariate analysis, advanced disease (HR=1.5, 95%CI, 1.3-1.7, 
p=0.003), recipient’s CMV status (HR =1.6, 95%, CI 1.4-1.8, p<0.0001), use 
of ATG (HR =1.5, 95% CI, 1.3-1.8, p=0.004) remained associated with NRM 
(Table 6-7).  
  
 
 
 
 
p=0.02 
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 Overall survival and disease-free free survival.  
With a median follow-up of 11.7 months (range, 0.1-183), estimated 5-year 
probability of overall survival (OS) was 40% (95%CI, 37-43). For patients in 
CR, 5-year OS was 45.6% (95%CI,42.2-48.8) compared with 10.5% 
(95%CI,6.7-16.1) for those patients with advanced disease (p<0.0001). In 
univariate analysis, recipient’s age (p<0.0001), stage of the disease 
(p<0.0001), recipient’s CMV status (p<0.0001), age of UCB (p=0.09), HLA 
mismatches (0.005), collected TNC dose (p=0.0001) and collected CD34+ 
cell dose (p=0.02), history of previous maternal pregnancies (p=0.007) were 
factors associated with OS (Table 6-5), (Figure 6-4).  
 
Table 6-5: Univariate analysis of factors associated with 5-year OS after UCBT for 1177 
patients with Acute Leukaemia. 
Variable N % (95%CI) p-value 
Recipient ‘s age 
≤ 18 y 
≥ 18 y 
 
664 
508 
 
47.1 (43.2-51) 
30.2 (26.1-34.7) 
 
0.0001 
Recipient’s gender 
Male 
Female 
 
628 
541 
 
39.7 (35.9-43.7) 
40.5 (36.3-44.9) 
 
0.8 
Recipient’s CMV 
serology 
Negative 
Positive 
 
 
428 
641 
 
 
 
 
46.2 (41.4-51.1) 
36.9 (33.1-40.9) 
 
 
0.0001 
Disease stage at UCBT 
CR 
 
959 
 
45.5 (42.2-48.8) 
 
0.0001 
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Other 178 
 
10.5 (6.7-16.1) 
Maternal CMV status 
Negative 
Positive 
 
514 
613 
 
38.3 (34.1-42.7) 
41.5 (37.5-45.7) 
 
0.3 
Maternal previous 
pregnancies 
No 
Yes 
 
 
320 
319 
 
 
36.3 (31-41.9) 
45.7 (40-51) 
 
 
0.002 
Conditioning 
MAC 
RIC 
 
947 
196 
 
41.2 (37.9-44.6) 
35.2 (28.5-42.5) 
 
0.1 
Number of HLA 
mismatches 
0 or 1 
≥ 2 
 
 
571 
532 
 
 
44.2 (39.9-48.5) 
36.0 (31.8-40.4) 
 
 
0.005 
Median TNC collected 
x10^7/kg 
≤ 4.7 
≥ 4.7 
 
 
559 
558 
 
 
34.3 (30.3-38.5) 
46.6 (42.3-50.9) 
 
 
0.0001 
Age of UCB, years 
>4.2 y 
<4.2 
 
 
584 
589 
 
37.9 (33.9-42.1) 
42.3 (38.3-46.5) 
 
0.09 
Median CD34+ 
collected x10^5/kg 
≤ 1.83 
≥ 1.83 
 
 
531 
527 
 
 
36.9 (32.7-41.3) 
43.7 (39.3-48.2) 
 
 
0.02 
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UCB storage duration did not have a significant impact on OS, but there was 
a trend towards worse survival rate after UCBT with older units (i.e. above 
median storage duration of 4.2 years) (p=0.09).  
 
Figure 6-4. Influence of maternal numbers of previous pregnancies to 5-year OS. 
 
Notably, there was no difference in 5-y OS between patients who received 
UCB from CMV seropositive mothers 41 %( 95% CI, 37-45.2) and those who 
received UCB from CMV seronegative mothers 38% (95%CI, 33.8-42.4), 
(HR=1.08, 95%CI 0.9-1.2, p=0.31), (Figure 6-5).  
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Figure 6-5: Influence of maternal CMV status on 5-year OS. 
 
In multivariate analysis, recipient’s age (HR =1.3, 95%CI, 1.1-1.5, p=0.002), 
disease stage at the time of UCBT (HR=2.6, 95%CI, 2.1-3.2, p<0.0001) and 
recipient’s CMV status (HR=1.2, 95%CI, 1.0-1.4, p=0.02) , history of 
maternal previous pregnancies (HR=0.4, 95%CI, 0.2-0.7, p=0.004) and 
maternal numbers of previous pregnancies (HR=1.4, 95% CI, 1.0-1.9, 
p=0.03) were factors associated with OS (Table 6-7).  
 
The probability of disease- free survival (DFS) at 5 years was 43% (95%CI, 
39.7-46.4) for patients in CR and 12% (95%CI,7.4-18.8) for those with 
advanced disease (p=0.001) (Figure 6-6).  
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Figure 6-6: The probability of 5-year DFS according to disease stage 
 
Factors, influencing 5-year DFS in univariate analysis are listed in Table 6-6. 
Notably, history of maternal previous pregnancies (p=0.009) and numbers of 
previous pregnancies (p=0.004) are associated with DFS. The 5-year DFS for 
patients receiving a UCB from a second or greater pregnancy (range, 2-7) was 
44.1% (95% CI, 35.5-47.1) compared with 34.4% (95%CI, 29-40.3) if the unit 
was from a first pregnancy (p=0.009) (Figure 6-7). Patients who received UCB 
from the second pregnancy had superior 5-y DFS at 48.4% (95%CI, 41.4-55.4) 
compared with patients whose UCB was from the first pregnancy- 34.4% 
(95%CI, 29-40) or third or greater pregnancy (range, 3-7) – 35.1% (26.1-45.3) 
(p=0.004) (Figure 6-8). 
 
 
Impact of maternal CMV serological status on UCBT outcome in recipients 
with acute leukaemia 
 140 
Table 6-6: Univariate analyses of 5-year DFS after UCBT for 1177 patients with Acute 
Leukaemia 
Variable N % (95%CI) p-value 
Recipient’s age 
≤ 18 y 
≥ 18 y 
 
604 
452 
 
46.3 (42.2-50.4) 
28.7 (24.6-33.2) 
 
0.0001 
Recipient’s CMV serology 
Negative 
Positive 
 
399 
598 
 
 
 
43.5 (38.5-48.6) 
36.2 (32.4-40.2) 
 
0.005 
Disease stage at UCBT 
CR 
Other 
 
896 
148 
 
 
43.5 (40.2-46.9) 
12.9 (8.2-19.6) 
 
0.0001 
Maternal CMV status 
Negative 
Positive 
 
455 
556 
 
37.5 (33.1-42.1) 
40.2 (36-44.6) 
 
0.3 
Maternal previous 
pregnancy 
Yes 
No 
 
 
298 
284 
 
 
44.1 (38.3-50) 
34.4 (29.40) 
 
 
0.009 
Maternal number of 
previous pregnancies 
0 
1 
>1 
 
 
284 
199 
95 
 
 
34.4 (29-40) 
48.4 (41.4-55.4) 
35.1 (26-45) 
 
 
 
0.004 
Conditioning 
MAC 
RIC 
 
947 
196 
 
41.2 (37.9-44.6) 
35.2 (28.5-42.5) 
 
0.1 
Serotherapy 
No 
 
198 
 
38.2 (31.6-45.2) 
 
0.9 
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Yes 
 
787 39.5 (36-43.1) 
Number of HLA 
mismatches 
0 or 1 
≥ 2 
 
 
519 
474 
 
 
43.1 (38.9-47.4) 
34.6 (30.2-39.2) 
 
 
0.01 
Median TNC collected 
x10^7/kg 
≤ 4.7 
≥ 4.7 
 
 
498 
513 
 
 
33.1 (28.9-37.5) 
45.2 (40.9-49.5) 
 
 
0.02 
Median CD34+ collected 
x10^5/kg 
≤ 1.83 
≥ 1.83 
 
 
473 
485 
 
 
35.3 (30.9-39.9) 
42.4 (38-47) 
 
 
0.07 
 
 
 
 
 
 
Figure 6-7. Influence of maternal previous pregnancies to 5-year DFS. 
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Figure 6-8: Influence of maternal number of previous pregnancies to 5-year DFS. 
 
 
In multivariate analysis, advanced disease (HR=2.5, 95% C, 2.0-3.1, p<0.0001), 
recipient’s older age (HR= 1.3, 95% CI, 1.1-1.5, p=0.01), history of maternal 
previous pregnancy (HR=0.4, 95% CI, 0.2-0.8, p=0.005) and numbers of maternal 
previous pregnancies (HR=1.4, 95% CI, 1.0-1.9, p=0.04)  were factors which had 
an effect on DFS (Table 6-7).   
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Table 6-7: Multivariate analysis of risk factors for each main outcome after UCBT for 1177 children 
and adults with AL. 
Outcomes and unfavourable risk 
factor 
Hazard ratio (95% 
CI) 
p-value 
 
Relapse  
 
Advanced disease  
Serotherapy 
RIC conditioning regimen 
 
 
 
 
 
2.4 (2.1-2.8) 
1.4 (1.3-2.5) 
1.3 (1.1-1.5) 
 
 
 
 
<0.0001 
0.007 
0.01 
 
Overall survival 
 
Advanced disease  
Older recipient’s age (≥18 y) 
Recipient’s CMV seropositivity 
Maternal previous pregnancies 
Maternal number of previous 
pregnancies 
 
 
 
 
 
2.6 (2.1-3.2) 
1.3 (1.1-1.5) 
1.2 (1.0-1.4) 
0.4 (0.2-0.7) 
1.4 (1.0-1.9) 
 
 
 
<0.0001 
0.002 
0.02 
0.04 
0.03 
 
 
 
Non-relapse mortality 
 
Advanced disease  
Recipient’s CMV seropositivity 
Serotherapy 
 
 
 
 
 
 
 
1.5 (1.3-1.7) 
1.6 (1.4-1.8) 
1.5 (1.3-1.8) 
 
 
 
 
0.003 
<0.0001 
0.004 
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Disease-free survival  
 
Advanced disease 
Older recipient’s age (≥18 y) 
Maternal previous pregnancies 
Maternal number of previous 
pregnancies 
 
 
 
 
2.5 (2.0-3.1) 
1.3 (1.1-1.5) 
0.4 (0.2-0.8) 
1.4 (1.0-1.9) 
 
 
<0.0001 
0.01 
0.005 
0.04 
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 Discussion 
Previous studies reported that several UCB characteristics influence UCBT 
outcomes. Most of these studies have focused on qualitative and 
quantitative characteristics of cord blood unit. Important factors (such as cell 
dose and HLA match) are outlined in the first chapter of my thesis. Evidence 
of bidirectional foeto-maternal exchange of information suggests that UCB 
contains cells from both the foetus and the mother.   Recent studies indicate 
that foeto-maternal interaction during pregnancy might enhance the 
alloreactive potential of cord blood units.  
 
This study analysed was the first to analyse the impact of maternal CMV 
status on UCBT outcome. This analysis pooled together records of 
unrelated single-unit UCBT in 1177 adults and children with acute 
leukaemia.  
 
My retrospective study confirms that cord blood represents a source of 
haematopoietic stem cells that can be successfully used for an unrelated 
transplant not only in children but also in adults lacking a suitable adult 
unrelated donor.  
 
In accordance with previous findings neutrophil engraftment was 
significantly slower when compared with data on adult unrelated donors (M. 
Eapen et al., 2010), (F Locatelli et al., 1999). However, the overall 
probability of donor derived neutrophil engraftment at day 100 was 88.6% 
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(95%CI, 86.8-90.4). Nonetheless, improving the speed of engraftment 
remains an on-going challenge. This study confirms previous reports that 
collected TNC and CD34+ cell dose are associated with the probability of 
neutrophil engraftment. These factors have been  recognised as affecting 
engraftment in a UCBT setting (L Tucunduva et al., 2014), (Gluckman & 
Rocha, 2006), (Arcese et al., 2006). Therefore, to improve engraftment, the 
main effort should be on increasing limited cell dose such as optimising UCB 
collection techniques, targeted storage of optimal units, further exploration 
of ex vivo expansion and broader use of double cord blood unit transplants. 
In addition, UCBTs performed before 2008 were associated with lower 
incidence of neutrophil engraftment. However, the absence of standardised 
laboratory methods in CD34+ enumeration across the centres precludes us 
from assessing the implication of this factor. 
 
To summarise, the recent improvements in outcomes are likely to reflect a 
greater understanding of factors influencing CBU transplant outcomes and 
the development and use of cord blood selection algorithms.  
 
The present study showed low incidences of acute and chronic GvHD, 
despite the fact that 45% of patients were mismatched with their cord blood 
donor at two or more HLA loci. This supports the findings of previous studies 
on GvHD occurrence after UCBT (Rocha et al.,2001), (F Locatelli et al., 
1999).  
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Non-relapse mortality at 2 years was 25.4% (95%CI, 86.6-90.4). It is 
significantly lower than in previously published reports which predominantly 
focused on adult patients (Arcese et al., 2006), (Mary Eapen et al., 2007). It 
might be explained by the fact, that the current study cohort included a 
significant number of paediatric patients (57%) and patients presented in 
CR at the time of UCBT (81.5%). These factors are well recognised for being 
associated with lower NRM. Other previously described negative prognostic 
factors, such as recipient’s CMV seropositivity at the time of UCBT and the 
use of serotherapy, were confirmed as being significant in the current study 
(Y. C. Cohen et al., 2011).  
 
The cumulative incidence of relapse at 5 years was 33.8% (95%CI, 31-
36.8). As expected, in this study we confirmed that such factors as advanced 
disease at the time of UCBT, and use of serotherapy and a RIC regimen 
were significant factors associated with relapse rate (L Tucunduva et al., 
2014), (Ballen et al., 2013), (Rocha et al., 2009) (Franco Locatelli, 
Schrappe, Bernardo, & Rutella, 2012).  
 
Advanced disease at the time of UCBT and recipient’s older age were 
factors that influenced DFS. Patients who were transplanted in advanced 
disease had unfavourable DFS rates (43%, 95%CI, 39.7-46.4) while DFS 
was better in patients transplanted in CR (12%, 95%CI, 7.4-18.8). These 
figures are similar to those reported in previous studies (Mary Eapen et al., 
2007), (L Tucunduva et al., 2014) (Arcese et al., 2006). As with the study 
performed by Arcese et al, I did not observe an effect of HLA disparity on 
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DFS. A possible explanation could be related to the interaction between cell 
dose and HLA mismatch (i.e. ‘larger units’ are more ‘acceptable’ with greater 
HLA disparity). Indeed, in our cohort the median collected TNC dose was 
4.47x10^7/kg. It has been published that an increase in TNC above the 
minimum threshold of 3.0x10^7/kg is not associated with a reduction in NRM 
and DFS (V. Rocha, E. Gluckman, 2009).  
 
The use of the RIC regimen in the context of unrelated UCBT for acute 
leukaemia was addressed by several retrospective studies (Veronika 
Bachanova, Verneris, Defor, Brunstein, & Weisdorf, 2009)and (Ringdén et 
al., 2009). In this study, a RIC regimen was associated with increased 
relapse rate, which was also observed in previous studies on adult 
recipients with ALL (L Tucunduva et al., 2014), (Ringdén et al., 2009). It was 
not associated, however, with inferior OS or superior NRM. In contrast to 
our study, a report from the EBMT group on a series of 449 adult patients 
transplanted in CR1 for acute leukaemia, showed that NRM was lower after 
RIC (Ringdén et al., 2009). The difference in results might be explained by 
the fact that our cohort had a lower proportion of RIC regimen recipients 
(16.7%).  
 
The rate of 5-year OS in our study was 40%. In line with previous reports, 
the current study showed that factors that associated with inferior survival 
rates were: lower TNC dose, older recipient’s age, recipient’s CMV 
seropositivity at the time of UCBT and advanced disease (Y. C. Cohen et 
al., 2011) , (F Locatelli et al., 1999),  (Rocha et al., 2010) (Mary Eapen et 
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al., 2007), (Rubinstein et al., 1998), (Arcese et al., 2006) and (L.Tucunduva 
et al., 2014). As observed in previous reports, this analysis found no link 
between recipient's gender, diagnosis and conditioning regimen and OS 
(Luciana Tucunduva et al., 2015), (Arcese et al., 2006) ,(F Locatelli et al., 
1999).  
 
This study for the first time provides evidence that the birth order of donated 
UCBs had an impact on transplant outcome for recipients with acute leukaemia. 
In this study, I discovered that patients who received UCBs from the second 
pregnancy had lower NRM and better DFS which translated to superior OS 
compared with recipients who received UCBs from either the first pregnancy or 
the third or greater pregnancy. However, the same difference was not observed 
in the probability of disease relapse. The maternal previous pregnancy effect 
on DFS and OS was independent factor to other well-established donor-
recipient risk factors, including recipient’s age, CMV status, stage of the disease 
and number of HLA mismatches.The major histocompatibility (MHC) identity of 
the donor and recipient is not the sole factor determining the immunological 
reactivity in HSCT. In an unrelated donor setting, even if the MHC antigens of 
the donor are identical to the recipient’s, alloreactive transplant reactions (like 
GvHD and rejection) may occur due to the difference in minor histocompatibility 
antigens (MiHAs). Previous studies have provided evidence that GvHD could 
be caused by a number of MiHAs, including H-Y (Choi et al., 2002), (Yang et 
al., 2003), (Araki et al., 2010). Immunological targeting of H-Y proteins results 
in a relatively high incidence of acute GvHD when male recipient receives a 
graft from a female donor in the context of adult unrelated donor HSCT (Stern 
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at al., 2006). Therefore, it will be logical to assume that in the context of UCBT, 
the gender of the previous maternal pregnancy might be an important factor. 
One of the explanatory factors might be the theory of persistent fetal 
microchimerism in mothers that has been supported by few studies.  In 1996, 
Bianchi et al studied venous blood samples of 40 women (32 currently pregnant 
women and 8 non-pregnant women, who had prior pregnancy). The group 
demonstrated that male DNA was detected in peripheral blood CD34+ or 
CD34+CD38+ cells in four women, pregnant with female foetus and six out of 
eight non-pregnant women. All previous offspring in these women were male 
gender and one woman had previous pregnancy 27 years prior to the blood 
collection. Median timing of blood sample for pregnant women was between 
three to eight months of pregnancy (Bianchi, Zickwolf, Weil, Sylvester, & 
DeMaria, 1996). In the context of UCBT, the clinical significance of this 
microchimerism is controversial. On the one hand, the presence of fetal 
microchimerism in maternal blood induces feto-maternal tolerance and prevent 
foetus rejection (Godfrey et al., 2005). On the other hand, it might be a potent 
alloreactivity inducer. For example, in 2010, Nielsen et al. performed a study on 
499,731 women to analyse the risk of stillbirth in relation to the gender of prior 
offspring. The report suggested that “women who had previously delivered a 
boy had a greater risk of stillbirth in subsequent pregnancies”. This effect was 
explained by a “possible maternal immune response to male -specific MiHAs 
(H-Y) initiated during pregnancies with boys which persisted for many years” 
(Nielsen et al., 2010). In addition, “possible association between fetal 
microchimerism in maternal blood  and autoimmune diseases in women have 
been described” (Miech, 2010) (Sarkar & Miller, 2004), (Leduc, Aractingi, & 
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Khosrotehrani, 2009), (Maloney et al., 1999). Therefore, subsequent transport 
of these alloreactive maternal cells acquired during previous pregnancy into 
cord blood unit of the subsequent offspring could affect UCBT outcome. 
Unfortunately, in this study, I did not have information of maternal previous 
pregnancy gender. Therefore, further studies assessing the effect of maternal 
previous pregnancy gender to UCB’s immunogenic potencies (such as superior 
graft-versus leukaemia effect) are required.  
 
Several studies have been performed to investigate the influence of IPA and 
NIMA on transplant outcomes. In 1988 Class et al found, that HLA broadly 
sensitised patients failed to produce antibodies against non-inherited maternal 
antigens (NIMA), but were fully capable of producing antibodies against 
inherited paternal antigens (IPA) (Claas, Gijbels, van der Velden-de Munck, & 
van Rood, 1988). This observation led to the hypothesis that recipient HLA 
antigens which are mismatched with the cord donor but are matched to the 
donor’s NIMA might be permissible HLA mismatches in the context of stem cell 
transplantation. Higher survival rates after NIMA-matched UCBT supports the 
theory of NIMA-induced immune tolerance. In 2009, J van Rood et al 
investigated 1121 recipients with haematological malignancies who received a 
single unit UCB with either single or double HLA mismatches. Of 1121 cases, 
79 recipients had at least one HLA antigen mismatch which was matched to the 
UCBs NIMA. The study demonstrated that recipients, who were transplanted 
with NIMA-matched units, had better transplant outcomes (lower TRM, better 
OS and lower incidence of relapse) than recipients whose UCBs were NIMA-
mismatched (van Rood et al., 2009). Another study analysed UCBT outcomes 
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on 164 UCB-recipient pairs for recipients with haematological malignancies. All 
of pairs in the study were matched in disease, age and transplant procedures  
(48 NIMA matched and 116 NIMA mismatched pairs) (Rocha et al., 2012). The 
group demonstrated, that in NIMA -matched pairs TRM was lower in 
comparison to NIMA-mismatched pairs (p=0.05), resulting in superior OS 
(p=0.04).   
 
Considering NIMA-matches as permissible when faced with the choice of 
multiple HLA- mismatched UCB, might help to identify mismatched units which 
can be better tolerated (Powley et al., 2016). In addition, it could increase the 
chances of finding a ‘suitable’ donor for a greater number of patients. A recent 
retrospective study on 4707 NIMA-defined UCBs from the UK-British Bone 
Marrow Registry (BBMR) showed that the cumulative incidence of finding a 
suitable graft was tripled in ethnic minority recipients and doubled in European 
Caucasoid recipients if an HLA mismatched but NIMA matched donor was 
considered (Powley et al., 2016).  
 
Because of the existence of feto-maternal tolerance, IPAs are more 
immunogenic than NIMAs. In 2012, J van Rood et al. observed that “a higher 
birth order of UCB donor was independently associated with a reduced 
incidence of relapse in patients with haematological malignancies” (Rood et al., 
2012). The group explained this as “better control of relapse risk through 
sensitisation to IPA, or an immune “booster” effect associated with repeated 
pregnancies”. However, the precise mechanisms underlying the NIMA and IPA 
heterogeneity are yet to be established. Unfortunately, in this study, the 
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information of maternal and paternal HLA typing was not recorded and therefore 
not assessed.  
 
Clinical evidence of the effect of maternal parity on the allo-SCT setting was 
observed in several studies. A retrospective analysis on 11365 recipients with 
haematological malignancies who received HLA identical sibling donor 
transplants, observed lower rates of acute and chronic GvHD when the donor 
was younger than the recipient, but no effect of birth order on relapse incidence 
or overall survival was found (Dobbelstein et al., 2013). The authors explained 
this outcome by “transient maternal microchimerism with an immunomodulatory 
(tolerogenic) effect to the ‘’older’ sibling present in younger sibling”. In contrast, 
Tamaki et. al reported that  maternal grafts were superior in terms of disease-
free survival, relapse incidence and mortality in the haploidentical SCT setting 
(Tamaki et al., 2001). The group had explained this observation by 
heterogeneity of the NIMA effect, which can be either tolerogenic or 
immunogenic, as in the latter case.  In line with the previously mentioned study 
on birth order effect in HLA matched sibling HSCT (Dobbelstein et al., 2013), I 
failed to find a previous maternal pregnancy effect on incidence of disease 
relapse. However, as mentioned above, J van Rood et al observed that relapse 
incidence in recipients with haematological malignancies was associated with 
birth order of selected UCB, with “higher” birth order providing anti-leukaemic 
effect (Rood et al., 2012). The difference between this study and that of J van 
Rood could be explained by a larger sample size in the latter (639 versus 1030 
recipients) and by the effect of ethnic background of the study subjects, which 
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might result in different genetic prognostic factors. In addition, the current study 
did not examine IPA of the selected UCB-recipient pairs.  
 
Another potential factor to consider is the duration and timing of fetal and 
mother exposure to non-self-expressed antigens. In that case, maternal 
pregnancy and delivery outcome (complicated or uncomplicated, i.e. 
intrauterine haemorrhage etc.), parity and age should be considered. For 
example, there is a suggestion that feto-maternal haemorrhage either in 
pregnancy or during delivery leads to “more active” information exchange 
between the foetus and the mother (Bianchi et al., 1996). In addition it was 
observed, that high maternal parity was associated with increased risk of 
placenta previa, which a risk of haemorrhage (Shah, 2010). Therefore, it might 
be possible that both mother and foetus did not have sufficient exposure to non-
self-antigens, in the case of uncomplicated pregnancies or deliveries. I did not 
have information on either maternal pregnancy (i.e. complicated or 
uncomplicated) or mode of the delivery.  
 
Another factor is  maternal age. For example, young maternal age (i.e. less than 
18 years) was described to be associated with pre-term deliveries (Kozuki et 
al., 2013). In was observed that gestational age was associated with quality of 
collected UCB. UCBs collected from full-term pregnancy have higher TNC 
count (Solves et al., 2005), (Shlebak et al., 1998).  Higher TNC count in UCB is 
associated with better OS after UCBT (Ballen et al., 2013). Therefore I 
hypothesise that maternal “younger” age might be associated with inferior 
UCBT outcome, due to the increased risk of pre-term deliveries. In this study, 
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full-term pregnancy was associated with better overall survival in univariate 
analysis when compared with pre-term pregnancy (47.6% and 39.9% 
respectively, p=0.03). Greater number of maternal previous pregnancy was 
associated with slightly higher risk of pre-term delivery (p=0.04), which supports 
above mentioned theory of TNC dose and gestational age and in current study 
resulted in inferior OS and higher NRM for recipient of UCBs from third of 
greater pregnancy.  
 
To summarise, undoubtedly maternal parity, age and other obstetric factors are 
an important elements in UCBT outcome. Based on the evidence presented in 
previous reports and results of this study, UCB grafts from the second 
pregnancy are superior in terms of higher DFS, lower NRM and better OS post-
UCBT. The impact of the exact numbers of previous maternal pregnancy is 
evident, but the reason for this is still not clear. What has become clear is that 
a very fine balance exists between T- and B-cells tolerance and reactivity. This 
balance swings in one direction or another over time and under certain 
conditions and events. When immunotolerance predominates, it results in 
better survival and lower incidence of GvHD. When the balance fluctuates 
towards alloreactivity, the graft-versus leukaemia effect is more noticeable, 
resulting in a lower incidence of disease relapse and perhaps higher rates of 
GvHD. Factors that could influence potential immunological consequences of 
exposure to maternal or fetal antigens might be: timing and duration of 
exposure, quantity and quality of antigen, maternal age, delivery mode and 
duration of delivery.  
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Based on evidence presented in this study, I may conclude that, in addition to 
UCB’s “classical “selection criteria (such as TNC dose and currently used UCB-
recipient HLA matching), information of maternal previous pregnancies could 
be taken into account when selecting UCB for transplantation. I suggest that if 
otherwise equally matched, a UCB from the second pregnancy may be superior 
to a UCB from first or third or greater pregnancy in terms of improved survival 
rate. Larger study which captures maternal parity, mode of the delivery, gender 
of offspring, and maternal and paternal HLA typing, are required to examine 
birth order effect on UCB transplant outcome.  
 
This analysis has several potential limitations. As in any retrospective study, 
additional potential unmeasured parameters may exist, for example, 
recipient’s CMV infection post-transplant, transplant centre practice, other 
maternal factors (like as age, previous pregnancy, gender of previous 
pregnancy etc.) and even maternal and paternal HLA typing. Unfortunately, 
missing variables (numbers of pregnancies, for example) was a major 
limitation when assessing the impact of various factors on transplant 
outcome in the larger cohort of patients. Some of the follow-up data was 
unavailable to the registry and some records had missing data.   
 
To conclude, maternal CMV status had no obvious influence on UCBT 
outcome in this study. However, other maternal factors should also be 
considered, such as maternal age, parity, UCB birth order etc. In line with 
previous studies, having disease in CR at the time of transplant and 
conditioning regimen (MAC and T-cell replete grafts) had a favourable 
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impact on the risk of relapse. Further larger studies, capturing multiple 
maternal factors (age, parity, sex of previous babies, HLA typing) and 
obstetric factors (mode of the delivery, collection technique) are needed in 
order to confirm findings of this study, that UCBT with CBU from the 2nd 
pregnancy provides better outcomes in terms of reduced NRM. And most 
important, to understand the biological mechanism/s of this phenomenon.  
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Chapter 7. Conclusions  
 
 Summary 
 
This thesis presents investigations of factors influencing the quality parameters 
of cord blood units and the selection criteria of unrelated cord blood units as a 
graft source for HSCT. A diverse group of parameters contribute to the final 
cord unit selection criteria. I have written a review of factors implicated in 
unrelated cord blood unit provision based on the previous experience of 
different clinical and research groups performing cord blood transplantation 
across the world. I have designed and carried out five research studies. In this 
chapter, the outcomes of these studies are summarised. I will also briefly 
discuss some of the challenges I faced in this work and propose future work 
that will further contribute to this field.   
 
Chapter 1 summarised the current evidence and practice of unrelated donor 
provision in the context of unrelated cord blood unit transplantation. It detailed 
factors influencing unit choice, taking the recipient’s diagnosis, age/weight, cell 
dose and HLA typing of the cord blood unit into consideration. Further factors 
that have emerged lately have also been described, such as the possible 
influence of the cord blood unit’s NIMA, IPA and KIR ligand on HSCT outcomes.  
There are only a few studies that have prospectively examined the effect of 
maternal factors (such as exposure to infections and previous pregnancies) on 
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transplant outcome and cord blood unit cell content. To my knowledge, my 
study was the first in-depth investigation into the influence of maternal viral 
serological status and previous pregnancies on transplant outcomes for 
patients with acute leukaemia.  
 
The study I conducted in Chapter 2 demonstrated the effect of delivery mode 
on cord blood unit cell content. It showed that more ‘’stressful’’ modes of 
delivery (i.e. instrumental vaginal and emergency Caesarean section) provide 
cord blood units, which have a higher total nucleated cell content, compared 
with other types of delivery. Given priority to those collections from above 
described “stressful” delivery modes might have a clear impact on the use of 
Anthony Nolan’s resources at cord blood unit collection sites. Besides, the 
possibility of the introduction of delayed cord blood clumping into standard UK 
practice should be reconsidered, given the previous experience of its safety and 
harmlessness, but possible benefit for the collected CBU qualitative 
parameters.  
 
Chapter 3 focused more on maternal factors that can influence cord blood unit 
cell content. It explored the influence of maternal previous exposure to viral 
infections (CMV, EBV and Toxoplasma gondii) on the cell count of the collected 
cord blood unit. The study was conducted in two sites: Barcelona’s Cord Blood 
Bank and Anthony Nolan Cell therapy Centre. The study found that cord blood 
units from mothers who had been previously exposed to the viruses, in 
particular to CMV, had a greater lymphocyte count. Cell dose still remains one 
of the most important factors when selecting cord blood units for 
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transplantation. In the future, therefore, maternal serological status might be an 
important consideration cord blood unit collection and in selection strategy. 
However, the question that remains unanswered is that of the phenotype of the 
cells present in cord blood units collected from CMV positive mothers.  
 
Chapter 4 explored cord blood unit-recipient HLA matching at high resolution. 
Analysis was performed on units, which were selected for transplant with UK 
patients. This study revealed a high degres of HLA mismatch between selected 
donor and recipient when applying matching at high resolution for HLA Class I 
and Class II genes (-A, -B,-C and –DRB1) opposed to ‘’classical’’ matching, i.e. 
low/intermediate level for HLA Class I genes (-A and –B) and high resolution 
for HLA Class II genes (mainly -DRB1). As previously published, better 
matching between cord blood unit and recipient at high resolution leads to better 
transplant outcomes. My study suggests that HLA matching at high resolution 
level should be implemented when selecting cord blood units. Therefore, it is 
highly desirable and clinically beneficial for cord blood banks to provide high 
resolution typing results for all cord blood units at the time of the search.  
 
Finally, in Chapters 5, 6 and 7, I presented a study of the influence of maternal 
CMV serological status and previous pregnancies on the outcome of unrelated 
donor single-unit umbilical cord blood transplant for paediatric and adult 
patients with acute leukaemia. This was the first study to examine the influence 
of maternal CMV serological status on transplant outcome. I found, that 
maternal CMV status does not impact on main transplant outcomes. An 
important finding, however, was that acute leukaemia patients, who received 
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cord blood unit that was collected from the 2nd pregnancy, had reduced non-
relapse mortality and superior overall survival. This knowledge could affect 
future recording of the data of cord blood unit’s quality parameters and could 
affect UCB selection strategies in the context of UCBT.  
 
 Challenges  
Inevitably there were many challenges presented by these projects.  
The greatest challenge I encountered during the studies described in this thesis 
occurred during data collection, particularly for the Eurocord study. Process 
involved coalition data from many different information sources delivered 
through different European Cord Blood Banks and Transplant Centres.  Often 
several different spreadsheets were required to provide the necessary 
information. This proved far more time consuming than I had anticipated.  
I needed to visit the Eurocord office in Paris to set up the study and establish 
collaboration and approval of the study proposal. Whilst I was able to receive 
the required information from most of the Cord Blood Banks contacted, many 
of the data points were still missing, in particular, number of previous 
pregnancies in respect of donor mothers. The same difficulty was encountered 
in obtaining the information on Cord Blood Unit transplant procedures which 
Eurocord receives from transplant centres.  
This particular study has highlighted the great diversity in the fashion in which 
data is managed at different transplant centres. Although Eurocord itself has an 
excellent data acquisition and management methodology in place, the 
upstream complications in transplant centres presented several challenges. 
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Sophisticated and complicated statistical analysis of data was also problematic. 
I needed to become confident working with SPSS and R code. It was a steep 
learning curve but I have gained a lot in return.  
 
When collecting the data for the collaborative study between Barcelona’s Cord 
Blood Bank and Anthony Nolan Cell Therapy Centre, the enormous size of the 
data set and spreadsheets was also a challenge. The data analysis therefore 
proved to be extremely time consuming and complex.  
 
Above challenges however, made me think out-of-the-box and come up with 
solutions / workarounds. At a personal level this has been a tremendous 
learning experience for me. 
 
 Future Projects 
 Immunophenotyping of cord blood units collected from CMV 
seropositive mothers 
I have discovered that the lymphocyte count of cord blood units collected 
form CMV seropositive mothers is higher than that collected from CMV 
seronegative mothers. It is of paramount importance to determine the origin 
and phenotype of these cells. The question to be answered is whether these 
cells are maternal cells that have crossed the placenta or de novo fetal cells 
developed in response to low level antigen present in mothers who 
experienced CMV infection before pregnancy. From the work that has been 
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done and still on-going on frozen and fresh UCBs at AN Research institute, 
it was found that low frequency (<4%) of memory phenotype CD4+ T-cells 
(CD4+CD45RA-CDRO+) could be identified in cord blood samples 
(personal communication, Richard Duggleby, unpublished). Of even greater 
importance is to discover the clinical implication of these cells.  
 A study of the influence of previous donor pregnancies on 
the outcome of unrelated cord blood transplants for malignant 
disorders.  
Following the observation from the retrospective study I performed in 
collaboration with Eurocord, that previous pregnancies of the UCB maternal 
donors may influence survival in UCB transplantation, Anthony Nolan are 
planning to initiate a new larger study using single cord blood transplants 
for all haematological and non-haematological  disorders. Primary data will 
be obtained from Barcelona’s CBB and Eurocord databases.  The study will 
capture birth order and gender of previous pregnancies. If data can be 
reproduced using a larger sample, it may dramatically change the future 
selection of the UCB for the transplant, making it more patient-tailored 
approach.  
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 Conclusion  
 
In the early 2000s, the usage of UCBT was predominantly limited to paediatric 
patients due to the greater difference between cord blood unit cell dose and 
patient weight in the adult recipients group. Since then, a better understanding 
of the minimum safe transplantable cell dose has improved quality and 
characterisation of the UCB inventory and the development of the double unit 
UCBT has broadened the applicability to the adult population. Since the results 
of UCBT for both adult and paediatric patients are comparable to the results of 
the adult unrelated donor transplants, cord blood represents an alternative graft 
source for those patents, who lack a well matched adult donor.  
 
The major challenge for modern cord blood banking is to demonstrate cost-
effectiveness and practicality. Through the studies and projects detailed in this 
thesis, I have been able to identify areas for improvement and potential cost 
reduction for cord blood banking.  It focuses first of all on the cord blood 
collection sites, given that there is an indication that cord blood units collected 
via instrumental vaginal deliveries and emergency Caesarean section are more 
likely to be stored for further clinical use.  It continues with maternal 
characteristics such as history of previous exposure to CMV infection, which 
leads to a higher cell count in the unit. Studying cord blood unit birth order 
appears which appears to be significant. Finally,the importance of adopting 
donor-recipient matching at high resolution level in order to improve cord blood 
unit transplant outcome.  
 
Conclusions 
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The adult unrelated donor characteristics, which make it the “perfect match”, 
are well established: younger age, CMV status, male gender for example. 
Regarding UCB selection, the “classical “selection strategy has been based on 
cell dose and HLA matching. But with knowledge of UCB-recipient tri-
dimensional relationships, new factors have to be taken into account, such as 
NIMA, IPA, birth order and gender of previous pregnancies.  
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Appendix – Supplemental Tables 
and Figures 
Figure S- 1: Study Proposal of Examining the Association between Maternal CMV 
Serostatus and UCB Cell Count Possible Influence Of Cytomegalovirus Status Of The Cord Blood Donor Infant’s Mother And Infant’s Cord Blood Unit (CBU)  On Quality Parameters Of The CBU (ie Total Nucleated Cell Dose (TNC), Haematopoietic Stem Cell Progenitors (or CD34+ cells) Count And Total Lymphocyte Count.  
 
Introduction: 
 
Human cytomegalovirus (CMV) infects most individuals in the word, usually 
without producing overt symptoms.  
Positivity of anti-CMV IgG antibody (AB) in the mother reflects the mother’s 
lifetime exposure to CMV. Anti-CMV IgM AB is a marker of a recent active 
CMV infection. At the time of the infant’s birth, anti-CMV IgG AB were found 
in 59% and anti-CMV IgM AB in 1.6% of  the mothers (M. Albano et al, 2015).  
 
The possibility of transmaternal cell flow has been described previously 
(M.Dieselhuis et al 2015, B. Momaas et al 2015). There is growing evidence 
that intrauterine antigenic stimulation has the potential to elicit immune 
response in fetus.  It is possible, that maternal cells, which were ‘’in contact’’ 
with antigen (virus), would gain an access to the placenta, where they might 
produce pro-inflamatory cytokines and promote cells proliferation. It has 
been described that CMV could be particularly efficient at promoting the 
activation and differentiation of CD8+ T cells early in life (A. Marchant et al, 
2003). Other potential targets of CMV in fetus have to be explored further.  
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In this study, we hypothesise that CBU obtained from CMV positive mothers 
might have higher cellularity, in terms of nucleated cell count, lymphocyte 
count and CD34+ cell count, as they come into contact with the maternal 
antigen through the transmaternal cell flow.  
Materials and methods 
 
We will include in the study CBU which were collected in both Nottingham’s 
Cell Therapy Centre and Barcelona’s Cord Blood Bank from October 2008 
to September 2014.Only CBU which were proved to be suitable for the 
clinical use (according to the local standards) will be included in the study.  
Data on CBU quality parameters will include post-processing and pre-thaw: 
NC count (per ml or per uL), CD34+ cell count (x10 ^6), total lymphocyte 
count (CD45+)  x10^3/ul), Data on maternal and CBU serological status 
(anti-CMV IgG and IgM AB) and viral DNA (when indicated) and CBU quality 
parameters, will be obtained from the databases of the above mentioned 
centers. We plan to include both infant’s weight (kg) and mode of the 
delivery (normal vaginal, instrumental vaginal, emergency Cesarean and 
elective Cesarean section. Those data will be collected from the database 
of both participating centers.  
 
We plan to evaluate subsequent groups (cohorts) :  
 
Group 1: CMV-IgG and CMV-IgM neg   
Group 2: CMV-IgG pos and CMV- IgM AB neg 
Group 3: CMV-IgG, -IgM  pos and CMV viral DNA pos  
Group 4: CMV-IgG, -IgM  pos and CMV viral DNA neg  
 
Statistics 
 
To determine difference between means in 4 groups, we plan to perform a 
parametric ANOVA  test, with a post Hoc test to compare all groups. The 
null hypothesis will be rejected at a P-value of <0.05.   
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Table S- 1: Example of a Spreadsheet used for the Study Examining the Association between Maternal 
CMV Serostatus and UCB Cell Count 
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Figure S- 2: Study Proposal for the Project on Donor Recipient Allele-level HLA Matching of Unrelated 
UCB 
 
Project name: Level of patient/CBU HLA matching in Cord HSCT 
 
Background: Unrelated cord blood is increasingly used as an alternative hematopoietic 
stem cell source in patients without suitable adult donor. The degree of HLA mismatch is 
associated with transplant outcomes, such as engraftment, TRM, GvHD. Traditionally 
HLA-match requirements have been less stringent (antigenic match for HLA-A, -B and 
allelic match for HLA-DRB1 alleles) with up to 2 alleles mismatch allowed. Recently, the 
new data has emerged showing HLA-C mismatch being associated with increased TRM 
in single CBU transplant recipients.  Also allele-level HLA matching on both Class I and 
Class II loci has been recommended to be considered in both single- and double-unit CBT. 
 
Aim: to establish 8/8 HLA matching, and see whether new matching criteria would change 
CBU selection  
 
Case group: all UK patients transplanted with unrelated CBU in 2013-14 – single or 
double CBT. N=144 
 
Method:  
Patient and CBU HLA typing will be compared based on: 
- Current matching criteria: 6/6 with HLA-A and –B at an antigenic level and –DRB1 at 
allelic level of resolution; 
- New matching criteria (recommendations approved by UK Cord Working Group, but not 
yet published): 8/8 with HLA-A, B, - C, -DRB1 at allelic level of resolution; 
- Clinical outcome (OS, TRM, chimerism, neutrophil/platelets engraftment, GvHD) to be 
collected through BSBMT 
-  
Staff involved: Head of Specialist Services and Search Advisor (HLA matching) and 
Medical Officer (patient outcome) 
 
Expected results:  
- Understanding of actual situation on patient/CBU HLA matching 
- Understanding of potential effect of introducing new matching criteria on CBU selection 
and availability 
-  
Time frame:  
- January 2015 – collecting HLA matching information 
- February – March 2015 – collecting patient outcome information 
- April 2015 – analysis 
- May 2015 – presentation, publication  
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Table S- 2: Example of a Spreadsheet used for the Study on Donor Recipient Allele-level HLA Matching of 
Unrelated UCB 
Patient Patient name Cord ID 
UK versus 
Import 
CBU 
Match 
grade 6/6 
Match 
grade 
8/8 LR 
Match 
grade 
8/8 HR 
Match grade 
8/8, predicted 
      Int+Int 4/6 5/8 4/8 NA 
      Int+Int 4/6 5/8 4/8 NA 
      Import 5/6 NA NA 6/8 
      Import 5/6 7/8 6/8 NA 
      Import 5/6 NA NA 7/8 
      Int+Int 4/6 NA NA 3/8 
      Int+Int 4/6 4/8 2/8 NA 
      UK+INT 5/6 6/8 NA 6/8 
      UK+INT 5/6 NA NA 5/8 
      Import 6/6 8/8 NA 8/8 
      Int+Int 5/6 NA NA 5/8 
      Int+Int 5/6 NA NA 5/8 
      UK+UK 5/6 6/8 6/8 NA 
      UK+UK 5/6 6/8 6/8 NA 
      UK+UK 4/6 6/8 6/8 NA 
      UK+UK 4/6 6/8 NA 6/8 
      Import 5/6 7/8 6/8 NA 
      Import 5/6 7/8 7/8 NA 
      Int+Int 4/6 5/8 NA 5/8 
      Int+Int 5/6 NA NA 6/8 
      Import 5/6 N/A N/A 6/8 
      Import 6/6 8/8 6/8 NA 
      Int+Int 5/6 6/8 6/8 NA 
      Int+Int 4/6 5/8 5/8 NA 
      Import 5/6 7/8 NA 7/8 
      UK 5/6 6/8 6/8 6/8 
      UK 6/6 8/8 NA 8/8 
      Int+Int 4/6 5/8 5/8 NA 
      Int+Int 4/6 5/8 5/8 NA 
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Figure S- 3:  Study Proposal for the Eurocord Study 
 
                                                
 
Possible Association of Cord Blood Unit and mother’s Serological Status 
(Cytomegalovirus, Ebstein-Barr Virus and Toxoplasma gondii), age, previous pregnancies, 
gestational age with Outcomes of Unrelated Donor Single-Unit Umbilical Cord Blood 
Transplant (UCBT) for paediatric and adult patients with Acute Leukaemias. 
A study proposal on behalf of Eurocord-CTIWP (EBMT) and Netcord, 
And Antony Nolan Research Institute (ANRI) 
 
Principal Investigators: 
 
• Olga Nikolajeva London, ANRI 
• Alejandro Madrigal London, ANRI 
 
Co-investigators: 
 
• Vanderson Rocha Eurocord, Hôpital Saint Louis, Paris and London CBB  
                                    NHSBT (Oxford) 
• Susana G Gomez        Nottingham Cell therapy Centre (ANRI) 
• Sergio Querol             Barcelona, Cord Blood Bank (Netcord) 
• Annalisa Ruggeri Eurocord and CTIWP-EBMT, Hôpital Saint Louis,    
                                    Paris                            
• Gesine Koegler           Düsseldorf, Cord Blood Bank (Netcord) 
• Etienne Baudoux        Service de thérapie cellulaire et génique, Belgium  
• Eliane Gluckman Eurocord, Hôpital Saint Louis, Paris 
 
 
Statistician 
• To be defined  
 
1. Rational 
Cytomegalovirus (CMV) status of the graft in the context of allogeneic Haematopoietic Stem Cell Transplant 
(HSCT) makes an impact on the transplant outcomes. Both CMV seropositivity of recipient and seronegative 
stem cell donor transplanted to seropositive patient are known risk factors for increased transplant related 
mortality (TRM) in context of allogeneic bone marrow or peripheral blood HSCT. 5  
Worldwide, approximately 0.5-2.0% of neonates are born with congenital CMV infection .4   Although we 
consider cord blood units (CBU)  CMV negative at the time of the transplant, many CBU will test positive 
for CMV IgG due to transmission of maternal antibodies across the placental barrier. 8 Group by Maria S. 
Albano et al in 2006, assessed the incidence of CMV infection after transplantation of CBU from unrelated 
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donors. Post-transplantation CMV infection, reported in 23% of 1,221 CBU recipients, was associated with 
patient pre-transplantation CMV serology but not with CMV serology in CBU donor’s mothers. The group 
did not analyse the impact of the CBUs serological status on the transplant outcomes. 1  
The correlation between the CMV infection and disease recurrence in patients with hematologic 
malignancies after allogeneic HSCT has been an area of ongoing scientific interest for several years. Green 
M et al, demonstrated a modest reduction in early relapse risk after adult related and unrelated donors HSCT 
associated with CMV reactivation in a large cohort of children and adults with haematological diseases 
(2,354 study subjects). 2 Authors could not identify what was the exact biological mechanism(s) between 
CMV reactivation and decreased early relapse observed in allogeneic HSCT recipients. In contrast to the 
above study, M Jeljeli et al, showed that CMV reactivation post allogeneic HSCT was associated with 
increased relapse rate in 108 paediatric patients who received myeloablative (MAC) unrelated/related or 
cord blood (with CBU as a graft source  in 17 cases) HSCT for acute leukaemias . They showed that recovery 
of anti-CMV and anti-adenovirus immunity of naïve CD4+ T-cells was faster in the non-relapse group. 3 
The Minnesota group had analysed the 1 year relapse rate of the 674 paediatric and adult patients with 
haematological malignancies after either reduced intensity (RIC) or MAC  conditioning regimen allogeneic 
related/unrelated HSCT (with CBU as a graft source in 470 cases). In multivariate analyses adjusting for 
recipient CMV status, conditioning regimen, donor type (MSD vs. UCB), diagnosis, gender, disease risk 
(standard vs. high) and prior autologous transplant, CMV reactivation was independently associated with 
lower relapse risk and increased disease free survival  following RIC, but not MAC HSCT. They 
hypothesised that lower relapse risk is due to in vivo expansion and survival of adaptive NK cells.10 
In addition, several obstetric, maternal and fetal factors (ie mode of delivery, maternal age and gestational 
stage) will make an impact on the quality of collected CBU. Pilar Soves et al, had investigated the impact 
of maternal and fetal factors on the cell count of the 300 CBUs. They found that maternal age and gestational 
stage did not have an impact on the cell dose.9  Group of Omori A, analysed 916 CBUs and observed 
significantly higher total nucleated cell count (TNC) in multiparous deliveries. TNC from the first neonates 
was significantly higher than that from the second, the third and subsequent neonates. TNC from primiparae 
aged 30–34 years was significantly higher than that from the primiparae aged 20–24 years. 6    The group of 
Jose Perez et al , retrospectively investigated the influence of acute CMV exposure on CD34+ cell count in 
857 CBUs. CBUs donated by anti-CMV IgM-positive women had lower number of CD34+ cells (2.48 × 106 
in anti‐CMV IgM-positive donors compared to 1.48 × 106 in unaffected donors). 7   
 
There are some evidence (Paul Griffiths, personal communication), that foetus may be exposed to CMV 
virus during pregnancy even if the mother only shows IgG antibodies positivity and have no symptoms of 
the CMV infection .It is hypothesised that this small viral load may lead to an early activation of the foetus 
immune system and generation of T- cell immune response but not infection.  
Possible association between the maternal serological infectious markers (CMV and possibly others, as EBV 
and Toxoplasmosis) and CBU transplant outcomes has to be yet explored.   
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Therefore, we hypothesise that infant donor’s maternal previous exposure to the infections (CMV, EBV and 
Toxoplasmosis), mother’s age, previous pregnancies and gestational age might enhance CBUs alloreactive 
(ie antiviral and antitumor) potentials due to the maternal-fetal cell flow and potential priming of fetal 
immune cells to viral load and/or other antigens during pregnancy. We assume that maternal previous 
exposure to the above mentioned antigens might have an impact on the transplant outcomes, such as 
decreased relapsed rate. Therefore with the aim to confirm this theoretical hypothesis we proposed a 
retrospective study that includes mothers characteristics of cord blood units delivered by European Cord 
Blood banks (CBB).   
2. Endpoints 
2.1 Primary 
 
Non- relapse mortality (NRM) and relapse incidence (RI) 
 
2.2 Secondary 
• Engraftment  
• Acute and chronic Graft-versus-Host Disease (GvHD) 
• Overall Survival (OS) 
• Disease free  survival (DFS) 
3. Materials and methods 
3.1 Study subjects 
Selection criteria 
1) Patients (children and adults) with primary Acute leukemias (ALL, AML and biphenotypic) transplanted 
in EBMT centres from 2000-2012 
2) First transplant of unrelated single cord blood unit 
3) European Cord Blood Banks  
4) At least 2 years follow-up of survivors  
 
3.2 Data collection from the European CBB 
 
European Cord Blood Banks will be contacted to provide the following information: 
 
1. ID number of the selected CBU 
2. Date of the collection 
3. Selected CBU post-processing, pre-freeze cell count (CD34+x10^6 and TNCx10^8)  
4. Mothers age and numbers of previous pregnancies before the donation (including terminated pregnancies) 
5. Gestational age  
6. Mothers and selected CBU  
• CMV status (anti -CMV IgG and IgM) 
• EBV status (anti-EBV IgG, IgM and EBNA, or any other confirmatory test in case of IgM positivity) 
• Toxoplasmosis status (IgG and IgM AB) 
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• Other infections markers if available  
 
3.3 Data from the EUROCORD database 
 
1. Patients and disease characteristics 
• Diagnosis (AML , ALL or biphenotypic) and disease status at transplant (CR1, CR2 or advanced disease) 
• Age at UCBT 
• Weight at the UCBT 
• Gender 
• Year of transplant 
• CMV, EBV  status (anti -CMV IgG and IgM, anti-EBV IgG and IgM) 
• Other infectious markers if present  
1.  
2. 2.  Donor characteristics 
3.  
• Level of HLA matching with the patient at 3 loci (For Class I - HLA –A, -B at low/intermediate resolution 
and for Class II- HLA-DRB1 at high resolution) 
• Infused CBU cell dose (TNC) x10x^8 and CD34+ x10^6) 
• ABO compatibility 
4. Transplantation 
 
• Conditioning regimen ( RIC vs MAC) 
• Use if serotherapy (ATG or Alemtuzumab) 
5. Statistical consideration 
 
5.1 Definitions of outcome 
Outcome Definition 
Neutrophil engraftment First date at which a neutrophil count of ≥0.5x109/l for 3 
consecutive days is achieved, without evidence of 
reconstitution with recipient bone marrow, nor graft 
rejection in the first 100 days 
Platelet engraftment First date at which an unsupported platelet count of 
≥20x109/l for 7 consecutive days is achieved, without 
evidence of reconstitution with recipient bone marrow, nor 
graft rejection in the first 100 days 
Acute GvHD According to Seattle criteria. 
 
Chronic GvHD According to Seattle criteria 
Evaluable if surviving without relapse for more than 100 
days with sustained donor engraftment 
Relapse Defined on the basis of morphological evidence of ALL in 
bone marrow, blood or extramedullary organs.  
Haematological, cytogenetic or molecular relapse dates 
should be reported separately. 
TRM All causes of non-relapse deaths 
DFS Time from transplant to relapse, death or last follow-up 
 
5.2 Statistical methods 
The following variables will be considered in a risk factor analysis for outcomes  
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• Donor characteristics: CMV, EBV and Toxoplasmosis  serological status of the maternal serum (positive vs 
negative), maternal age at the time of donation, gestation stage, number of previous pregnancies before the 
donation 
 
• Patients characteristics (age at UCBT, gender, CMV status (positive vs negative) and other infectious 
markers if available information is present.  
 
Two separate groups will be analysed.   
Group N1:  Patients, who received UCBT from anti -CMV IgG and anti- CMV IgM negative CBU. 
Group N2:  Patients, who received UCBT from anti -CMV IgG positive and anti- CMV IgM negative or 
positive CBU (NB: CBU with positive anti-CMV IgM are tested for the CMV DNA. In case of the positive 
CMV DNA, CBU is not suitable for clinical use).  
 
• Disease characteristics: disease status at transplant (complete remission 1 or 2, advanced disease), presence 
or absence of minimal residual disease at transplantation according to centre definition  
• Transplant characteristics: HLA compatibility (based on intermediate/low resolution for Class I – A and B; 
high resolution for DRB1; ABO compatibility, total nucleated cell dose, CD34+ cell dose, year of 
transplant, conditioning regimen (RIC vs MAC); serotherapy use). 
 
Cumulative incidence curves will be used in a competing risks setting, death being treated as a competing 
event to calculate probabilities of relapse, acute and chronic GvHD, neutrophil recovery, TRM. Probabilities 
of overall and disease-free survival will be calculated using the Kaplan-Meier estimate. The prognostic 
significance of base-line covariates will be studied by two-sided log-rank tests.  
 
All variables found to have a P value of less than 0.05 will be included in proportional sub-
distribution hazard regression model of Fine and Gray (relapse, acute and chronic GvHD, neutrophil 
recovery, TRM), or as binary covariates in a Cox proportional-hazards model (Disease Free Survival and 
Overall Survival) with the use of a stepwise procedure and a type I error of 0.05. Relative risks for the 
association between covariates and events will be estimated with 95 percent confidence intervals.   
Statistical analyses will be performed with SPSS (Inc., Chicago) software packages. 
6. Publication rules 
 
EBMT rules of publication will be used. All participating centres will receive the draft of the 
manuscript to allow them to give their input. The order of the authors will be discussed in function of the 
amount of work given on each manuscript and the number of cases included. All centres will be included 
either in the authors or if there are too many names in an appendix. 
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Figure S- 4: Letter sent to CBB giving synopsis of the study and requesting approval 
 
Dear Colleagues, 
 
Eurocord, under the direction of Profs. Eliane Gluckman and Vanderson Rocha, would like to perform a 
retrospective study titled  
 
“Possible Association of Cord Blood Unit and mother’s Serological Status (Cytomegalovirus, Ebstein-
Barr Virus and Toxoplasma gondii), age, previous pregnancies, gestational age with Outcomes of 
Unrelated Donor Single-Unit Umbilical Cord Blood Transplant (UCBT) for paediatric and adult patients 
with Acute Leukaemias” 
 
The rationale of this study is to know if there are maternal’ factors (associated with possible alloreactivity) that 
can impact outcomes of UCBT. We have included only European CBB to facilitate data collection. The Eurocord 
database shows that 1,326  patients are eligible for this study were transplanted with single-unit cord blood from 
2000 through 2012. In order to perform this analysis, we would be very grateful if you could provide the following 
relevant data on your shipped Cord Blood Units (CBU).  
 
Mother’s CMV serology 
Mother’s EBV serology 
Mother’s Toxoplasmosis serology 
Mother’s date of birth 
Number of previous pregnancies to this donation  
Gestational age 
Date of the CBU collection  
 
Find attached the synopsis for the study and attached an excel spreadsheet/s with a list of CBUs from your bank 
that met the requirements for this study, containing the information retrieved from the Eurocord database 
(patients with acute leukemia, who received 1st unrelated single-unit cord blood transplant).  
 
Please indicate whether or not your bank is interested in participating in this study and that you have the above 
data. If you do not have mothers age, number of previous pregnancies and gestational age.  
 
Please submit the requested information to Eurocord. The deadline for data submission July 1st  to the email 
chantal.kenzey@aphp.fr.  
 
We thank you in advance for your assistance and collaboration, and we are looking forward to hearing from 
you. 
 
Please, feel free to contact us if you have any questions or concerns regarding this request. 
 
 
Best regards, 
 
Olga Nikolajeva 
On behalf of Eurocord group  
 
Eurocord  
Hôpital Saint Louis 
1, Av Claude Vellefaux 
75475 Paris Cedex 10 France 
Phone: +33.1.42.49.48.23 
Fax: +33.1.42.46.26.99 
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Table S- 3: Example of a Spreadsheet used for the Collection of Information on UCBs from CBBs 
participating in the Eurocord study 
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Table S- 4: Example of a Spreadsheet on Patients, Graft and Transplant Characteristics and UCBT 
Outcome Received from the Eurocord Electronic Database – Part 1 
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Table S- 5: Example of a Spreadsheet on Patients, Graft and Transplant Characteristics and UCBT 
Outcome Received from the Eurocord Electronic Database – Part 2 
 
Appendix – Supplemental Tables and Figures 
 195 
Table S- 6: Example of a Spreadsheet on Patients, Graft and Transplant Characteristics and UCBT 
Outcome Received from the Eurocord Electronic Database – Part 3 
 
